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Abstract 
Toll-like receptors (TLRs) expressed by antigen-presenting cells of the innate 
immune system, such as macrophages, detect microbial products and activate 
signalling cascades that initiate specific gene expression programmes that define 
the subsequent adaptive immune response. However, it is poorly understood how 
TLR-specific responses arise, as many of the signalling components are common 
to multiple TLRs, and it is likely that as yet undiscovered phosphorylations of 
signalling proteins contribute to specificity of TLR pathways. TLR4, the receptor for 
lipopolysaccharide (LPS), is used as a model system for TLR signalling, as it 
activates many of the signalling mechanisms utilised by other TLRs, and I 
attempted to discover novel regulatory phosphorylations in LPS-activated RAW 
264.7 macrophages. Because it is not yet possible to accurately predict post-
translational modifications from genomic data, the exact sites of phosphorylation 
have to be identified experimentally, and the method of choice for this is mass 
spectrometry-based phosphoproteomics. Using an optimised phosphoproteomics 
workflow and stringent filtering criteria, I identified 445 phosphorylation sites in 
unstimulated and LPS-treated RAW macrophages, several of which were potential 
LPS-induced regulatory phosphorylations, including a previously uncharacterised 
phosphorylation of the NF-κB protein p105, a key regulator of TLR and other 
inflammatory signalling pathways. Following validation of a phospho-specific p105 
antibody, I demonstrated that the novel phosphorylation of p105 was induced by 
LPS, other TLR ligands, tumour necrosis factor (TNF)-α, and prostaglandin E2 in 
RAW macrophages and primary human macrophages, and by interleukin (IL)-1β in 
4
primary human skin fibroblasts. Moreover, the LPS-induced phosphorylation of 
p105 was blocked by the protein kinase A (PKA) inhibitor H89. These results 
indicate that the novel phosphorylation of p105 may be important for the regulation 
of TLR and other inflammatory signalling pathways in both hemopoietic and non-
hemopoietic cells. 
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RSV  Respiratory syncytial virus  
S6K1  Ribosomal protein S6 kinase beta-1  
SAP  Shrimp alkaline phosphatase  
SCF-βTrCP  SKP1, CDC53/cullin1, and F-box protein-β-transducing repeat-containing 
protein  
SCX  Strong cation-exchange  
SDS  Sodium dodecyl sulphate  
SDS-PAGE  SDS polyacrylamide gel electrophoresis  
SH2 domain  Src homology 2 domain  
SH3 domain  Src homology 3 domain  
SHIP  SH2-containing inositol phosphatase  
shRNA  Short hairpin RNA  
SILAC  Stable-isotope labelling by amino acids in cell culture  
SIMAC  Sequential elution from IMAC  
siRNA  Small interfering RNA  
TAB  TAK1 binding protein  
TAG   TRAM adaptor with GOLD domain  
TAK  TGF-β-associated kinase  
TBK1  TANK-binding kinase 1  
27
TBS  Tris-buffered saline  
TBS-T  TBS/ 0.5% v/v Tween 20  
TFA  Trifluoroacetic acid  
Tfh cell  Follicular helper T cell  
TGF-β  Transforming growth factor-β  
Th cell  T helper cell  
TIR domain  Toll/IL-1 receptor domain  
TIRAP  TIR-domain-containing adaptor protein  
TiO2 Titanium dioxide 
TLR  Toll-like receptor  
TNF  Tumour necrosis factor  
TOF  Time-of-flight  
TPL2  Tumour progression locus 2  
TRAF  TNF receptor-associated factor  
TRAM  TRIF-related adaptor molecule  
TRIF  TIR-domain-containing adaptor-inducing interferon-β  
Tris 2-Amino-2-hydroxymethyl-propane-1,3-diol 
VASP  Vasodilator-stimulated phosphoprotein  
z Charge 
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One-Letter Code for Amino Acids 
A Alanine Ala M Methionine Met 
C Cysteine Cys N Asparagine Asn 
D Aspartic acid Asp P Proline Pro 
E Glutamic acid Glu Q Glutamine Gln 
F Phenylalanine Phe R Arginine Arg 
G Glycine Gly S Serine Ser 
H Histidine His T Threonine Thr 
I Isoleucine Ile V Valine Val 
K Lysine Lys W Tryptophan Trp 
L Leucine Leu Y Tyrosine Tyr 
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1.1 Mass Spectrometry-Based Phosphoproteomics 
1.1.1 Protein Phosphorylation in Cell Signalling 
Reversible phosphorylation of intracellular proteins is involved in the regulation of 
most cellular processes, and aberrant phosphorylation is implicated in a variety of 
human diseases (Cohen, 2001). In eukaryotes, covalent attachment of phosphate 
groups to serine, threonine, and tyrosine residues is the main mode of 
phosphorylation, altering protein activity, subcellular localisation, and interaction 
with other proteins (Cohen, 2000). According to recent estimates, the relative 
abundance of phosphorylated serine, threonine, and tyrosine residues is about 
40:5:1 in eukaryotic cells (Olsen et al., 2006), and it is estimated that more than 
30% of proteins are phosphorylated at any one time (Hunter, 1998). Attachment 
and removal of phosphate groups is catalysed by protein kinases and 
phosphatases, respectively, with more than 500 kinases and 100 phosphatases 
encoded by the human genome (Manning et al., 2002; Venter et al., 2001). The 
specificity of kinases for their substrates is regulated through mechanisms 
including multisite phosphorylation (Cohen, 2000) and interactions with other 
proteins (Pawson and Scott, 1997), and there is crosstalk between phosphorylation 
and other post-translational modifications, such as ubiquitination (Hunter, 2007), 
forming protein interaction networks that integrate signals from multiple pathways 
to elicit specific cellular responses (Scott and Pawson, 2009). 
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1.1.2 Characterisation of Cellular Phosphorylation Pathways 
Despite recent advances in the computational analysis of kinase recognition motifs 
(Linding et al., 2007; Miller et al., 2008), it is not yet possible to accurately predict 
in vivo phosphorylations from genomic data, and the exact sites of protein 
phosphorylation have to be identified experimentally in order to understand their 
significance in cellular function (Preisinger et al., 2008). Although chemical 
approaches, such as Edman degradation, have led the way in phosphorylation site 
analysis (Yan et al., 1998), their limited throughput does not permit the large-scale 
identification of phosphorylation sites required to characterise complex signalling 
networks. Recent advances in mass spectrometry (MS)-based approaches have 
enabled the identification and quantitation of over 20,000 phosphorylation events 
from a single experiment (Olsen et al., 2010), and have become the method of 
choice for the characterisation of the phosphoproteome (Macek et al., 2009). 
However, the identification of phosphorylation sites remains challenging owing to 
the low expression levels of many signalling proteins, and the reversibility and 
often low stoichiometry of signalling-induced phosphorylation (Mann et al., 2002). 
Identification and characterisation of phosphorylated sequences thus requires 
specific enrichment and targeted analysis of phosphorylated proteins.  
1.1.3 Enrichment of Phosphorylated Proteins and Peptides 
Most current MS based approaches identify phosphorylation sites at the peptide 
rather than protein level, and so require proteolysis of protein samples prior to 
analysis. Selective enrichment can, however, be performed either at the protein or 
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peptide level, and the available methods follow three main approaches: 
immunoprecipitation, chromatography, and chemical modification. 
1.1.3.1 Immunoprecipitation 
Immunoprecipitation of phosphorylated proteins can be achieved with antibodies 
raised against individual proteins or consensus kinase recognition motifs, but 
unbiased phosphoproteomics requires the use of antibodies that recognise a 
phosphorylated residue independently of the surrounding peptide sequence. 
Currently, only anti-phosphotyrosine antibodies permit efficient and specific 
immunoprecipitation, whereas anti-phosphoserine/ threonine-antibodies suffer from 
low binding efficiency and have found limited application (Gronborg et al., 2002). 
First used in 1981 for immunoprecipitation of tyrosine phosphorylated proteins 
(Ross et al., 1981), several antibodies now exist that enable the large-scale 
analysis of tyrosine phosphorylation following immunoprecipitation at the protein or 
peptide level. As a consequence, numerous studies have used this approach to 
identify tyrosine phosphorylation sites, leading to their relative overrepresentation 
in phosphoprotein databases (Diella et al., 2008; Tan et al., 2009). Because of the 
low abundance of tyrosine phosphorylated proteins, large amounts of starting 
material are required for immunoprecipitation, particularly at the peptide level, and 
studies are limited mostly to cell lines or abundant sources of tissue (Villen et al., 
2007). 
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1.1.3.2 Chromatography 
1.1.3.2.1 Strong Cation-Exchange Chromatography 
Strong cation-exchange (SCX) chromatography is the main method currently used 
for charge-based enrichment, separating positively charged peptides by the 
strength of their interaction with a negatively charged matrix (Beausoleil et al., 
2004). Because negatively charged phosphate groups reduce a peptide’s solution 
charge state and therefore the binding interaction with the matrix, phosphorylated 
peptides can be separated from non-phosphorylated peptides. However, SCX 
separation of peptides does not result in complete enrichment, because 
phosphopeptides containing several basic residues elute with the bulk of non-
phosphorylated peptides (Trinidad et al., 2006). For this reason, SCX is used 
mainly for crude enrichment prior to more selective affinity chromatography 
(Gruhler et al., 2005). Recently, hydrophilic interaction chromatography (HILIC) has 
been introduced as an alternative to SCX. HILIC is based on hydrogen bonding 
between peptides and a neutral hydrophilic matrix, and peptides elute in order of 
increasing polarity, permitting the selective enrichment of phosphopeptides in 
discrete fractions (McNulty and Annan, 2008). 
1.1.3.2.2 Immobilised Metal Affinity Chromatography 
Immobilised metal affinity chromatography (IMAC) was originally described by 
Porath and co-workers for protein fractionation (Porath et al., 1975), and later 
applied to the selective enrichment of phosphorylated proteins (Andersson and 
Porath, 1986) and peptides (Posewitz and Tempst, 1999). Metal ions, such as Fe3+ 
or Ga3+, immobilised to a solid support chelate negatively charged phosphate 
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groups in a relatively weak binding interaction, permitting the selective enrichment 
of phosphorylated proteins and peptides. Enrichment by IMAC is normally 
performed at the peptide level, but suffers from binding of non-phosphorylated 
peptides containing negatively charged carboxylic acid side chains (Figure 1.1). 
This can be reduced by using acidic buffers for the binding step (Posewitz and 
Tempst, 1999). O-methyl esterification of carboxylic acid side chains with 
methanolic HCl also blocks their binding to IMAC resin (Ficarro et al., 2002), but 
the reaction is inefficient and entails loss of sample (Trinidad et al., 2006). Pre-
fractionation of peptides by SCX (Gruhler et al., 2005), and protein extracts by gel 
electrophoresis (Li et al., 2007) prior to IMAC has been shown to increase the 
efficiency of phosphopeptide enrichment. 
1.1.3.2.3 Metal Oxide Affinity Chromatography 
Metal oxide affinity chromatography (MOAC) has been introduced recently for the 
enrichment of phosphopeptides using titanium dioxide (Pinkse et al., 2004) or 
zirconium dioxide (Kweon and Hakansson, 2006), and aluminium hydroxide for 
phosphoproteins (Wolschin et al., 2005). Phosphopeptides form a relatively strong 
adduct with metal oxides, and the binding interaction is more tolerant of salt than 
IMAC (Jensen and Larsen, 2007), though MOAC is also prone to unwanted binding 
of acidic non-phosphorylated peptides. Titanium dioxide (TiO2) has found the most 
widespread use since the introduction of binding buffers containing salicylic acid 
derivatives (Larsen et al., 2005) or aliphatic hydroxyl acids (Sugiyama et al., 2007) 
that compete for binding sites with carboxylic acid side chains but not with 
phosphate groups (Figure 1.1), permitting the selective exclusion of acidic non-
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phosphorylated peptides. TiO2 is also more tolerant of acidic binding buffers than 
IMAC, enabling more efficient protonation of carboxylic acid side chains, which 
further reduces binding of non-phosphorylated peptides (Larsen et al., 2005). Like 
IMAC, enrichment by TiO2 profits from pre-fractionation by SCX (Olsen et al., 
2006), although direct enrichment of complex peptide mixtures has been reported 
(Sugiyama et al., 2007). 
1.1.3.3 Chemical Modification 
Several chemical modification strategies have been devised to derivatise 
phosphate groups for tagging approaches, but have found limited application in 
phosphoproteomics studies owing to a lack of control over derivatisation rates and 
unwanted side reactions (Reinders and Sickmann, 2005). Phosphoramidate 
conversion (PAC) was developed by Aebersold and co-workers and involves O-
methyl esterification of carboxylic acid side chains to prevent their reaction in 
subsequent steps, followed by derivatisation and phosphoramidate linkage of 
phosphate groups to a solid support, and acid hydrolysis of the phosphoramidate 
linkage to free bound phosphopeptides (Zhou et al., 2001; Tao et al., 2005). PAC 
has not found widespread use, presumably because the elaborate workflow is time 
consuming and entails loss of sample, and inefficient O-methyl esterification can 
lead to co-enrichment of non-phosphorylated peptides. 
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Figure 1.1 Phosphopeptide enrichment by IMAC and TiO2. 
(A) Co-ordination of Fe3+ IMAC (left) and TiO2 (right) resins with a phosphorylated peptide (red 
wave line). (B) Co-ordination of TiO2 resin with 2,5-dihydroxy benzoic acid (DHB), a salicylic acid 
derivative. (C) Co-ordination of IMAC and TiO2 resins with a carboxylic acid side chain. DHB and 
other salicylic acid derivatives bind more strongly to TiO2 than carboxylic acid side chains, but less 
strongly than phosphopeptides, permitting the selective exclusion of acidic non-phosphorylated 
peptides. Figure from (Rogers and Foster, 2009). 
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1.1.3.4 Comparison of Phosphopeptide Enrichment Methods 
Each method requires extensive adaptation and optimisation in the hands of 
different researchers and conflicting results have been reported. The Aebersold 
group identified comparable numbers of phosphorylation sites from enrichment of 
non-fractionated digests of whole cell extract by IMAC, TiO2, and PAC 
(Bodenmiller et al., 2007), whereas superior enrichment of TiO2 over IMAC was 
shown by Larsen and co-workers for a simple test mixture (Larsen et al., 2005). 
The Gygi group tested IMAC and TiO2 in conjunction with pre-fractionation by 
preparative gel electrophoresis and identified similar numbers of phosphorylation 
sites, although phosphopeptide enrichment by IMAC was less selective than TiO2, 
and  IMAC exhibited a preference for basic amino acid residues (Wilson-Grady et 
al., 2008). In contrast, Aebersold’s group noted that IMAC was more selective than 
TiO2, but also reported a preference of IMAC for basic residues (Bodenmiller et al., 
2007). This suggests that the same method can give different results depending on 
experimental setup, and that the combined use of TiO2 and IMAC may be required 
to enable comprehensive identification of phosphopeptide sequences. To this end, 
Thingholm and co-workers described enrichment  by sequential elution from IMAC 
(SIMAC) (Thingholm et al., 2008). Whereas multiply phosphorylated peptides are 
routinely detected from IMAC eluates (Ficarro et al., 2002; Gruhler et al., 2005), 
TiO2 has been shown to be more biased toward singly phosphorylated peptides 
(Bodenmiller et al., 2007), and Thingholm has argued that multiply phosphorylated 
peptides are not recovered from TiO2 because the binding of phosphate groups to 
TiO2 is stronger than to IMAC resin. SIMAC employs limiting quantities of IMAC 
resin to preferentially retain multiply phosphorylated peptides, followed by TiO2 
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enrichment of singly phosphorylated peptides from the IMAC flow-through. Use of 
SIMAC may therefore also compensate for any bias the two methods have toward 
specific phosphopeptide sequences. 
1.1.4 Tandem Mass Spectrometry 
1.1.4.1 General Principles 
Tandem mass spectrometry (MS/MS) permits the identification of the amino acid 
sequence of a peptide, together with the type and site of attachment of post-
translational modification, such as phosphorylation. In order to generate peptides 
of suitable size for analysis, proteins are typically digested with the endoprotease 
trypsin, which cleaves the peptide bonds C-terminal to arginine and lysine, except 
when the following residue is proline (Olsen et al., 2004). Tandem mass 
spectrometers exist in various configurations and geometries, but all consist of: (1) 
an ionisation source to charge and transfer peptides (or other analytes) to the gas 
phase, (2) one or more mass analysers that separate ionised peptides and their 
fragments according to their mass-to-charge ratio (m/z), and (3) a detector that 
measures the number of ions per m/z. 
1.1.4.2 Ionisation Methods 
The two main methods for ionisation of peptides are electrospray ionisation (ESI) 
(Fenn et al., 1989) and matrix-assisted laser desorption/ionisation (MALDI) (Karas 
and Hillenkamp, 1988).  
First proposed by Dole (Dole et al., 1968), ESI was developed as an ionisation 
source for MS by Fenn and co-workers (Yamashita and Fenn, 1984). In ESI, a fine 
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spray of charged droplets is emitted from a capillary at high electrical potential, and 
analytes are charged in the liquid phase and transferred to the gas phase through 
solvent evaporation (Kebarle and Verkerk, 2009). Because analytes compete for 
charges, in complex mixtures analytes of higher concentration or better ionisability 
are observed preferentially, e.g. suppression of phosphopeptides by more 
abundant non-phosphorylated peptides (McLachlin and Chait, 2001). Peptide ions 
are also unlikely to be observed at high salt concentration (> 1 mM), and samples 
are commonly desalted prior to analysis (Glish and Vachet, 2003). For peptide 
analysis ESI is usually performed in positive ion mode and, depending on the mass 
of the peptide, multiply protonated molecules, typically 2-4 charges, will be 
detected at distinct m/z values. ESI has become the method of choice for large-
scale proteomics owing to its inherent compatibility with liquid chromatography 
(LC)  (McCormack et al., 1997). 
MALDI normally generates singly charged peptides through laser irradiation of 
peptides co-crystallised with a photo-ionisable matrix, resulting in ionisation and 
transfer to the gas phase of the protonated peptides. Although analysis of complex 
mixtures by off-line LC-MALDI-MS/MS is possible, MALDI is used mainly for 
targeted identification of phosphorylation sites from simpler mixtures (Bennett et 
al., 2002). 
1.1.4.3 Mass Analysers 
Several parameters determine a mass analyser’s performance and suitability for 
specific applications, including mass accuracy, resolving power, mass range, 
sensitivity, and data acquisition speed. High mass accuracy permits measurement 
41
Chapter 1                                                                                                                            Introduction 
of accurate molecular masses; at high resolving power, spectral peaks of similar 
m/z can be resolved; mass range determines the limit of m/z that can be 
measured; sensitivity should ideally be high over the full mass range; and rapid 
data acquisition speed is critical for LC-MS/MS, because of narrow 
chromatographic peak widths (Lim and Lord, 2002). Mass analysers commonly 
used in proteomics are time-of-flight (TOF), quadrupole (Q), ion traps, Fourier-
transform ion-cyclotron resonance (FT-ICR), and orbitrap (Glish and Vachet, 2003; 
Domon and Aebersold, 2006). 
Tandem mass spectrometers either have inherent MS/MS capability, such as ion 
traps, or are comprised of two mass analysers separated by a collision cell for 
fragmentation of peptides or other analytes. The most popular MS/MS instruments 
for proteomics are QTOF (Figure 1.2), TOF-TOF, ion traps, triple quadrupole, 
quadrupole-linear ion trap (e.g. Thermo’s LTQ), LTQ-Orbitrap (Figure 1.3), and 
LTQ-FT-ICR (Domon and Aebersold, 2006; Yates et al., 2009). 
TOF analysers separate ions according to their velocity by accelerating them 
through a fixed potential inside a drift tube, with a detector at the end of the flight 
path registering the flight time and number of ions impinging on it. Because an 
ion’s flight time is proportional to the square root of m/z, this information can be 
converted into a mass spectrum showing abundance vs. m/z. TOF analysers have 
high mass accuracy (tens of ppm), resolving power of at least 10,000 (i.e. separate 
m/z 1000.0 from m/z 1000.1), theoretically unlimited mass range, and permit rapid 
data acquisition. 
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The quadrupole mass analyser functions as a mass filter by selectively 
destabilising the passage of ions outside a selected m/z range through an 
oscillating radio frequency (RF) field between four charged rods. While rapidly 
scanning a range of m/z, a detector measures the number of ions exiting the 
quadrupole, which is converted into a mass spectrum. Quadrupoles have limited 
mass range (up to m/z 4000), mass accuracy in the hundreds of ppm, and are 
normally set at unit resolving power over the full mass range (i.e. separate m/z 500 
from m/z 501, and m/z 1000 from m/z 1001). 
The quadrupole ion trap (QIT) consists of a ring-shaped electrode and two end-cap 
electrodes, which generate a three-dimensional oscillating electrical field to 
accumulate ions into the small volume of the trap. The trajectory of ions is 
selectively destabilised, and ions are ejected according to m/z and detected. The 
QIT is also capable of MS/MS whereby only ions of selected m/z are retained, 
electronically activated and fragmented, and product ion spectra are recorded by 
selective ejection and detection; this process can be iterated (MSn) to record 
product ion spectra of product ions. QITs offer high sensitivity and rapid data 
acquisition at similar mass accuracy, resolving power, and mass range to 
quadrupole mass filters, but in practice can suffer from space-charge effects (a 
distortion of the electrical field when too many ions are confined in the trap, leading 
to impaired performance), and low mass limits due to poor trapping efficiency of 
low mass ions. By contrast, linear ion traps (LIT) store ions inside the larger 
volume of a quadrupole, where ions are axially confined by a two-dimensional RF 
field applied to the ends of the rods. The reduced space-charge effects result in 
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greater sensitivity, mass accuracy, resolving power, and mass range than three-
dimensional ion traps. 
The FT-ICR analyser traps ions in a high magnetic field that forces the ions into 
circular motion. The frequency of circular motion is inversely related to m/z, and the 
image current induced by the ions is measured, deconvoluted by Fourier transform, 
and converted into a mass spectrum. Like ion traps, FT-ICR analysers are capable 
of MS/MS, but at low fragmentation efficiency. FT-ICR analysers achieve very high 
mass accuracy (sub ppm) and resolving power (up to millions) at high sensitivity 
over the full mass range, but require large and expensive superconducting 
magnets, limiting their use. 
The orbitrap analyser traps ions in an electrostatic field around a small spindle-
shaped electrode, and, similar to FT-ICR, image currents are recorded and 
converted into a mass spectrum. The orbitrap achieves very high mass accuracy 
(less than 5 ppm) and resolving power (150,000) at high sensitivity over a mass 
range up to m/z 6000, making it a popular alternative to FT-ICR instruments. 
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Figure 1.2 Diagrammatic representation of a QTOF mass spectrometer. 
Sample solution is injected via the electrospray capillary (ESI), and peptides are ionised and 
transferred to the gas phase. The quadrupole mass analyser is used for ion focussing when 
operating in TOF-MS mode. In the orthogonal TOF analyser, a parallel beam of ions is 
accelerated through a fixed potential, giving equal kinetic energy to ions of the same charge. As 
ions of lower mass have higher velocities, the ions separate according to m/z in the TOF drift 
tube. The reflectron effectively doubles the length of the flight path, and aids ion focussing. 
When an ion strikes the detector, the total time of flight over the fixed length of the flight tube is 
measured, and used to calculate the ion’s velocity. The velocity is related to the ion’s known 
kinetic energy to determine m/z (using Ekinetic = ½ m v
2). The number of ions at each m/z is 
measured and converted into a mass spectrum. In MS/MS mode, the quadrupole mass filter 
selects precursors for fragmentation in the hexapole collision cell, and product ions are 
analysed by TOF-MS to generate a tandem mass spectrum. Figure adapted from Micromass 
catalogue (www.waters.com). 
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Figure 1.3 Diagrammatic representation of a LTQ-Orbitrap mass spectrometer. 
Sample solution is injected via the electrospray capillary (ESI). Gas phase ions are admitted via 
multipoles and transferred to the linear ion trap (LTQ), where they are stored and ejected into the C-
trap via a transfer octopole. From the C-trap a tight cloud of ions is ejected into the orbitrap for 
analysis at high mass accuracy and resolving power. Several MS/MS modes are possible, with 
fragmentation in the LTQ, C-trap, or octopole collision cell, and fragment ion measurement by LTQ 
or orbitrap. For qualitative MS/MS, precursor ion masses are normally measured in the orbitrap, and 
selected precursors are fragmented and analysed in the LTQ. For iTRAQ MS/MS, precursor ion 
masses are measured in the orbitrap, precursors are selected in the LTQ and transferred to the 
octopole collision cell for fragmentation by higher-energy collision dissociation (HCD), and 
fragments are analysed in the orbitrap. Openings represent sites of differential pumping. Figure 
from (Olsen et al., 2007). 
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1.1.4.4 Tandem Mass Spectrometry Experiments for Phosphopeptide Identification 
Fragmentation of peptides occurs mainly along the peptide backbone and 
produces a set of truncated peptide ions (Figure 1.4). Fragmentation is often 
favoured for specific amino acid sequences, aiding the interpretation of tandem 
mass spectra (Tabb et al., 2006). The attachment of a phosphate group to serine, 
threonine, or tyrosine residues increases the mass of all ions that contain the 
modification by 80 Da, enabling localisation of the phosphorylated residue within 
the peptide sequence. Several types of MS/MS experiments are useful in 
identifying phosphorylated peptides, depending on the type of mass spectrometer 
employed. 
All MS/MS instruments are capable of performing product ion scans, in which a 
precursor ion is selected by the first mass analysers (MS1), fragmented usually by 
collision-induced dissociation (CID) with an inert gas, and the product ions are 
analysed by the second mass analyser (MS2); in ion traps, the experiment is 
performed sequentially by the same mass analyser through selective electronic 
destabilisation of ions. Product ion scanning is the most common type of MS/MS 
experiment in large-scale proteomics, usually in the form of data-dependent 
acquisition (DDA), in which MS1 acquires a full-scan mass spectrum (survey scan) 
and several multiply charged ions (typical of peptides) above a selectable threshold 
signal intensity are automatically selected for fragmentation, followed by return to 
full-scan mode and repeat of the cycle. DDA is usually performed for up to five 
precursors and duty cycles of five seconds or less are routine (Domon and 
Aebersold, 2006). 
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Figure 1.4 Ion types produced by peptide fragmentation. 
Roepstorff and Fohlman nomenclature for fragment ions (Roepstorff and Fohlman, 1984). Collision-
induced dissociation produces mainly b- and y-ions, whereas electron capture dissociation and 
electron transfer dissociation produce mainly c- and z-ions. Figure from www.ionsource.com. 
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In positive ESI mode, fragmentation of phosphorylated peptides often results in the 
neutral loss of H3PO4 (-98 Da) from phosphorylated serine and threonine residues 
and less often loss of HPO3 (-80 Da) from phosphorylated tyrosine in preference to 
informative sequence-specific fragmentation of the peptide backbone. In some 
cases, this makes it impossible to identify the peptide sequence and 
phosphorylation site(s) by conventional DDA experiments. Neutral loss of H3PO4 is 
observed with all types of instruments, but is more pronounced in ion traps owing 
to the nature of the excitation process.  
In neutral loss scanning, MS2 and MS1 are synchronised so that MS2 scans for 
product ions with a specified mass difference to the precursor ion, and detection of 
this mass difference triggers a product ion scan to identify the peptide sequence. 
The detection of a neutral loss of 98 Da indicates the presence of a serine or 
threonine phosphorylated peptide that exhibited facile loss of phosphate, triggering 
a product ion scan that permits the selective identification of this class of peptides, 
but this often results in fragment ion spectra of poor quality. Phosphopeptide 
identification by neutral loss scanning has been implemented successfully on ion 
traps, where detection of significant neutral loss of phosphate can be set to trigger 
an MS3 experiment to induce further fragmentation of the product ion, which can 
enable identification of the peptide sequence and exact site(s) of phosphorylation 
(Beausoleil et al., 2004). A similar experiment, termed pseudo-MS3 or multistage 
activation (MSA), can be performed on hybrid ion traps, such as the LTQ-Orbitrap 
(Olsen et al., 2006). 
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In precursor ion scanning on triple quadrupole and quadrupole-LIT instruments, 
MS2 is set to transmit only product ions of selected m/z, while MS1 is scanned, 
enabling detection of all precursors from which the product originates. In negative 
ion mode, fragmentation of phosphopeptides generates a characteristic product ion 
at m/z 79 (PO3¯) that is detected by precursor ion scanning, followed by a switch to 
positive ion mode to identify the peptide sequence and location of the 
phosphorylation site(s) in a product ion scan (Carr et al., 1996). In a similar way, 
precursor ion scanning on modern QTOF instruments in positive ESI mode detects 
the immonium ion of phosphorylated tyrosine residues at m/z 216.043, permitting 
the selective identification of tyrosine phosphorylated peptides (Steen et al., 2001). 
Electron capture dissociation (ECD) and electron transfer dissociation (ETD) are 
gentler fragmentation methods than CID that do not cause facile loss of phosphate 
groups. In CID, the vibrational excitation of peptides through collision with inert gas 
induces fragmentation via the lowest energy pathways, yielding mainly b- and y-
ions and often resulting in phosphate loss. By contrast, ECD induces fragmentation 
via capture of low energy electrons, generating charge-reduced radical cation 
species that rapidly dissociate to produces c- and z-type ions without breakage of 
amino acid side chains  (Figure 1.4) (Sweet and Cooper, 2007). ECD is currently 
effective only on FT-ICR instruments and has long duty cycles owing to the low 
peptide fragmentation efficiency, limiting its use for routine application. Sweet and 
co-workers conducted a large-scale phosphoproteomics study to compare ECD 
and CID fragmentation of phosphopeptides and reported that ECD permitted more 
confident localisation of phosphorylation sites, although more phosphopeptides 
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were identified by CID (Sweet et al., 2009). Fragmentation by ETD  is similar to 
ECD, but uses radical anions as electron donors to induce peptide fragmentation 
(Syka et al., 2004), and has been implemented on quadrupole-LIT, LTQ-Orbitrap, 
and QTOF mass spectrometers. Several studies have shown the suitability of ETD 
for large-scale phosphoproteomics, but conflicting results have been obtained from 
comparison of ETD and CID. Two studies reported more phosphopeptide 
identifications and greater confidence in phosphorylation site localisation with ETD 
(Molina et al., 2007; Swaney et al., 2009), but comparable confidence in site 
localisation was also demonstrated (Aguiar et al., 2010). Nevertheless, ETD has 
been shown to enable more efficient fragmentation of large peptides of higher 
charge state and multiply phosphorylated peptides (Molina et al., 2007; Domon et 
al., 2009). Swaney and co-workers have developed a data-dependent decision tree 
method that is implemented on the LTQ-Orbitrap (with ETD module), whereby the 
instrument automatically uses CID or ETD depending on the precursor charge 
state and m/z (Swaney et al., 2008), which may present an optimal strategy to 
enable identification of different classes of phosphopeptides. 
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1.1.5 Identification of Phosphopeptides from Tandem Mass Spectra 
1.1.5.1 Automated Protein Database Searching of Tandem Mass Spectra 
As it is not practical to manually interpret the thousands to several hundred 
thousand tandem mass spectra generated by large-scale phosphoproteomics 
studies, uninterpreted spectra are searched against protein databases using 
search tools such as Sequest (Eng et al., 1994), Mascot (Perkins et al., 1999), 
Phenyx (Colinge et al., 2003), OMSSA (Geer et al., 2004), and X!Tandem (Craig 
and Beavis, 2004). These search tools operate on the principle of correlating 
theoretical spectra that have been derived from the sequences in the database 
with the experimental spectrum, and use different scoring algorithms to determine 
the validity of the match (Nesvizhskii et al., 2007). The search space is restricted 
by user-defined criteria, including the type and specificity of endoprotease, mass 
tolerance (estimated error of mass measurement), and post-translational 
modifications. First, the protein sequences in the database are digested in silico 
according to the cleavage specificity of the endoprotease (typically trypsin) to 
generate a set of peptide sequences. Second, molecular masses are calculated for 
each in silico peptide, taking into consideration fixed modifications of amino acid 
residues (e.g. those intentionally introduced during sample preparation) and any 
variable modifications (e.g. phosphorylation). Third, theoretical tandem mass 
spectra are generated for the subset of in silico peptides with masses inside the 
experimental precursor mass tolerance window; this subset of in silico peptide 
sequences is the effective database searched for that particular precursor mass. 
The type and abundance of theoretical fragment ions is also dependent on the type 
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of mass spectrometer used. Fourth, the search tool compares the experimental 
tandem mass spectrum with the theoretical spectra, taking into account the user-
defined fragment ion mass tolerance, and ranks the most likely peptide sequence 
matches to the experimental mass spectrum. Each search tool employs its own 
scoring scheme to identify peptide matches, but all are based on similar general 
principles (Nesvizhskii, 2007), which are described in the following for Mascot, the 
tool used in this work (information about Mascot was compiled from 
www.matrixscience.com, as many details remain unpublished).  
1.1.5.1.1 The Mascot Search Tool 
Mascot uses probabilistic scoring to match theoretical spectra against experimental 
fragment ion masses. The scoring algorithm favours fragment ions of high signal 
intensity to prevent matching of noise-level peaks, and incorporates empirical 
observations of fragmentation pathways for particular peptide sequences, iterating 
possible fragment ion matches until the sequence match with the maximum ion 
score has been determined. For Mascot, a peptide sequence is a significant match 
to the precursor and fragment ion masses when the ion score exceeds the identity 
score. The identity score (or identity threshold) is calculated from the probability 
that the precursor mass is a random match to the peptide sequence, determined 
by the number of sequences within the precursor mass window and statistical 
significance threshold. Thus, if the effective database consists of 50 in silico 
peptide masses, and a 1/ 20 chance of a random match is permitted (p < 0.05), 
than the probability of a random match is 1/ 1000. This probability P is converted 
into the identity score using the formula: 
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Identity score = -10 x Log10 P e.g. -10 x Log (1/ (20 x 50) = 30 
Consequently, the identity threshold depends on the number of sequences present 
in the protein database, and increases when considering missed tryptic cleavage 
sites and potential post-translational modifications, as in silico peptides are 
generated for both cleaved and uncleaved sequences with all possible iterations of 
potential modifications. Because phosphorylation can impede cleavage at nearby 
tryptic sites (Campbell and Morrice, 2002), and variable modification of serine, 
threonine, and tyrosine residues must be considered, identity thresholds for 
phosphoproteomics studies are generally high.  Furthermore, variable oxidation of 
methione residues is frequent owing to the number of sample handling steps 
involved in the phosphoproteomics workflow, which further increases the size of 
the effective database. If the ion score does not exceed the identity threshold but is 
an outlier from the distribution of lower scoring matches, the match is unlikely to be 
random. In such cases Mascot determines the homology score, and matches 
exceeding this threshold often identify the correct sequence or a close homologue 
(Choudhary et al., 2001). 
1.1.5.2 Statistical Validation of Phosphopeptide Identifications 
Owing to the different scoring schemes employed by database search tools it is 
difficult to compare their results, and matches to the same spectra may exceed the 
significance threshold of some tools but not of others (Kapp et al., 2005). In 
particular, phosphopeptide identifications were shown to be more dependent on 
the choice of search tool than identifications of unmodified peptides (Bakalarski et 
al., 2007). Therefore, it is desirable to estimate the confidence of identification by 
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independent means. Target-decoy strategies permit such an estimate by repeating 
the search against a reversed or randomised copy of the target database using 
identical parameters to the target search (Peng et al., 2003). The false discovery 
rate (FDR) is calculated from the number of decoy matches divided by the sum of 
target and decoy matches, and FDR of 1% or less are generally considered 
evidence of good data quality (Peng et al., 2003; Elias et al., 2005). In Mascot, 
decoy searches are performed against automatically generated random protein 
sequences of equal length to the query sequence and of the same amino acid 
composition as the average composition of the target database, which can provide 
more accurate statistical estimates than reversed sequences (Nesvizhskii, 2007). 
However, the target-decoy strategy estimates only the cumulative FDR and does 
not provide an objective estimate of the probability that an individual peptide is a 
false match. This issue is addressed by the Peptide Prophet algorithm, which 
permits the independent validation of results from different database search tools 
using Bayesian statistics to calculate the probability of a correct match for each 
peptide (Keller et al., 2002). Similarly, the confidence of phosphorylation site 
localisation has also been shown to depend on the choice of search tool 
(Beausoleil et al., 2006), and two groups have developed algorithms for confident 
assignment of phosphorylation sites from spectra acquired on LTQ-FT and LTQ-
Orbitrap instruments (Beausoleil et al., 2006; Olsen et al., 2006). 
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1.1.6 Quantitative Phosphoproteomics 
While the identification of large numbers of phosphorylation sites can provide 
valuable clues about which proteins may be regulated by stimulus-induced 
phosphorylation, it is not possible to distinguish basal from induced levels of 
phosphorylation for a particular site without validation by alternative methods. By 
contrast, large-scale quantitation of phosphorylated peptides can establish the 
extent of regulation of each identified phosphorylation site, and in multiplexed form 
also the kinetics of phosphorylation. Most strategies for relative quantitation of non-
phosphorylated peptides have also been implemented in phosphoproteomics 
studies, including metabolic labelling, chemical tagging, and label-free techniques.  
Stable-isotope labelling by amino acids in cell culture (SILAC) (Ong et al., 2002) 
involves culturing cells with isotopically labelled amino acids, normally arginine and 
lysine to ensure that each tryptic peptide carries the mass difference, and permits 
up to three conditions per experiment (arginine – unlabelled;13C6;
 13C6/ 
15N4, lysine 
– unlabelled; 2H4; 
12C6/ 
15N2). After mixing the samples, the mass difference 
between ‘heavy’ and ‘light’ labels is detected, and the MS signal intensities of 
peptides are used to determine relative abundances (Figure 1.5, A). Further 
multiplexing is achieved by combining experiments normalised to a shared 
condition, which enables characterisation of phosphorylation kinetics (Olsen et al., 
2006). With computational correction for incomplete labelling, SILAC permits 
reliable quantitation owing to multiple measurements of precursors over their 
chromatographic elution profile, but because labelling increases mass spectral 
complexity at the survey scan level, high resolution mass spectrometers are 
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required. SILAC is limited mostly to cell culture, although whole organism labelling 
is available at considerable financial cost, including mouse (Kruger et al., 2008).  
Chemical tagging approaches involve reactive labelling of proteins or peptides with 
stable isotopes. Labelling with amine-reactive isobaric tagging reagents, such as 
isobaric tags for relative and absolute quantitation (iTRAQ) (Ross et al., 2004), 
introduces a label at the peptide level and is therefore applicable to any type of 
sample. iTRAQ reagents consist of a reporter group linked to a primary amine-
reactive balancing group that forms N-hydroxysuccimide (NHS)-ester bonds with 
peptide N-termini and ε-amino groups of lysine residues. Reporter and balance 
groups are isotopically labelled so that each tag is isobaric and labelled peptides 
are indistinguishable at the survey scan level. Following peptide fragmentation, low 
mass reporter ions are detected at specific m/z and the fragment ion signal 
intensities are used for quantitation (Figure 1.5, B); this approach permits up to 
eight-plexing (Pierce et al., 2007). Because of the low mass cut-off of ion traps, 
iTRAQ-labelled samples were originally analysed by QTOF-MS/MS, but the recent 
introduction of higher-energy collision dissociation (HCD) (Olsen et al., 2007) (see 
Figure 1.3) has enabled iTRAQ quantitation of non-phosphorylated and 
phosphorylated peptides on the LTQ-Orbitrap (Bantscheff et al., 2008; Zhang et al., 
2009). Accurate quantitation requires extensive chromatographic separation to 
prevent simultaneous fragmentation of coeluting peptides of similar mass, because 
a coeluting precursor of low abundance can contribute reporter ions while 
appearing as noise in a chimeric spectrum, making it almost impossible to detect 
this source of error (Ong and Mann, 2005). A further disadvantage of iTRAQ for 
57
Chapter 1                                                                                                                            Introduction 
phosphoproteomics is the requirement for repeat experiments, because a 
phosphorylation site is frequently identified by a single phosphopeptide, in which 
case quantitation is based on a single measurement of reporter ion intensities, 
possibly giving inaccurate results (Trinidad et al., 2008). A simple and cost-
effective alternative to iTRAQ is O-methyl esterification of carboxylic acid side 
chains with deuterated methyl groups prior to IMAC enrichment (Salomon et al., 
2003), but the method suffers from incomplete labelling, which increases spectral 
complexity at the survey scan level, and does not allow multiplexing. 
Label-free quantitation is gaining increasing popularity and several approaches 
have been employed in phosphoproteomics studies, including integration of MS 
signal intensities over their chromatographic elution profiles (Hoffert et al., 2006), 
spiking the sample with standard peptides as a reference (Cao et al., 2007), and 
spectral counting (Rikova et al., 2007), although the latter two approaches have 
only been applied in conjunction with specific enrichment of tyrosine 
phosphorylated peptides. These approaches are attractive because no expensive 
reagents are used, but require separate LC-MS/MS runs for each cell treatment, 
with associated quantitation errors from inconsistent sample processing and 
instrument performance. 
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Figure 1.5 Peptide quantitation by SILAC and iTRAQ. 
(A) SILAC. Cells are grown in the presence of metabolically labelled amino acids, the cell lysates 
are mixed, and peptide extracts are analysed by MS for quantitation, followed by MS/MS analysis 
for sequence and phosphorylation site determination. Up to three experimental conditions are 
possible. (B) iTRAQ. Peptide extracts are reacted with isobaric tags, mixed, and analysed by 
MS/MS, where each tag produces a low mass reporter ion (114, 115, 116, and 117), permitting 
quantitation of all four extracts from a single tandem mass spectrum. iTRAQ reagents are available 
in four-plex and eight-plex formats. Figures adapted from (Amanchy et al., 2005) and (Ross et al., 
2004), respectively. 
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1.2 Toll-Like Receptors and Innate Immunity 
1.2.1 Regulation of Innate and Adaptive Immunity 
Metazoan organisms are hosts to microbial populations, some of which are 
symbiotic and beneficial or necessary for survival, such as the intestinal microflora, 
and others that are pathogens and threaten the host’s integrity and survival. 
Interaction with microbial populations is facilitated by the immune system, which in 
mammals and other jawed vertebrates is comprised of innate and adaptive 
immunity. The main effector cells of the innate immune system are phagocytes, 
including macrophages and dendritic cells (DCs), which are typically resident in 
tissues where microbial contact is frequent, such as mucosal membranes, and 
detect microbial products via a limited number of pattern recognition receptors 
(PRRs). PRRs have broad specificity for molecular structures shared by particular 
classes of microbes and comprise several types of intracellular and cell surface 
receptors, the best studied of which are toll-like receptors (TLRs). By contrast, B 
and T lymphocytes of the adaptive immune system are resident mainly in lymph 
nodes and spleen, and express numerous clonally distributed antigen receptors 
that arise from somatic recombination of immunoglobulin (Ig) genes and permit 
specific recognition of unique antigens (Medzhitov, 2007). 
An effective immune response arises from the interplay between innate and 
adaptive immunity, and both recognition of pathogens and self depend critically on 
the interactions between antigen-presenting cells (APCs) and CD4+ T cells. APCs, 
the most important of which are macrophages and DCs, recognise pathogens via 
PRRs. Activated PRRs induce expression of cytokines and chemokines to activate 
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the inflammatory response by recruiting other immune cells to the site of infection 
or trauma. PRR-activated APCs ingest microbes through phagocytosis or receptor-
mediated endocytosis, and following digestion inside phagolysosomes present 
specific peptide antigens on the cell surface via major histocompatibility complex 
(MHC) class II molecules. APCs then migrate to lymph nodes where peptide 
antigens are recognised by antigen receptors of naive CD4+ T cells. However, T 
cell activation requires further co-stimulation by APCs through cell surface proteins 
of the B7 family, including CD80 and CD86, which are recognised by CD28 
receptors of T cells. The expression of B7 molecules by APCs is regulated by 
microbial activation of PRRs, and in the absence of B7 expression, as is the case 
when APCs present self-antigens, T cell antigen recognition results in permanent 
inactivation of T cell clones specific for that antigen, thus preventing future 
autoimmune responses (Medzhitov and Janeway, 1997; Iwasaki and Medzhitov, 
2004). 
Differentiation of naive T cells into pathogen-specific CD4+ T helper (Th) subtypes 
further requires PRR-induced expression of specific cytokines by APCs. Interleukin 
(IL)-12 and interferon (IFN)-γ induce Th1 cell differentiation (Figure 1.6), and Th1 
cells in turn produce IFN-γ to activate macrophages and other immune cells to 
combat intracellular infection with bacteria, viruses, or protozoa, and stimulate B 
cells to produce IgG2 antibodies. IL-4 regulates differentiation of Th2 cells, which 
produce IL-4, IL-5, and IL-13 to recruit eosinophils and basophils to the site of 
helminth infection. Th2 cells also instruct B cells to produce IgE antibodies, which 
bind to high affinity receptors for IgE on mast cells and basophils, enabling them to 
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respond to antigen by releasing histamine and other inflammatory mediators 
selectively toxic for helminths. Transforming growth factor (TGF)-β and IL-6 induce 
differentiation of Th17 cells, which produce IL-17 and IL-22 to stimulate chemokine 
production by epithelial cells, activating neutrophils to defend against infection by 
extracellular bacteria or fungi. And secretion of IL-21 by APCs regulates 
differentiation of follicular helper T (Tfh) cells that regulate antigen-specific B cell 
development. Finally, TGF-β, retinoic acid (RA), and IL-2 induce differentiation of 
regulatory T (iTreg) cells that down-regulate the inflammatory response to limit 
tissue damage. Other types of Th cells may exist, such as the recently discovered 
Th9 and Th22, but their identity as distinct subtypes has yet to be confirmed 
(Medzhitov, 2007; Zhou et al., 2009). 
The adaptive immune response is thus tightly controlled by APCs, which in turn are 
tightly regulated by pathogen recognition by PRRs. It is thus clear that specificity of 
PRR-induced signals is critical, and a detailed understanding of the molecular 
mechanisms by which this specificity is achieved is important not only to 
understand microbial infection and inflammation-driven disease processes (Cook 
et al., 2004), but also tolerance to the symbiotic microflora (Rakoff-Nahoum et al., 
2004). 
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Figure 1.6 Differentiation of CD4
+
 T cells. 
Antigen-presenting cells (APCs) of the innate immune system, such as dendritic cells and 
macrophages, secrete cytokines to instruct the differentiation of naive CD4+ T cells into T helper 
(Th)1, Th2, Th17, regulatory T cells (iTreg), and follicular T helper (Tfh) cells. The cytokines 
secreted by APCs are regulated by pattern recognition receptors (PRRs), such as toll-like receptors 
(TLRs), which specifically recognise microbial products. Interferon (IFN)-γ and interleukin (IL)-12 
induce differentiation of Th1 cells, and IL-4 of Th2 cells. IL-6 and transforming growth factor (TGF)-
β regulate differentiation of Th17, and TGF-β, retinoic acid (RA), and IL-2 of iTreg cells. IL-21 is 
important for Tfh differentiation. The differentiation of these T cell subtypes is regulated by specific 
transcription factors, including T-bet for Th1, GATA3 for Th2, RORγt for Th17, and Foxp3 for iTreg. 
It is now thought that some T cell types can convert to other subtypes in response to cytokine 
stimulation. iTregs can convert to Th17 cells in the presence of IL-6 and IL-21, and also to Tfh cells 
under certain conditions. Th17 cells can convert into Th1 or Th2 cells when induced by IL-12 and 
IL-4 respectively. Th2 cells can also convert to Th9 cells in the presence of TGF-β, although it is not 
clear if Th9 cells are a distinct subtype. Figure from (Zhou et al., 2009). 
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1.2.2 Toll-Like Receptor Signalling 
The existence of PRRs was predicted in 1989 by Janeway, who argued that 
beyond the specific recognition of self versus non-self antigens afforded by clonally 
distributed antibodies, a mechanism of pathogen recognition must exist that directs 
the adaptive immune system to mount an appropriate response against specific 
types of pathogens (Janeway, 1989). At the time, it was known that antigen 
recognition by T cells in the absence of co-stimulation by APCs inactivates mature 
T cells (Jenkins and Schwartz, 1987), and Janeway proposed that the expression 
of co-stimulatory molecules by APCs was regulated by PRRs that recognised 
pathogen-associated molecular patters (PAMPs) (Janeway, 1989). The first PRR 
was discovered in 1996, when the Drosophila protein toll was shown to mediate 
immunity against fungal infections (Lemaitre et al., 1996), and in 1997Janeway’s 
group showed that TLR4, the human homologue of Drosophila toll, regulates 
expression of inflammatory cytokines and B7 costimulatory molecules required for 
T cell activation, thus confirming Janeway’s initial prediction (Medzhitov et al., 
1997). 
To date, there are 12 known functional TLRs in mammals that exist as homo- or 
heterodimers. TLRs 1-10 have been identified in humans, and TLRs 1-9 and 11-13 
in mice. Of these, TLRs 1, 2, 4, 5, 6, and 11 are cell surface receptors, and TLRs 
3, 7, 8, and 9 are expressed in intracellular vesicles, which is necessary for their 
recognition of microbial nucleic acids. TLR4 is unique in that it activates two 
separate pathways through sequential signalling from the cell surface and 
endosomes (Kagan et al., 2008). Most cell surface TLRs recognise a variety of 
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microbial molecules, although heterodimers consisting of TLR2 in combination with 
TLR1 or TLR6 specifically recognise lipids. The ligands of human TLR10 and 
murine TLRs 12 and 13 are not known (Akira et al., 2006). 
All TLRs activate signalling through their Toll/IL-1 receptor (TIR) domain, which is 
shared with the IL-1 receptor family, as are many of the downstream signalling 
components. TLR pathways are normally divided into two branches, depending on 
the receptor proximal TIR domain-containing adaptors that are utilised to activate 
downstream signalling (Figure 1.7): the myeloid differentiation response gene 
(MyD)88-dependent pathway is utilised by all TLRs except TLR3, and the MyD88-
independent pathway requiring TIR-domain-containing adaptor-inducing interferon-
β (TRIF) is utilised by TLR3 and TLR4. Two further TIR domain adaptors link 
between the receptor and MyD88 or TRIF: TIR-domain-containing adaptor protein 
(TIRAP)/ MyD88 adaptor-like (MAL) connects TLRs 1, 2, 4, and 6 to MyD88, and 
TRIF-related adaptor molecule (TRAM) connects TLR4 to TRIF. The two branches 
initiate separate signalling cascades: the MyD88-dependent pathway activates 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
mitogen-activated protein (MAP) kinases, resulting in expression of pro-
inflammatory cytokines including tumour necrosis factor (TNF)-α and IL-1, and the 
TRIF-dependent pathway activates NF-κB and interferon-regulatory factor (IRF)3, 
resulting in expression of type 1 IFNs including IFN-β (Akira et al., 2001). TLR4, 
the receptor for lipopolysaccharide (LPS), is the only TLR that signals through both 
MyD88 and TRIF. The TLR4 pathway is also the best characterised and involves 
all of the main signalling components utilised by other TLRs, although cell type 
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specific differences exist. TLR4 is thus frequently used as a model system to study 
TLR signalling. 
 
 
Figure 1.7 Toll-like receptor signalling pathways in macrophages and dendritic cells. 
Toll-like receptors (TLRs) are localised either on the cell surface (dimers of TLR2 and TLR1 or 
TLR6, TLR4, TLR5, and TLR11) or in endosomes (TLR3, TLR7, and TLR9). Intracellular TLRs are 
sequestered in the endoplasmic reticulum and delivered to endosomes by the transporter UNC-
93B. With the exception of TLR3, all TLRs signal via the adaptor MyD88, and TLR1, TLR2, TLR4, 
and TLR6 additionally require the adaptor TIRAP to recruit MyD88. TLR3 and TLR4 signal via the 
adaptor TRIF, and TLR4 requires the adaptor TRAM to recruit TRIF. TRIF-dependent signalling of 
TLR4 occurs in endosomes (not shown). In the MyD88-dependent pathway, transcription of 
inflammatory genes induced by NF-κB and MAP kinases is activated through IRAK kinases, 
TRAF6, TAK1, and the IKK complex. In the TRIF-dependent pathway, NF-κB and MAP kinases are 
activated through TRAF6 and RIP1, and transcription of type 1 interferons (IFNs) is activated 
through TRAF3, TBK1/ IKKi, and IRF3 and IRF7. TLR 7 and TLR9 signal solely through MyD88 and 
activate NF-κB and MAP kinases via IRAK kinases, TRAF6, TAK1, and the IKK complex, and 
activate IRF7 via TRAF3, IRAK kinases and IKKα. Figure from (Kumar et al., 2009). 
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1.2.2.1 The TLR4 Pathway 
The main TLR4 ligand is LPS, or endotoxin, which is an essential component of the 
cell wall of Gram-negative bacteria, illustrating the principle that TLRs and other 
PRRs generally recognise molecules that are essential for a microbe’s survival and 
therefore cannot be subject to spontaneous mutation. LPS is structurally diverse 
between bacterial strains and consists of an O antigen, core polysaccharide, and a 
glycophospholipid known as lipid A, which is the main part of the molecule 
recognised by TLR4 (Beutler and Rietschel, 2003). TLR4 is abundantly expressed 
on monocytes and macrophages,  and their over-activation can result in systemic 
inflammation and septic shock (Guha and Mackman, 2001). Other ligands of TLR4 
include envelope proteins from respiratory syncytial virus (RSV) and mouse 
mammary tumour virus (MMTV), and endogenous molecules, often associated with 
cell or tissue damage, such as fibrinogen and heat shock protein (HSP) 60 and 
HSP70 (Akira et al., 2006). LPS does not activate TLR4 directly, but binds to 
soluble LPS binding protein (LBP) in the blood stream, is taken up by CD14 on the 
cell membrane of monocytes and transferred to the lymphocyte antigen 96 (MD2)/ 
TLR4 complex, where it binds the leucine-rich repeat (LRR) motif of the receptor, 
resulting in receptor dimerisation and activation of signal transduction (Palsson-
McDermott and O'Neill, 2004). 
TLR4 signals in two phases: the MyD88-dependent pathway is initiated from the 
cell surface, and is followed by receptor internalisation and activation of TRIF-
dependent signalling from endosomes (Kagan et al., 2008). For MyD88-dependent 
signalling, dimerised TLR4 recruits MyD88 via TIRAP, and MyD88 binds serine/ 
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threonine kinases of the IL-1 receptor-associated kinase (IRAK) family through 
interaction with their death domains (DD). IRAK4 sequentially phosphorylates and 
activates IRAK1 and IRAK2, and there is evidence that IRAK4 and IRAK1 
phosphorylate TIRAP, resulting in its K48-linked polyubiquitin-dependent 
degradation by the proteasome, thus forming a negative feedback loop that limits 
MyD88-dependent signalling (Dunne et al., 2010) (note: ubiquitin subunits can be 
attached via several lysine (K) residues: linkage via K48 results in proteasomal 
degradation, whereas K63 linkage enables binding of other signalling proteins). 
Activated IRAKs associate with TNF receptor-associated factor (TRAF)6, which 
has (E3) ubiquitin ligase activity and in collaboration with (E2) ubiquitin conjugating 
enzymes UBC13 and UEV1A autocatalyses its K63-linked polyubiquitination. 
TRAF6 auto-ubiquitination generates an unconjugated free K63 polyubiquitin chain 
that recruits the kinase TGF-β-associated kinase (TAK)1 together with TAK1 
binding protein (TAB)1, TAB2, and TAB3, and the association of these proteins is 
critical for activation of the NF-κB pathway. Dimers of NF-κB transcription factors 
are sequestered in the cytoplasm by inhibitor of NF-κB (IκB) proteins. IκBs are 
phosphorylated by the IκB kinase (IKK) complex, which consists of IKK1, IKK2, and 
NF-κB essential modulator (NEMO), and phosphorylation of IκBs results in their 
K48-linked polyubiquitination and proteasomal degradation, thus releasing NF-κB 
transcription factors. The IKK complex is activated through K63 polyubiquitination 
of NEMO by TRAF6 and phosphorylation of IKK2 by TAK1. IKK2 then 
phosphorylates IκBα and the ‘atypical’ IκB p105 at a conserved motif, resulting in 
their K48-linked polyubiquitination and degradation, thus enabling nuclear 
translocation of NF-κB transcription factors. In parallel, the MAP kinases are 
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activated by two pathways: TAK1 phosphorylates MAP kinase kinase (MKK)6, 
which activates c-Jun N-terminal kinase (JNK) and p38, and degradation of p105 
frees the kinase tumour progression locus (TPL)2 to phosphorylate MKK1 and 
MKK2, which in turn phosphorylate and activate extracellular signal-regulated 
kinase (ERK) (Beinke and Ley, 2004). Furthermore, TRAF6 in association with 
MyD88 activates IRF-5, which together with NF-κB and MAP kinase-regulated 
transcription factors of the activator protein (AP)-1 family induces expression of 
cytokines, chemokines, inflammatory mediators, and also negative regulators of 
TLR signalling that limit the inflammatory response (Kawai and Akira, 2010). 
Following activation of the MyD88-dependent pathway, the TLR4/ MD2/ LPS 
complex is internalised and TRIF-dependent signalling is initiated from early 
endosomes (Kagan et al., 2008). TLR4 recruits TRIF via TRAM, and TRIF 
associates with TRAF3 and TRAF6, and also with the serine/ threonine kinase 
receptor-interacting protein (RIP)1. TRAF3 activates the IKK related kinases 
TANK-binding kinase (TBK)1 and IKKi that phosphorylate and activate IRF-3, 
which translocates to the nucleus to induce transcription of IFN-β and other 
interferon-inducible genes important for the antiviral response. TRAF6 and RIP1 
activate the TAK1 complex, resulting in activation of the NF-κB and MAP kinase 
pathways in a similar manner to the MyD88-dependent pathway but with delayed 
kinetics (Kawai and Akira, 2010), which may account for different gene expression 
patterns between the pathways. TLR4 signalling is terminated by TRAM adaptor 
with GOLD domain (TAG), a splice variant of TRAM that inactivates TRIF-
dependent signalling and promotes degradation of TLR4 in late endosomes 
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(Palsson-McDermott et al., 2009). The requirement for internalisation of TLR4 prior 
to signalling via TRIF is thought to arise from the TRAF3-dependence of this 
pathway: TRAF3 does not localise to the plasma membrane, and as a result all 
TLRs that active IFN expression (TLRs 3, 4, 7, and 9) signal from endosomal 
locations (Kagan et al., 2008). The location of TLRs may also dictate their 
requirement for the sorting-adaptors TRAM and TIRAP, which recruit cytosolic 
TRIF and MyD88 to the plasma membrane, respectively. A bipartite motif of TRAM 
regulates its trafficking between the plasma membrane and endosomes, which 
enables TLR4 to recruit TRIF (Kagan et al., 2008), and TIRAP contains a pleckstrin 
homology (PH) domain that interacts with phosphatidylinositol 4,5-bisphosphate 
(PIP2) at the plasma membrane and enables TLR2 and TLR4 to recruit MyD88 
(Kagan and Medzhitov, 2006). However, TLR5 and TLR11 are also located at the 
plasma membrane and do not require TIRAP, and other sorting adaptors may exist 
that recruit MyD88 to these TLRs. Likewise, as yet undiscovered sorting-adaptors 
may be required to recruit MyD88 to endosomal TLRs and TRIF to TLR3 
(Fitzgerald and Chen, 2006). 
1.2.3 How Does Toll-Like Receptor Specificity Arise? 
Shared signalling mechanisms enable all TLRs to induce inflammatory response 
genes via the NF-κB and MAP kinase pathways, and the subset of endosomal 
TLRs all activate transcription of IFNs and IFN-inducible genes via the IRF 
pathway, posing the question how TLR-specific responses are achieved. 
Comparison of microarray datasets has shown that a core group of genes is 
induced by all TLRs in a cell type-specific manner and that these genes are 
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predominantly regulated by NF-κB (Jenner and Young, 2005), but TLR-specific 
induction of NF-κB-dependent genes has also been shown (Huang et al., 2001). 
Similarly, a recent study employed short hairpin RNAs (shRNAs) to systematically 
perturb regulators of transcriptional programs downstream of TLRs 2, 3, 4, 7, and 9 
in primary murine DCs, and discovered that groups of NF-κB dependent pro-
inflammatory genes and IRF-dependent antiviral response genes clustered 
according to cell-surface and endosomal pathways, respectively, but also observed 
TLR-specific responses (Amit et al., 2009). The continuing discovery of both known 
and novel TLR signalling proteins that are regulated by post-translational 
modifications suggests that these modifications are critical for TLR specificity. The 
interplay between different TLRs and interactions with other PRRs, such as NOD-
like receptors (NLRs), is probably also regulated by post-translational modification 
and may be important in shaping TLR signalling (Takeuchi and Akira, 2010). 
Therefore, if the complexity of TLR signalling is to be understood, purely genomic 
approaches cannot be sufficient and must be complemented by unbiased 
proteomics approaches that have the ability to characterise regulation at the post-
transcriptional level. 
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1.3 Aims of This Work 
Toll-like receptors (TLRs) are important regulators of innate and adaptive immunity 
with functions in human health and disease, yet it is not known how TLR-specific 
regulation is achieved. It is likely that post-translational modifications, in particular 
phosphorylation, of known and uncharacterised signalling proteins contribute to 
TLR specificity. The aim of this work was to discover uncharacterised 
phosphorylations in a model system of TLR4 signalling in macrophages. Specific 
aims were: 
1. To develop a mass spectrometry-based methodology for the large-scale 
identification of phosphorylation sites from cultured cells 
2. To conduct a phosphoproteomics screen of LPS-stimulated macrophages to 
identify novel regulatory phosphorylations 
3. To independently validate and characterise a proposed regulatory 
phosphorylation 
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2.1 Materials 
2.1.1 Chemicals 
Standard laboratory chemicals were from BDH Chemicals. All other reagents were 
from Sigma-Aldrich unless otherwise stated, and were of the highest grade 
available. 
2.1.2 Antisera 
Antibody dilutions and product codes are given in brackets. Primary antibodies 
used for immunoblotting were: from Cell Signaling Technology, anti-phospho-ERK 
(1/2000; 9101L), anti-phospho-JUN (1/2000; 9261), and anti-p105 (1/1000; 4717); 
anti-p38 antibody was prepared in-house (1/1000; SAK7 (Finch et al., 1997)). 
Secondary horse radish peroxidase (HRP)-conjugated antibodies (1/2000) were 
from Dako. FLAG-fusion proteins were immunoprecipitated with anti-FLAG M2 
affinity gel (20 µl ml-1; A2220) and immunoblotted with anti-FLAG M2 HRP-
conjugate (1/10,000; A8592), both from Sigma. TNF-α neutralisation was 
performed with anti-mouse TNF-α antibody (100 µg ml-1; TN3-19.12, Leinco 
Technologies). 
The antibody against p105 phosphorylated at S937 (human)/ S940 (mouse) 
(1/1000) was generated by Eurogentec using their 28-day Super Speedy 
polyclonal antibody protocol. The peptide immunogen (RKLphosphoSFTESLT) 
was conjugated with keyhole limpet haemocyanin (KLH) and injected into two 
rabbits, with boosting injections after 7, 10, 21, and 28 days. Antibody titres in final 
bleeds were determined by enzyme-linked immunosorbent assay (ELISA). 
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Antibodies from one rabbit were purified by affinity chromatography with positive 
selection against the phosphorylated immunogen, followed by negative selection 
against the non-phosphorylated counterpart. 
2.1.3 Plasmids 
The eukaryotic expression vector p105pcDNA3FLAG was a gift from Prof. C. 
Scheidereit (Max Delbrück Centrum, Berlin, Germany). The vector contains the 
human p105 sequence with N-terminal FLAG-tag ligated into a 5’HindIII/ 3’XhoI 
site.  A point mutation in the p105 sequence (S937 → A937; S937A) was 
generated by the following procedure, using kits from Qiagen and Stratagene 
according to the manufacturers’ instructions. All primers were synthesised and 
sequencing performed by MWG. The p105pcDNA3FLAG plasmid was digested 
with HindIII and XhoI (New England Biolabs). The 5’-FLAG-p105-3’ fragment was 
purified by gel electrophoresis using a QIAquick Gel Extraction Kit (Qiagen), ligated 
into a pCR2.1 TOPO vector (Invitrogen), and transformed into TOP 10 competent 
cells (Invitrogen). Plasmid DNA was prepared using a Plasmid DNA Purification Kit 
and QIAprep Spin Miniprep Kit (both from Qiagen). Restriction digests were 
performed to identify positive clones and to check the orientation of the insert. Site 
directed mutagenesis was carried out using a Quick Change II Site-Directed 
Mutagenesis Kit (Stratagene) to generate the S937A point mutation. The primers 
used were: 
Forward: 5'-ACATCCTTCCGCAAACTCGCCTTTACCGAGTCTCTGAC-‘3 
Reverse: 5'-GTCAGAGACTCGGTAAAGGCGAGTTTGCGGAAGGATGT-‘3 
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Plasmid DNA was transformed into XL1-Blue Supercompetent cells (Stratagene) 
and spread onto LB-Ampicillin plates. Three colonies were selected and plasmid 
DNA was prepared as described. DNA sequencing was performed to validate the 
presence of the mutation using the primer 5’-TTAATAATGCCTTCCGGCTG-‘3. 
Plasmid DNA was digested with HindIII and XhoI to isolate the 5’-FLAG-p105-‘3 
fragment, which was purified as described. The fragment was ligated into the 
pCDNA3 vector (Invitrogen) via 5’HindIII/ 3’XhoI sites and transformed into TOP 10 
competent cells. Plasmid DNA was prepared and restriction digests were 
performed as described, followed by large-scale preparation using a Plasmid Maxi 
Prep Kit (Qiagen). This work was performed by Dr. A. Lanfrancotti and Mrs S. 
Begum (Kennedy Institute). 
2.2 Methods 
2.2.1 Proteomics 
2.2.1.1 In-Solution Digestion 
Protein stock solutions were prepared at 100 µM in 0.1% formic acid (FA) and 
stored at -20 °C. Following dilution with 50 mM ammonium bicarbonate/ 10% 
acetonitrile (ACN), proteins were reduced with 5 mM dithiothreitol (DTT; Alexis 
Biochemicals) for 1 h at 56 C, alkylated with 15 mM iodoacetamide (IAM) for 30 
min in the dark, and the reaction was quenched with 5 mM DTT for 15 min. 
Proteins were digested overnight at 37 C with sequencing grade modified porcine 
trypsin (Promega) at 20 µg trypsin per mg protein. Digests were acidified to pH 3 
with acetic acid (verified by pH strip; Panpeha, Whatman), lyophilised (Edwards 
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Modulyo), and stored at -20 °C. Digestion of lysates in 8 M urea buffer was 
performed in the same way, except that alkylation was at 37 C and lysates were 
diluted with four volumes of 25 mM ammonium bicarbonate prior to digestion with 
trypsin. 
2.2.1.2 In-gel Digestion 
Laboratory-cast 10% acrylamide (Severn Biotech) preparative gels (150 x 150 x 
1.5 mm) were run until the dye-front had migrated 5 cm into the gel and stained 
with Coomassie Brilliant Blue. Gels were cut into twelve horizontal strips, and each 
strip was cut into 1 mm3 cubes and in-gel digested as described by Shevchenko 
but with larger volumes (Shevchenko et al., 1996). Alternatively, in-gel digestion 
was performed using a ProGest Protein Digestion Station (Genomic Solutions) 
using an optimised digestion protocol. 
2.2.1.3 Phosphopeptide Enrichment by TiO2 Chromatography and IMAC 
For methods development, three published buffer systems were compared for TiO2 
chromatography (Olsen et al., 2006; Thingholm et al., 2006; Macek et al., 2007) 
and IMAC (Larsen et al., 2005; Raida et al., 2006; Bodenmiller et al., 2007). 
Digests were dissolved in binding buffer and incubated with 1 mg equilibrated TiO2 
(Titansphere, 5µm, Hichrom) or 10 µl equilibrated Fe3+-IMAC (PHOS-Select, 
Sigma) for 30 min in microfuge tubes with shaking, and transferred to pipette tips 
(GELoader, Eppendorf) fritted with C8 membrane disks (Empore, 3M) (Larsen et 
al., 2005), where washing and elution was performed using air pressure applied 
with a 1 ml disposable syringe (Terumo). Eluates were acidified to pH 2 with acetic 
acid and lyophilised. For large-scale experiments using a published buffer system 
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(Thingholm et al., 2006), 2.5 mg TiO2 was used per in-gel digested slice of a 
preparative gel, or per 100 µg of in-solution digested protein from cell lysate. 
Digests were dissolved in binding buffer and incubated with equilibrated TiO2 for 30 
min in microfuge tubes with shaking, and transferred to fritted spin columns 
(Mobicol, Mobitech). For washing and elution, TiO2 resin was repeatedly 
suspended using a pipette, followed by centrifugation at 6000 x g for 10 seconds. 
Eluates were acidified to pH 2 with acetic acid and lyophilised.  
2.2.1.4 Desalting of Peptides 
Digests were desalted using C18 cartridges of different capacities, depending on 
the amount of peptide: up to 10 µg of peptides were desalted on C18 STAGE tips 
(200 µl tip, Proxeon), up to 300 µg on Sep-Pak 1cc cartridges, and greater 
amounts on Sep-Pak Plus cartridges (both Waters). Digests were acidified with 
trifluoroacetic acid (TFA), and loaded onto the cartridges, washed with 0.1% TFA, 
and eluted with 80% ACN/ 0.1% TFA by applying air pressure with a disposable 
syringe. 
2.2.1.5 iTRAQ Labelling 
Digests were desalted as described and labelled with four-plex iTRAQ reagents 
(Applied Biosystems) according to the manufacturer’s instructions. 
2.2.1.6 Off-Line HPLC 
Peptides were dissolved in 0.1% TFA and separated by high performance liquid 
chromatography (HPLC) on a SMART-system equipped with a 2.1 x 100 mm C2/ 
C18 column (Amersham). Peptides were eluted with a 60 min ACN/ 0.1% TFA 
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gradient at a flow rate of 150 µl min-1 and the SMART-system was set to 
automatically collect 36-48 fractions in 500 µl microfuge tubes. Solvent was 
evaporated from the fractions using a Speed Vac concentrator (Labconco), 
followed by lyophilisation. 
2.2.1.7 QTOF Mass Spectrometry 
The QTOF mass spectrometer was interfaced to a CapLC capillary chromatograph 
(both Waters). Samples were dissolved in 0.1% FA, and 6 µl were injected onto a 
Pepmap C18 column (300 µm x 0.5 cm; LC Packings) and washed for 3 min with 
0.1 % FA. The flow rate was then reduced to 1 µl min-1 and the peptides were 
eluted into the mass spectrometer with an ACN / 0.1% FA gradient (5% to 70 % 
ACN over 20 minutes).  
The capillary voltage was usually 3100 to 3500 V, and data-dependent MS/MS 
acquisitions using argon collision gas were performed on precursors with charge 
states of 2, 3, or 4 over a survey m/z range 350-1400. The collision voltage was 
varied between 18 and 45 V, depending on the charge and mass of the precursor, 
using empirically determined values in a look up table. Up to three peptides from 
each survey were automatically selected for data-dependent MS/MS analysis if 
their intensity exceeded 15 counts s-1. Both survey and MS/MS scans were of 1 s 
duration, and the instrument returned to survey scanning when the signal level 
dropped to 1 count s-1, or after 7 s if sooner. Known trypsin autolysis products and 
keratin-derived precursor ions were automatically excluded using an exclusion list. 
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The resulting product ion spectra were transformed onto a singly charged m/z axis 
using a maximum entropy method (MaxEnt3) as implemented in the MassLynx 
module peptide auto (Waters), and the values were written to a text file in pkl 
format for subsequent submission to Mascot. QTOF mass spectrometry was 
performed in collaboration with Dr R. Wait (Kennedy Institute). 
2.2.1.8 LTQ-Orbitrap Mass Spectrometry 
The LTQ-Orbitrap XL mass spectrometer was interfaced to a MicroAS autosampler 
with Accela pump (both Thermo Fisher Scientific). Peptides were dissolved in 
aqueous 0.1% FA and injected onto a trap column (CapTrap, Michrom 
Bioresources). Peptide separation was performed on a C18 (Reprosil) 100 µm x 15 
cm packed electrospray capillary column (Nikkyo Technos).  Flow was passively 
split from 200 µl min-1 to 200 nl min-1 using a T-piece and peptides were eluted with 
a 120 min ACN/ 0.1% FA gradient directly into the mass spectrometer. A survey 
scan in the orbitrap at a resolving power of 60,000 (at m/z 400) over the m/z range 
300-1800 was used to identify protonated peptides with charge states of 2 or 
greater. Up to five peptides were automatically selected for data-dependent 
MS/MS analysis if their intensity exceeded 1000 counts s-1, and fragmented in the 
linear ion trap by collision with helium. iTRAQ-labelled peptides were fragmented in 
the HCD collision cell by collision with nitrogen and product ions were measured in 
the orbitrap at a resolving power of 7500 (at m/z 400). Known trypsin autolysis 
products and keratin-derived precursor ions were automatically excluded using an 
exclusion list. LTQ-Orbitrap mass spectrometry was performed by Dr J. Ho 
(Thermo Fisher Scientific, Hemel Hempstead). 
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2.2.1.9 Protein Database Searches 
Uninterpreted tandem mass spectra were searched against entries in the Swiss-
Prot database (version 58_11 or earlier) using Mascot, version 2.2.04 
(www.matrixscience.com) (Perkins et al., 1999). Two missed tryptic cleavages per 
peptide were allowed, with carbamidomethylation of cysteine residues as fixed 
modification, and oxidation of methionine and phosphorylation of serine, threonine, 
and tyrosine residues as variable modifications. For QTOF data the precursor and 
fragment ion mass tolerances were set to 50 ppm and 0.6 Da, and for LTQ-
Orbitrap data to 5 ppm and 0.6 Da, respectively. False discovery rates were 
determined from searches against a decoy database at a 5% probability of a 
random match. 
Spectra of iTRAQ-labelled peptides were searched with carbamidomethylation of 
cysteine, and iTRAQ-labelling of lysine residues and peptide N-termini as fixed 
modifications; for phosphopeptide-enriched samples, additional variable 
modifications were oxidation of methionine and phosphorylation of serine, 
threonine, and tyrosine residues. The precursor and fragment ion mass tolerances 
were set to 5 ppm and 0.05 Da, respectively. Peptide quantitation was performed 
in Mascot, applying minor correction for isotope impurity associated with the iTRAQ 
reagents according to data supplied by the vendor (Applied Biosystems).  
Mascot output files were further processed with Scaffold, version 2.06.01 
(Proteome Software). Validation was restricted to the peptide level by setting the 
protein probability to the minimal value. The peptide probability was set to 95%. 
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2.2.1.10 Spectral Interpretation 
Peptide sequences matched to tandem mass spectra were interrogated by manual 
comparison of the tandem mass spectra with predicted product ion masses using 
the MS-Product component of ProteinProspector (http://prospector.ucsf.edu), and 
product ion intensities were assessed according to published criteria (Wysocki et 
al., 2000; Steen and Mann, 2004; Medzihradszky, 2005; Tabb et al., 2006). 
Tandem mass spectra were displayed in Scaffold, and image files were exported 
and further annotated using PowerPoint 2007 (Microsoft). 
2.2.1.11 Gene Ontology Analysis 
Enrichment analysis using tools from the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) (Dennis et al., 2003) and retrieval of annotations 
using GORetriever (McCarthy et al., 2006) were carried out using default settings. 
2.2.2 Cell Biology 
2.2.2.1 Cell Culture 
Cell-lines were stored in liquid nitrogen. Cells were grown as monolayer cultures in 
a humidified 5% CO2 incubator at 37 °C. Cell-lines were not maintained beyond 20 
passages. All reagents were from PAA unless otherwise stated. HTB94 cells 
(ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 25 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 
supplemented with 10% fetal calf serum (FCS; Gibco), penicillin (100 IU ml-1), and 
streptomycin (100 µg ml-1). RAW 264.7 cells (ATCC) were cultured in the same 
way, but DMEM was from Lonza and FCS from Biosera. HEK293–TLR4-
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CD14/MD2 cells (Invivogen) were grown in DMEM/ 25 mM HEPES/ 10% FCS 
supplemented with 10 mg ml-1 blasticidin and 50 mg ml-1 hygromycin B (both from 
Invivogen). Human skin fibroblasts (HSFs) were a gift from Dr G. Ryzhakov 
(Kennedy Institute) and were cultured under the conditions described for HTB94 
cells; HSFs were not maintained beyond 12 passages. 
Enriched populations of human monocytes were obtained from the blood of healthy 
donors (buffy coats) by Ficoll-Hypaque centrifugation and monocyte separation in a 
Beckman GEL elutriator. Monocyte purity was assessed by flow cytometry using 
directly conjugated anti-CD45 and anti-CD14 antibodies and was typically greater 
than 80%. Monocyte-derived macrophages (MDMs) were obtained after 5 days of 
culturing human monocytes with 100 ng ml-1 macrophage colony-stimulating factor 
(M-CSF; Peprotech) in Roswell Park Memorial Institute (RPMI) 1640 medium 
containing 10% FCS (Biosera) and supplemented with penicillin (100 IU ml-1) and 
streptomycin (100 µg ml-1). Preparation of MDMs was performed by Dr M.J. Peirce 
and members of the Udalova and Foxwell groups (Kennedy Institute). 
2.2.2.2 Transfection 
HEK293-TLR4-CD14/MD2 cells were transiently transfected using Lipofectamine 
(Invitrogen), and RAW 264.7 cells were transfected using the Amaxa Nucleofector 
system (Amaxa Biosystems) according to the manufacturers’ instructions. Stable 
RAW cell transfectants were selected in the presence of 750 µg ml-1 G418 
(Invitrogen) for 2–3 weeks. 
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2.2.2.3 Stimulation and Kinase Inhibition 
LPS from Escherichia coli was from Invivogen. Poly(inosine:cytosine) (Invivogen) 
and Pam3CSK4 (Alexis Biochemicals) were free of detectable LPS according to the 
Limulus amebocyte lysate (LAL) assay (QCL-1000 Chromogenic LAL Endpoint  
Assay, Cambrex; performed by Mr Sunil R. Modi, Kennedy Institute). Human and 
mouse IL1-β and TNF-α (both Peprotech) and prostaglandin E2 (Sigma) where 
prepared according to the manufacturers’ instructions. The kinase inhibitor H89 
was a gift from Dr R.O. Williams (Kennedy Institute). Reagents were added to cell 
cultures either directly or diluted with serum-free culture medium. 
2.2.2.4 Phosphatase Inhibitor Treatment 
Pervanadate (1 mM Na3VO4/ 50 µM H2O2) and calyculin A (100 nM; Cell Signaling 
Technology) were added to adherent cell cultures, followed by incubation for 5-10 
min. 
2.2.2.5 Lysis 
Adherent cells were scraped into ice-old lysis buffer, incubated with shaking for 20 
min at 4C, and nucleic acids and cell debris were removed by centrifugation at 
13,000 x g for 20 min at 4 C. Lysis buffers were: 
Radio-immunoprecipitation assay (RIPA) buffer: 20 mM Tris-HCl (pH 7.4), 5 mM  
EDTA, 150 mM NaCl, 1% w/v deoxycholate, 0.1% w/v SDS, 1% w/v Triton X-100. 
Modified RIPA buffer: 20 mM Tris-HCl (pH 7.4), 5 mM EDTA, 150 mM NaCl, 1% 
w/v deoxycholate, 0.1% w/v SDS, and 1% w/v NP-40. 
8 M urea buffer: 50 mM Tris-HCl (pH 7.4), 8 M urea, and 75 mM NaCl. 
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All lysis buffers were supplemented with 1% v/v protease inhibitor cocktail (Sigma) 
and phosphatase inhibitors (100 nM calyculin A, 1 mM NaF, 1 mM β-
glycerophosphate, 1 mM Na3VO4, and 10 mM sodium pyrophosphate).  
For lysis buffer comparison, HTB94 cells were lysed with modified RIPA buffer, 8 M 
urea buffer, or TRI Reagent (Ambion) according to the manufacturer’s instructions. 
For phosphoproteomics experiments, HTB94 and RAW 264.7 cells were lysed with 
8M urea buffer. For immunoblotting and immunoprecipitation, cells were lysed with 
RIPA buffer. 
2.2.2.6 Immunoprecipitation 
Lysates were incubated with protein A-agarose beads (10 µl ml-1; P7786, Sigma) 
and rabbit serum (1 µl ml-1; Eurogentec) for 2 h at 4 C with end-over-end rotation. 
Supernatants were incubated in the same way with protein A-agarose beads and 
primary antibodies. Beads were washed 5 x with ice-cold RIPA buffer and eluted 
by boiling in Laemmli sample buffer for 5 min. Lysates from cells expressing FLAG-
fusion proteins were incubated with anti-FLAG M2 affinity gel (20 µl ml-1; A2220, 
Sigma) for 2 h at 4 C with end-over-end rotation, and beads were washed and 
eluted as above. 
2.2.2.7 Phosphatase Treatment 
FLAG-fusion proteins were immunoprecipitated as described. Prior to elution, 
beads were incubated for 2 h at 37 C with 5 U shrimp alkaline phosphatase 
(M820A, Promega) or protein phosphatase 2A (V631A, Promega) according to the 
manufacturer’s instructions. 
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2.2.2.8 SDS-PAGE 
Protein concentration was determined using the bicinchoninic acid (BCA) assay 
(Pierce). Lysates were boiled in Laemmli sample buffer for 5 min and separated by 
gel electrophoresis on NuPAGE Novex Bis-tris mini gels (10% or 8-12%, 1.5 mm) 
(Invitrogen). Precision Plus Protein All Blue Standards (Bio-Rad) were used as 
molecular weight markers.  
2.2.2.9 Peptide Competition Assay 
Stock solution of Phospho-S937/940 p105 antibody in phosphate buffered saline 
(PBS)/ 0.01% thimerosal/ 0.1% bovine serum albumin (BSA) was diluted 100-fold 
with Tris-buffered saline (TBS), and antibody at a concentration of 10 nM was 
incubated with 50-200-fold molar excess of peptide immunogens in a reaction 
volume of 1.2 ml for 1 h at room temperature. Immune complexes were removed 
by centrifugation at 13,000 x g for 10 min at 4 C prior to immunoblotting. 
2.2.2.10 Immunoblotting 
Proteins separated on mini gels were transferred onto polyvinylidene difluoride 
(PVDF) membranes (DuPont) using a Bio-Rad transfer system at 100V for 1.3 h. 
Membranes were washed with TBS/ 0.5% v/v Tween 20 (TBS-T), blocked in TBS-
T/ 5% w/v dry non-fat milk (Tesco) for 1 h, washed for 5 min with TBS-T, incubated 
with primary antibody in TBS-T/ 5% w/v BSA for 1 h (or overnight at 4C), washed 
3 x 5 min with TBS-T, incubated with secondary HRP-conjugated antibody in 
blocking buffer for 1 h, and washed 3 x 5 min with TBS-T. Membranes were 
developed using an enhanced chemiluminescence (ECL) detection system (GE 
Healthcare) and Fuji imaging film. For re-blotting with a different antibody, 
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membranes were incubated with Re-Blot Plus stripping solution (Millipore) for 20 
min and washed with TBS-T for 5 min, and blocking and all other steps were 
performed as described above. 
2.2.2.11 Densitometry 
Immunoblots were quantified by scanning films on an ImageScanner III using 
Labscan 6.0 software (GE Healthcare) and measuring the relative optical density 
(ROD) of bands using Phoretix 1D, version 2003.02 (Nonlinear Dynamics). ROD 
measurements from treated cells were normalised to the loading control and 
expressed as fold-changes over untreated cells. 
2.3 Data Manipulation and Presentation 
Scaffold and Mascot reports were exported to Excel 2007 (Microsoft) and 
manipulated using logical functions. Venn diagrams were created with 
VennDiagramPlotter (http://omics.pnl.gov/software/VennDiagramPlotter.php) and 
VENNY (Oliveros, 2007). Graphs and charts were prepared in Excel or GraphPad 
Prism (GraphPad Software). All statistical analyses were performed in GraphPad 
Prism. 
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3.1 Introduction 
The first aim of this work was to develop a phosphoproteomics methodology within 
the framework of existing equipment and facilities to enable the large-scale 
identification of phosphorylation sites from cultured cells. As this approach would 
be centred on phosphopeptide enrichment by manual chromatography, I first 
evaluated TiO2 chromatography and IMAC. Second, I developed a workflow 
incorporating sample preparation, fractionation, phosphopeptide enrichment and 
separation by off-line HPLC prior to LC-ESI-MS/MS. 
3.2 Evaluation of TiO2 and IMAC Chromatography for Phosphopeptide 
Enrichment 
3.2.1 Description of Test Sample and Enrichment Method 
The phosphopeptide enrichment procedure was optimised using a mixture of three 
phosphorylated (α-casein, β-casein, ovalbumin) and three non-phosphorylated 
proteins (BSA, carbonic anhydrase, β-lactoglobulin). Tryptic digestion of this 
mixture theoretically yields more than 30 phosphopeptides with up to five 
phosphate groups and 300 non-phosphorylated peptides (considering one missed 
tryptic cleavage), making it a suitable sample to test the enrichment efficiency of 
TiO2 chromatography and IMAC (Larsen et al., 2005). 
To test for protein purity and ensure that proteins had not been degraded during 
storage, an aliquot of each stock solution was separated by SDS-PAGE (Figure 
3.1). The bulk of protein material appeared as single bands at the expected 
molecular weight, but fainter bands of lower molecular weight were observed for 
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carbonic anhydrase, ovalbumin, and β-casein. As expected, doublets were 
observed for α-casein (consists of the subunits S1 and S2) and β-lactoglobulin 
(consists of the isoforms A and B). The quality of the protein stock solutions was 
deemed sufficient for the purposes of this study. 
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Figure 3.1 SDS-PAGE of protein stock solutions. 
Stock solutions of the phosphorylated proteins ovalbumin, α-casein, β-casein and the non-
phosphorylated proteins BSA, carbonic anhydrase, and β-lactoglobulin were prepared at 100 
µM in 0.1% formic acid and stored at -20 °C. Aliquots of 160 pmol were separated by SDS-
PAGE on a 10% mini gel and stained with Coomassie Brilliant Blue. 
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Manual chromatography is normally performed using pipette tip microcolumns or a 
batch loading approach. Microcolumns are prepared by placing a small frit (e.g. C8 
membrane) inside a pipette tip and packing the resin on top (Gobom et al., 1999) 
(Figure 3.2); alternatively, commercially available pipette tips for desalting can be 
used (Pozuelo Rubio et al., 2005). Solutions are applied to the top and forced 
through the column by applying air pressure with a syringe. However, it can be 
difficult to control the flow rate to ensure efficient loading, washing, and elution, 
which affects experimental repeatability. Also, the limited loading capacity of this 
approach hinders analysis of larger volumes if splitting the sample over several 
columns is to be avoided (Thingholm et al., 2006). An alternative approach is batch 
loading, where peptide solution is incubated with the resin in a microfuge tube for a 
set time, followed by transfer of the loaded resin to a fritted spin column for 
washing and elution (Gruhler et al., 2005) (Figure 3.2). The large volume of spin 
columns allows for scale-up, but is not suitable for small volumes of resin, which 
cannot be suspended efficiently in solution during the washing step. In this study, a 
hybrid approach was used: loading and washing were performed in a microfuge 
tube, spinning down the resin and carefully replacing solutions, which was followed 
by transfer of the resin to a pipette tip microcolumn for elution. This enabled use of 
a small elution volume, reducing the risk of adsorptive losses during drying down 
(Campbell and Morrice, 2002), while maximising repeatability of the loading and 
washing steps. Eluates were analysed by LC-ESI-MS/MS, and TOF-MS survey 
scans were summed over the peptide elution window. Efficiency of phosphopeptide 
enrichment was evaluated by comparing the relative intensities of the protonated 
molecules of phosphorylated and non-phosphorylated peptides.  
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Figure 3.2 Comparison of microcolumn and batch loading.  
Schematics of a TiO2 microcolumn, which is loaded, washed and eluted by forcing solutions 
through the column with air pressure, and the batch loading approach, in which loading in a 
microfuge tube is followed by transfer of the resin to a fritted spin column for washing and 
elution. 
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3.2.2 Comparison of Buffer Protocols for TiO2 and IMAC 
To choose an optimal buffer system for phosphopeptide enrichment by TiO2 
chromatography or IMAC, three published protocols were tested for each resin 
(Table 3.1). Because carboxylic acid groups can also bind to TiO2 and IMAC 
resins, loading and washing buffers must be of pH 2-3 to ensure complete 
protonation of carboxylic amino acid side chains (pKa ≥ 3.8) while leaving the 
phosphate groups (pKa ≤ 1.8) negatively charged (Larsen et al., 2005). For TiO2, 
protocol A used a loading buffer of pH 2, and protocols B and C of pH 2.5. For 
IMAC, all loading buffers were of pH 2.5 as the chemical integrity of the IMAC resin 
is compromised at lower pH. TiO2 loading buffers also contained phthalic acid, as 
TiO2 binds the hydroxyl groups of phthalic acid more strongly than carboxylic 
amino acid residues, but less strongly than phosphate groups, permitting 
preferential exclusion of non-phosphorylated peptides (Larsen et al., 2005). Elution 
buffers were highly alkaline (protocols A-E) or used buffer containing excess 
phosphate (protocol F) to displace bound phosphopeptides, and some contained 
organic solvent (protocols B, C, E) to reduce hydrophobic interactions.   
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Table 3.1 Enrichment protocols compared for TiO2 and IMAC 
  TiO2   IMAC  
Protocol A B C D E F 
Load 80% ACN        
2% TFA 
Phthalic 
acid 
80% ACN 
0.1% TFA 
Phthalic 
acid 
80% ACN 
0.1% TFA 
Phthalic 
acid 
30% ACN 
1.5% Acetic 
acid 
30% ACN 
1.5% Acetic 
acid 
30% ACN 
1.5% Acetic 
acid 
Wash 1 Loading 
buffer 
50% ACN         
0.2% TFA 
80% ACN 
0.1% TFA 
Loading 
buffer 
Loading 
buffer 
Loading 
buffer 
Wash 2 80% ACN 
0.1% TFA 
50% ACN 
0.2% TFA 
10% ACN 
0.1% TFA 
Loading 
buffer 
Loading 
buffer 
Loading 
buffer 
Wash 3 0.1% TFA  -    -  Loading 
buffer 
Loading 
buffer 
ddH2O 
Elute 1 NH4OH          
pH 10.5 
40% ACN 
NH4OH           
pH 10.5 
20% ACN 
NH4OH            
pH 10.5 
NH4OH           
pH 10.5 
30% ACN 
NH4OH               
pH 10.5 
50 mM 
Na2PO4       
pH 9a
 
Elute 2   40% ACN 
NH4OH             
pH 10.5 
 100 mM 
Na2PO4       
pH 9a
 
Published protocols are: A (Thingholm et al., 2006), B (Macek et al., 2007), C (Olsen et al., 
2006), D (Larsen et al., 2005), E (Raida et al., 2006), F (Bodenmiller et al., 2007). Phthalic acid 
solution was saturated. ACN; acetonitrile, TFA; trifluoroacetic acid. aEluates were desalted. 
 
  
95
Chapter 3                                                                                         Phosphoproteomics Methodology 
The six protocols were compared for the enrichment of 1.5 pmol of the peptide test 
mixture (Figure 3.3). Without enrichment, no phosphorylated peptides were 
detected (Figure 3.3,G). For TiO2, protocol A resulted in exclusive detection of 
phosphorylated peptides, whereas mostly non-phosphorylated peptides were 
detected from enrichment using protocols B and C (Figure 3.3, left pane). For 
IMAC, all protocols resulted in detection of mostly phosphorylated peptides, but the 
phosphopeptide signal intensity was highest using protocol A (Figure 3.3, right 
pane). Overall, protocols A and D showed the greatest selectivity and were also 
more efficient than the other protocols in their enrichment of doubly phosphorylated 
peptides. 
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Figure 3.3 Comparison of buffer protocols for TiO2 and IMAC. 
A mixture of three phosphorylated and three non-phosphorylated proteins (1.5 pmol each) was 
digested, enriched for phosphopeptides by TiO2 (A-C) or IMAC (D-F) using the protocols 
detailed in Table 3.1, and analysed by LC-ESI-MS. Singly and doubly phosphorylated peptides 
are marked with single or double asterisks, respectively (asterisks in brackets indicate the triply 
charged potassium adduct corresponding to the doubly charged phosphopeptide at m/z 1031). 
Without enrichment, no phosphopeptides were detected (G). Peptides were separated over a 20 
min chromatographic gradient. TOF-MS spectra were summed from 3-4 survey scans over the 
one-minute peptide elution window and normalised to an ion intensity of 250. A single 
experiment was performed in triplicates and representative spectra are shown. 
  
 
 
 
 
Figure 1. Comparison of buffer protocols for TiO2 and IMAC. Mass spectra 
obtained from a digest of three phosphorylated and three nonphosphorylated 
proteins (1.5 pm l each) enrich d by TiO2 or IMAC (batch loading) using the 
protocols detailed in Table 1. For TiO2, the best pr tocol (A) used 2% TFA
loading buffer, three washes, and elution buffer free of ACN. Loading buffer with 
0.1% TFA, two washes, and one step (B) or two step elution (C) with buffers 
containing ACN resulted in decreased detection of phosphopeptides. For IMAC, 
the best protocol (D) used elution buffer fr e f ACN. Elution buffer with 30% 
ACN (E) and a two step elution protocol using phosphate buffer (F) caused a 
decrease in enrichment efficiency.  Without enrichment no phosphopeptides 
were detected (G). Representative Tof-MS spectra from triplicate experiments 
were normalised to an ion intensity of 250. Singly and doubly phosphorylated 
peptides are marked with asterisks (asterisk in brackets indicates the triply 
charged potassium adduct corresponding to the doubly charged 
phosphopeptide at m/z 1031). ACN; acetonitrile, TFA; trifluoroacetic acid. 
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3.2.3 Comparison of the Performance of TiO2 and IMAC in the Presence of 
Excess Non-Phosphorylated Peptides 
The selectivity of protocols A for TiO2 and D for IMAC was tested further using 500 
fmol of phosphopeptides mixed with increasing concentrations of non-
phosphorylated peptides (Figure 3.4). For the equimolar mixture, at a three-fold 
lower concentration than the previous experiment (compare Figure 3.3, A & D), 
fewer phosphopeptides were detected from both TiO2 and IMAC enrichment, 
particularly doubly phosphorylated peptides (Figure 3.4, 1:1). IMAC enrichment 
was more compromised at the lower peptide concentration than TiO2, resulting in 
detection of only two phosphopeptides at low signal intensity. However, there was 
no increase in the number of non-phosphorylated peptides detected. Enrichment of 
phosphopeptides from 10-fold excess of non-phosphorylated peptides was similar 
to the equimolar mixture for both TiO2 and IMAC (Figure 3.4, 1:10). At 50-fold 
excess, no phosphopeptides were detected from IMAC enrichment (Figure 3.4, 
1:50). By contrast, TiO2 enrichment resulted in detection of phosphopeptides at 
lower signal intensity, but without an increase in the number of non-phosphorylated 
peptides detected. Consequently, TiO2 enrichment with buffer protocol A was used 
in all subsequent experiments.  
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Figure 3.4 Comparison of the performance of TiO2 and IMAC in the presence of excess non-
phosphorylated peptides. 
Digests of three phosphorylated proteins (500 fmol) and three non-phosphorylated proteins (500 
fmol; 1:1; 5 pmol; 1:10, 25 pmol; 1:50) were mixed, enriched for phosphopeptides, and analysed by 
LC-ESI-MS. Protocols detailed in Table 3.1 were A for TiO2 (left panels) and B for IMAC (right 
panels). Singly and doubly phosphorylated peptides are marked with single or double asterisks, 
respectively (asterisks in brackets indicate the triply charged potassium adduct corresponding to the 
doubly charged phosphopeptide at m/z 1031). Peptides were separated over a 20 min 
chromatographic gradient. TOF-MS spectra were summed from 3-4 survey scans over the one-
minute peptide elution window and normalised to an ion intensity of 150. A single experiment was 
performed in triplicates and representative spectra are shown. 
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The phosphopeptides identified in this study are detailed in Table 3.2. Only singly 
and doubly phosphorylated peptides from α-casein and β-casein were identified. 
Casein peptides with three or more phosphate groups and singly phosphorylated 
peptides from ovalbumin were not detected, although they were theoretically 
present in the mixture,  
 
 
 
Table 3.2 Phosphorylated peptides identified by tandem mass spectrometry following 
TiO2 and IMAC phosphopeptide enrichment. 
Protein Peptide sequence z m/z 
m/z adduct 
  Na          K 
Phospho 
sites 
Oxidation 
Alpha casein S1 DIGsESTEDQAMEDIK 2 924.4   S61  
Alpha casein S1 DIGsESTEDQAmEDIK 2 932.4   S61 M69 
Alpha casein S1 DIGsEsTEDQAMEDIK 2 964.3 975.3 983.3 S61, S63  
Alpha casein S1 DIGsEsTEDQAmEDIK 2 972.3   S61, S63 M69 
Alpha casein S1 VPQLEIVPNsAEER 2 830.9 841.9  S130  
Alpha casein S1 YKVPQLEIVPNsAEER 2 976.5   S130  
Alpha casein S2 EQLsTsEENSK 2 706.3   S144, S146  
Alpha casein S2 EQLsTsEENSKK 2 770.3   S144, S146  
Alpha casein S2 TVDMEsTEVFTK 2 733.8   S158  
Alpha casein S2 TVDmEsTEVFTK 2 741.8   S158 M156 
Beta casein FQsEEQQQTEDELQDK 3  695.3 700.6 S50  
Beta casein FQsEEQQQTEDELQDK 2 1031.4   S50  
S1/S2 denotes protein subunits; modified residues are in lowercase in the peptide sequence 
and identified by amino acid number. 
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Figure 3.5 shows the tandem mass spectrum for the singly phosphorylated peptide 
VPQLEIVPNsAEER from α-casein. Typically for many phosphopeptide spectra, a 
facile loss of the phosphate group is observed from the precursor and product ions 
containing the phosphorylated residue. 
 
 
 
 
 
 
Figure 3.5 Tandem mass spectrum for the α-casein phosphopeptide VPQLEIVPNsAEER. 
The peptide sequence (phosphorylated residue in lowercase) with the masses of corresponding b-
ions, y-ions and phosphate losses (-H3PO4) is shown on top. Identified y-ions, b-ions and 
phosphate losses are underlined, and marked in the spectrum. (M+H)+ is the parent ion. 
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3.3 Optimisation of Sample Preparation and Fractionation of 
Phosphopeptide Extracts for Large-Scale Analysis 
Following optimisation of TiO2 chromatography for phosphopeptide enrichment, a 
large scale workflow for the analysis of whole cell extracts from cultured cells was 
developed. For this purpose, HTB94 chondrosarcoma cells were treated for 30 min 
with the tyrosine phosphatase inhibitor pervanadate (10mM) and the 
serine/threonine phosphatase inhibitor calyculin A (100 nM); this treatment ensured 
efficient detection of phosphorylated peptides during the methods development 
process.  
3.3.1 Comparison of Lysis Buffers 
The first step in sample preparation is the generation of whole cell extracts. Three 
common lysis buffers were tested: TRI Reagent, radio-immunoprecipitation assay 
(RIPA) buffer, and 8 M urea buffer. TRI Reagent is a phenol/chloroform-based 
extraction method permitting the stepwise isolation of DNA and RNA, with a final 
protein precipitation step (Chomczynski and Sacchi, 1987); here, precipitated 
proteins were re-solubilised with 10 M urea. RIPA buffer is popular because of its 
compatibility with many downstream applications, such as kinase assays, and 
contains detergents for cellular membrane disruption and SDS for protein 
denaturation (Harlow and Lane, 1988); here, the non-ionic detergent NP-40 and 
the anionic detergent deoxycholate were used along with protease inhibitors. 
Buffers containing high concentrations of urea effectively disrupt cellular 
membranes and denature protein without the need for added detergents or 
protease inhibitors (Rabilloud, 1996), which has the advantage of compatibility with 
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in-solution digestion protocols; here, 8 M urea buffer was used without addition of 
protease inhibitors. 
Confluent HTB94 cells were lysed using the three lysis buffers and separated by 
SDS-PAGE. Coomassie Brilliant Blue staining of the gel revealed some differences 
in staining patterns, particularly in the region of 50-60 kDa (Figure 3.6). Overall, 
lysis with 8 M urea buffer resulted in the richest staining pattern and was therefore 
used in subsequent experiments. 
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Figure 3.6 Comparison of lysis buffers. 
Confluent HTB94 cells were lysed using TRI Reagent, RIPA or 8 M urea buffers. Equal amounts of 
lysate were separated by SDS-PAGE on a 8-12% Bis-tris mini gel and stained with Coomassie 
Brilliant Blue. The gel shown is representative of two experiments 
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3.3.2 Optimisation of the Large-Scale Workflow 
As the detection of phosphopeptides from TiO2-enriched test samples was less 
efficient at higher concentrations of non-phosphorylated peptides (Figure 3.4), 
protein extracts were fractionated by preparative SDS-PAGE to reduce sample 
complexity prior to enrichment. Adapting a protocol by the Gygi group (Li et al., 
2007), cleared whole cell lysate was separated by SDS-PAGE on a laboratory-cast 
10% gel. The gel was run until the dye front had migrated 5 cm into the gel, and 
the entire gel was cut into twelve horizontal strips (Figure 3.7, A). The upper six 
strips were in-gel digested with trypsin and enriched for phosphopeptides by TiO2 
chromatography using batch loading. 
In order to optimise and streamline the method, automated and manual in-gel 
digestion were tested. Desalting peptide extracts prior to TiO2 chromatography and 
the effect of post-enrichment fractionation were also evaluated. Manual in-gel 
digestion proved more efficient than automated digestion on a ProGest Protein 
Digestion Station, resulting in two-fold greater yield of phosphopeptides and 
increased enrichment efficiency (Figure 3.7, B). Desalting of peptide digests on C18 
reversed phase material is often performed prior to phosphopeptide enrichment to 
prevent competitive binding of contaminants to the resin, but is also associated 
with losses of hydrophilic peptides (Neubauer and Mann, 1999). In-gel digestion 
might be inherently desalting because it involves thorough washing during peptide 
extraction, possibly obviating a separate desalting step. To test this hypothesis, 
phosphopeptide enrichment by TiO2 was performed without prior desalting, 
resulting in a modest reduction in phosphopeptide yield and enrichment efficiency 
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compared with desalting on C18 resin (Figure 3.7, C). Because the test sample was 
small (half a gel strip) this modest reduction was unlikely to be significant; 
therefore, the C18 desalting step was omitted. Fractionation of complex mixtures by 
HPLC prior to MS/MS analysis is normally required to ensure selection of the 
maximum number of peptides for MS/MS sequence analysis, but also entails a 
commensurate increase in analysis time. Because the LC-MS/MS setup used in 
this study permitted no more than a 20 minute analytical gradient, additional off-line 
fractionation was investigated. Halves of two gel strips were manually digested and 
phosphopeptide extracts were analysed without fractionation, or separated on C18 
microcolumns (Rappsilber et al., 2003) into four fractions. However, this resulted in 
few phosphopeptide identifications at low enrichment efficiency (Figure 3.7, D), and 
off-line HPLC on a 2 mm x 10 cm analytical C18 column was tested. Separation into 
24 fractions showed only a modest improvement in phosphopeptide yield over four 
fractions, but at improved enrichment efficiency. Separation of phosphopeptide 
extracts from two manually digested whole strips into 48 fractions increased 
phosphopeptide yield up to threefold over 24 fractions and greatly improved 
enrichment efficiency (Figure 3.7, D), although the variable yield from the two 
identically treated strips indicated that direct comparison of yield and enrichment 
efficiency between different strips was problematic. 
The overall phosphopeptide enrichment efficiency averaged from the six strips was 
63% (Figure 3.7, E), and ranged from 29% for a single fraction to 85% for 48 
fractions (Figure 3.7, D). A total of 219 phosphopeptides were identified with 
Mascot scores above significance threshold when searching the Swiss-Prot 
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database/ taxonomy human (Appendix A). A maximum of 49 phosphopeptides was 
identified from a single gel strip (Figure 3.7, D). The distribution of serine, 
threonine, and tyrosine phosphorylated residues was close to published figures, 
except for a fourfold greater incidence of tyrosine phosphorylation (Olsen et al., 
2006), probably reflecting the use of a tyrosine phosphatase inhibitor in this study 
(Figure 3.7, E). 
The final workflow is depicted in Figure 3.8, comprising preparative gel 
electrophoresis, cutting the gel into 12 strips, manual in-gel digestion, batch TiO2 
chromatography, and separation by off-line HPLC into 48 fractions prior to LC-ESI-
MS/MS. 
   
107
Chapter 3                                                                                         Phosphoproteomics Methodology 
A  
 
B C D 
   
  
E 
 
 
Figure 3.7 Optimisation of the phosphoproteomics methodology. 
(A) Five milligrams of protein extract from HTB94 cells was separated by SDS-PAGE. Following 
light staining with Coomassie Brilliant Blue, the entire gel was cut into 12 strips. The upper six 
strips were separately in-gel digested with trypsin, desalted, and enriched for phosphopeptides 
with TiO2. (B) Halves of strips #3 and #4 were in-gel digested using a ProGest digestion robot, 
the other halves were manually in-gel digested. (C) Strip #6 was digested as described for strips 
#3 and #4, followed by pooling of the peptide-extracts. One half of the pooled extract was not 
desalted and the other half desalted on a C18 cartridge prior to TiO2 enrichment. (D) Following 
manual in-gel digestion, desalting, and TiO2 enrichment, phosphopeptide extracts were 
analysed by LC-ESI-MS/MS in a single fraction (half of strip #6), separated on a C18 
microcolumn into four fractions (half of strip #4), or separated by off-line HPLC into 24 fractions 
(half of strip #3) or 48 fractions (strips #1 and #2). (E) Distribution of total identified peptides and 
phosphorylated amino acid residues. 
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Figure 3.8 Workflow of the phosphoproteomics methodology. 
Cell lysate is separated by preparative SDS-PAGE; the gel is cut into horizontal strips; peptides 
(squiggles; red dot represents phosphate group) are extracted by manual in-gel digestion, enriched 
for phosphopeptides by TiO2 chromatography, separated by off-line HPLC and analysed by LC-
MS/MS; uninterpreted tandem mass spectra are searched by Mascot against a protein database for 
identification of peptide sequences and phosphorylation sites. 
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3.4 Discussion 
3.4.1 Evaluation of TiO2 and IMAC for Phosphopeptide Enrichment 
The first task in developing a phosphoproteomics methodology was the evaluation 
of TiO2 chromatography and IMAC. Using a test mixture of three phosphorylated 
and three non-phosphorylated proteins, I showed that phosphopeptide enrichment 
by TiO2 chromatography was more efficient than IMAC. 
Testing three published buffer protocols for each resin resulted in considerable 
differences in enrichment efficiency (Figure 3.3). For TiO2, the superior 
performance of the protocol using highly acidic loading buffer and an additional 
washing step with loading buffer might be explained by the more efficient 
protonation of carboxylic acid side chains, resulting in less competition between 
non-phosphorylated peptides and phosphopeptides for binding sites. However, the 
use of ACN in washing and elution buffers might equally account for the poorer 
enrichment efficiencies of the other two protocols, because non-phosphorylated 
peptides that bind to TiO2 resin through hydrophobic interactions would be eluted 
by ACN-containing buffers but not by solvent-free elution buffers; the detection of 
fewer phosphopeptides might then be the result of ion suppression of 
phosphopeptides by the more abundant non-phosphorylated peptides. In reality, 
both effects probably contributed to the observed results. For IMAC, the slightly 
poorer performance of the protocol using 30% ACN in the elution buffer might be 
explained by a small decrease in pH caused by the addition of ACN (Subiratsa et 
al., 2007), resulting in incomplete elution of phosphopeptides. The low signal 
intensity of phosphopeptides detected using phosphate elution buffer indicates that 
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a more alkaline buffer would have been required for efficient elution of 
phosphopeptides from IMAC resin, especially more strongly binding doubly 
phosphorylated peptides. Indeed, addition of aqueous ammonia to increase the pH 
of phosphate buffer has been reported (Gruhler et al., 2005). It should be noted, 
however, that all six protocols have been used successfully in phosphoproteomics 
studies, indicating that particular combinations of sample, extraction procedure, 
and mass spectrometric analysis require adjustment of the chemical composition of 
the buffer systems. Furthermore, the purpose of this study was the selection of the 
protocols that gave the best performance from a number of published protocols, as 
opposed to a comprehensive comparison of the protocols. The results shown were 
representative of a single experiment in three technical repeats (i.e. each sample 
enriched on three separate microcolumns using identical buffer solutions). 
Therefore, minor differences in phosphopeptide enrichment, such as those 
observed between protocols D and E, may not be significant when performing 
triplicate experimental repeats with fresh sample and buffer solutions. 
When testing the best TiO2 and IMAC protocols at a threefold lower peptide 
concentration (Figure 3.4), the lower signal intensity of phosphopeptides and the 
smaller number of doubly phosphorylated peptides detected was probably due to 
reaching the sensitivity limit of the LC-MS platform, as doubly phosphorylated 
peptides showed low signal intensity already at the threefold higher sample 
concentration. At 50-fold excess of non-phosphorylated peptides, the lower relative 
intensity of the phosphopeptides enriched by TiO2 without increased detection of 
non-phosphorylated peptides indicates that excess concentrations of non-
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phosphorylated peptides impede binding of phosphorylated peptides; the lack of 
detection of non-phosphorylated peptides in the eluate might again be explained by 
their not being eluted from the resin by the solvent-free elution buffer. For IMAC, on 
the other hand, increasing concentrations of non-phosphorylated peptides seem to 
outcompete phosphopeptides for binding sites, as evidenced by the large number 
of non-phosphorylated peptides detected at 50-fold excess, although it is equally 
possible that both phosphorylated and non-phosphorylated peptides bound to the 
resin, but that ion suppression effects prevented detection of phosphopeptides. 
These results suggested that fractionation of complex protein extracts is required 
prior to phosphopeptide enrichment, a conclusion supported by the use of pre-
fractionation in most phosphoproteomics studies. 
Although Larsen and co-workers also reported superior performance of TiO2 
chromatography over IMAC (Larsen et al., 2005), others showed that both methods 
efficiently enriched for phosphopeptides (Bodenmiller et al., 2007; Wilson-Grady et 
al., 2008). Aebersold and co-workers reported that the selectivity of TiO2 and IMAC 
resin for phosphopeptides was influenced by the ratio of starting material to resin, 
and suggested that variation in this parameter might be the cause of conflicting 
results between studies (Bodenmiller et al., 2007). As this parameter was not 
tested in the present work, or by Larsen and co-workers, the poorer performance of 
IMAC might be due to this factor.  
Failure to detect peptides with three or more phosphate groups (Table 3.2) using 
ESI-LC-MS/MS was also reported by Larsen, who detected most multiply 
phosphorylated peptides present in a digest of the same proteins that were used in 
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this study by MALDI-MS/MS, suggesting an inherent limitation of ESI in the positive 
ion mode to effectively ionise peptides with more than two phosphate groups 
(Larsen et al., 2005). Failure to detect any phosphopeptides from ovalbumin might 
be due to its non-stoichiometric phosphorylation (Huntington and Stein, 2001), 
resulting in lower abundance of ovalbumin phosphopeptides compared with 
peptides from α- and β-casein, which are stoichiometrically phosphorylated. 
3.4.2 Optimisation of Sample Preparation and Fractionation of 
Phosphopeptide Extracts for Large-Scale Analysis 
Following optimisation of the phosphopeptide enrichment method, the second task 
was to develop a high-throughput procedure for phosphopeptide extraction from 
cultured cells. Pre-fractionation of whole cell lysate by preparative SDS-PAGE, 
cutting the gel into twelve strips, followed by manual in-gel digestion, TiO2 
enrichment, and fractionation of the phosphopeptide extracts by off-line HPLC 
enabled the identification of up to 49 phosphopeptides from a single strip of the 
preparative gel. As the objective of this part of the study was optimisation of the 
workflow in a robust cell system, phosphatase inhibitor treatment was used to 
achieve high levels of phosphorylation to test the selectivity of phosphopeptide 
enrichment of more complex samples. Therefore, no conclusions can be drawn 
from these data about the sensitivity of the method when more physiological stimuli 
are used. 
Testing three lysis buffers showed only minor differences when comparing patterns 
on a Coomassie stained gel (Figure 3.6). It proved difficult to prepare samples 
containing equal amounts of protein at equivalent purity, because the TRI Reagent 
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method produces extracts largely free of RNA and DNA, but is more prone to 
adsorptive losses during re-solubilisation of precipitated protein. By contrast, 
extracts obtained from lysis with RIPA or 8 M urea buffers require a pre-clearing 
step to pellet nucleic acids and cellular debris, which is often inefficient for urea 
extracts, especially for small volumes. Furthermore, the resultant protein extracts 
interfere with protein assays in different ways (several assays were tested), so that 
readings could not be compared; in the end, volumes were adjusted by trial and 
error. Consequently, no conclusions were drawn from differences in staining 
intensity; only the presence of bands was compared, resulting in the selection of 8 
M urea buffer. Although no thorough assessment of the lysis buffers was 
performed in the present study, comparison of urea and RIPA buffers has shown 
that urea buffer is most efficient at extracting extracellular matrix and cytoskeletal 
proteins from breast tumour tissue, whereas RIPA buffer is more efficient at 
extracting nuclear, cytoplasmic, and mitochondrial proteins (Ngoka, 2008), but it 
remains to be demonstrated that such differences apply to cultured cells. 
Having settled on a workflow that employs preparative SDS-PAGE to fractionate 
protein extracts prior to manual TiO2 chromatography, I investigated if in-gel 
digestion could be performed using a robotic system, and if desalting of peptide 
extracts was necessary prior to TiO2 enrichment. Automated in-gel digestion was 
less efficient than manual in-gel digestion (Figure 3.7, B), which might be explained 
by the fact that digestion robots are designed for extraction of peptides from 
conventional gels that contain relatively small amounts of protein, rather than 
preparative gels that have been loaded to their maximum capacity. Desalting of 
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digests prior to enrichment by TiO2 resulted in a modest increase in enrichment 
efficiency (Figure 3.7, C), which was deemed insignificant because of the small 
sample size. In support of this, Jensen and Larsen have demonstrated that TiO2 
chromatography is tolerant of high salt concentrations (Jensen and Larsen, 2007), 
and TiO2 enrichment of SCX fractions has been performed without desalting by 
Mann and co-workers (Olsen et al., 2006; Macek et al., 2007). Next, I tested the 
effect of fractionation of phosphopeptide-enriched extracts prior to LC-MS/MS. 
Increasing separation resulted in increased detection of phosphopeptides and a 
concomitant decrease in the number of non-phosphorylated peptides detected 
(Figure 3.7, D). This indicates that relatively few non-phosphorylated peptides of 
high abundance were present in the extracts, which were able to suppress 
ionisation of the less abundant phosphopeptides when the extracts were not 
fractionated sufficiently. Indeed, most non-phosphorylated peptides were detected 
from abundant structural proteins, which supports this notion. However, the small 
increase in the number of phosphopeptides detected from 24 fractions compared 
with four fractions, and also the different yield of phosphopeptides from the two 
extracts separated into 48 fractions, indicates that extracts from different gel strips 
contained variable amounts of phosphopeptides. In fact, Gygi and co-workers 
reported fourfold differences in the number of phosphopeptides enriched by TiO2 
from the first six strips of a preparative gel cut into 12 strips (Wilson-Grady et al., 
2008). It may therefore be of limited value to compare phosphopeptide yield and 
enrichment efficiency between different gel strips, especially since these 
parameters are influenced by the degree of peptide separation prior to MS/MS 
analysis. 
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Extrapolating from the ideal case of nearly 50 phosphopeptides identified from a 
single strip, the optimised workflow should enable the identification of several 
hundred phosphopeptides from a complete gel, although this remains to be 
demonstrated when using more physiological stimuli in a different cell system. 
3.5 Summary 
I showed that TiO2 chromatography was superior to IMAC when enriching for 
phosphopeptides from complex mixtures, and developed a phosphoproteomics 
workflow incorporating TiO2 chromatography for the large-scale identification of 
phosphopeptides from cultured cells. Using this workflow, I identified more than 
200 phosphopeptides from phosphatase inhibitor-treated cells. 
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4.1 Introduction 
Having developed a workflow for the large-scale identification of phosphopeptides 
from cultured cells, I applied this methodology to conduct a phosphoproteomics 
screen of RAW 264.7 cells. RAW cells are a murine macrophage-like cell-line that 
was established from pristane-elicited peritoneal macrophages that were 
transformed with Abelson leukemia virus (Raschke et al., 1978). These cells show 
phenotypic resemblance to primary macrophages and respond to a variety of 
innate immune stimuli (Natarajan et al., 2006). As a model system of TLR 
signalling in macrophages, RAW cells were stimulated with LPS to activate TLR4, 
which signals through both MyD88- and TRIF-dependent pathways and shares the 
main signalling components used by other TLRs. 
Two independent screens were conducted using different LC-MS/MS platforms. 
The first experiment followed the phosphoproteomics workflow described in the 
previous chapter and was analysed by QTOF-MS/MS. The second experiment 
used a gel-free approach, without fractionation of protein extracts, and 
phosphopeptide-enriched digests were analysed by on-line LC-LTQ-Orbitrap-
MS/MS. The second experiment also included analysis of an iTRAQ-labelled 
sample. In order to permit the confident identification of a maximum number of 
phosphorylation sites, particular emphasis was placed on the analysis and 
validation of tandem mass spectra generated by the two platforms. 
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4.2 First Screen – QTOF Data 
4.2.1 LPS Stimulation and Preparative SDS-PAGE 
To establish an optimal duration of LPS stimulation that ensured high levels of 
phosphorylation, RAW cells were treated with LPS over a 90 min timecourse and 
lysates were immunoblotted for phosphorylated ERK as readout of cell activation. 
Phosphorylation of ERK1/2 peaked by 30 minutes of LPS stimulation and was 
induced several-fold over basal level (Figure 4.1), indicating strong activation by 
LPS. 
In order to prepare cell extracts for the preparative SDS-PAGE-based 
phosphoproteomics workflow, RAW cells were left unstimulated or treated with 
LPS for 30 minutes and lysed with 8 M urea buffer. Cleared lysates (5 mg of 
protein) were separated by SDS-PAGE and gels were stained with Coomassie 
Brilliant Blue; this approach was highly reproducible (Figure 4.2). 
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Figure 4.1 Timecourse of LPS stimulation of RAW cells. 
Cells were treated for the indicated times with 10 ng ml-1 LPS. Lysates were prepared and 
immunoblotted with a phospho-ERK (P-ERK) antibody. The membrane was stripped and 
reprobed with a total p38 antibody as loading control. 
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Figure 4.2 Preparative SDS-PAGE of RAW cell extracts. 
(A) Cells were left untreated or (B) treated with 10 ng ml-1 LPS for 30 min. For each condition 5 mg 
of protein extract was separated by SDS-PAGE. Gels were run until the dye front had migrated 5 
cm into the gel and lightly stained with Coomassie Brilliant Blue. Each gel was cut into 12 strips, 
which were separately digested with trypsin and enriched for phosphopeptides with TiO2. Peptide 
extracts were separated by off-line HPLC and analysed by LC-QTOF-MS/MS. 
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4.2.2 Sample Processing and Analysis by QTOF-MS/MS 
The preparative gels from resting and LPS-treated cells were in-gel digested and 
enriched for phosphopeptides, followed by separation by off-line HPLC into 36 
fractions. Although 48 fractions were used during methods development, the 
number of fractions was reduced to 36 owing to the large number of LC-MS/MS 
runs required to analyse two gels (2 gels x 12 strips x 36 fractions = 864 samples). 
Pairs of gel strips were processed in parallel, and the resultant off-line HPLC 
fractions were analysed by LC-QTOF-MS/MS, with separation over a 20 minute 
acetonitrile/ 0.1% formic acid gradient. Parallel processing of pairs of gel strips 
ensured minimal variations arising from sample handling and equipment 
performance. 
4.2.3 Data Analysis 
Uninterpreted tandem mass spectra were searched with Mascot (p <0.05). In order 
to determine optimal search parameters, the tandem mass spectra from LPS-
treated cells were searched using several combinations of precursor mass 
tolerance, database, and number of missed tryptic cleavage sites (Table 4.1). From 
previous experience, precursor mass tolerance was initially set at ± 50 ppm and 
fragment mass tolerance was kept constant at the default value of ± 0.6 Da. 
Carbamidomethylation of cysteine was fixed, and variable modifications were 
oxidation of methione and phosphorylation of serine, threonine, and tyrosine 
residues. 
Searching the Swiss-Prot database with a requirement for complete tryptic 
cleavage resulted in the lowest number of peptide identifications and highest false 
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discovery rate (FDR). Repeating the search with up to two missed cleavages gave 
the greatest number of identifications at low FDR, and the same search with 
peptide mass tolerance settings of ± 100 ppm or ± 25 ppm resulted in a small 
decrease in identifications and doubling of the FDR. A repeat search of the larger 
NCBInr database with peptide mass tolerance settings of ± 50 ppm and two 
missed cleavages gave the lowest FDR and the second lowest number of identified 
peptides. Based on these results, search parameters of ± 50 ppm precursor mass 
tolerance and two missed tryptic cleavages were used for subsequent searches. 
 
 
Table 4.1 Comparison of database search parameters for QTOF-MS/MS. 
Precursor 
mass 
tolerance 
Database 
Missed 
tryptic 
cleavages 
Overall 
indicative 
identity 
threshold a 
Peptide 
matches 
above identity 
threshold 
False 
Discovery 
Rate 
± 50 ppm Swiss-Prot 0 24 651 1.08% 
± 50 ppm Swiss-Prot 1 28 830 0.36% 
± 50 ppm Swiss-Prot 2 30 872 0.23% 
± 25 ppm Swiss-Prot 2 28 849 0.59% 
± 100 ppm Swiss-Prot 2 32 845 0.47% 
± 50 ppm NCBInr 2 39 787 0.13% 
Tandem mass spectra from MS/MS runs of LPS-treated samples were merged into single file and 
searched with Mascot (p < 0.05). Fragment mass tolerance was ± 0.6 Da. Carbamidomethylation of 
cysteine was fixed, and variable modifications were oxidation of methione and phosphorylation of 
serine, threonine, and tyrosine residues. Databases searched with taxonomy Mus were: Swiss-Prot 
58_11 (16261 sequences), NCBInr (downloaded 30 Nov 2009) (145830 sequences). aSupplied by 
Mascot as indicator only; identity thresholds for individual peptide ions vary. 
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Using parameter settings of ± 50 ppm precursor mass tolerance and two missed 
tryptic cleavage sites, Mascot searches of spectra from resting and LPS-treated 
cells against the Swiss-Prot database resulted in FDRs of 0.49% and 0.23%, 
respectively, at a 5% probability of a random match (p < 0.05) (Table 4.2). For 
additional validation Mascot output files were analysed by Scaffold, which 
incorporates a modified version of the Peptide Prophet algorithm (Keller et al., 
2002; Searle et al., 2008). The algorithm calculates the difference between Mascot 
ion score and identity score, defined as the discriminant score, and uses Bayesian 
statistics to define the populations of correct and incorrect Mascot identifications of 
peptides of equal charge states. Whereas the Mascot significance threshold by 
definition equals a discriminant score of 0.0, Scaffold calculates the discriminant 
score at which a peptide match has a 95% probability of belonging to the 
population of correct matches. For peptide matches from resting and LPS-treated 
cells, Scaffold 95% thresholds were slightly lower than Mascot thresholds, 
especially for triply charged peptides, whereas for doubly charged peptides from 
LPS-treated cells the Scaffold threshold was marginally higher (Figures 4.3 and 
4.4). Two doubly charged peptides from LPS-treated cells identified by Mascot 
were invalidated by Scaffold, and 32 additional phosphopeptides were identified, 
representing a 4% gain over Mascot, with the majority of additional 
phosphopeptides from LPS-treated cells (Table 4.2). Overall, 13% more 
phosphopeptides were identified from LPS-treated than resting cells (all identified 
phosphopeptides are listed in Appendix B). The total number of peptides was 
similar, with phosphopeptides contributing 40% of about 900 peptide matches for 
each dataset. Doubly phosphorylated peptides accounted for 2% of 
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phosphopeptides, the majority of which were identified from LPS-treated cells. 
About 30% of peptides from either dataset contained oxidised methionine residues. 
 
 
 
Table 4.2 Peptide match statistics for QTOF dataset. 
 Resting LPS 
Mascot FDR 0.49% 0.23% 
Scaffold a   
Peptide matches 865 905 
Non-phosphopeptides 529 524 
Phosphopeptides 337 381 
Percentage phosphopeptides 39% 42% 
Scaffold gain over Mascot   
Non-phosphopeptides 16 8 
Phosphopeptides 11 21 
Scaffold loss over Mascot   
Non-phosphopeptides 0 1 
Phosphopeptides 0 1 
   
Doubly phosphorylated peptides 6 11 
Methionine-oxidised peptides 261 256 
aPeptide identifications were at greater than 95% probability as 
specified by the Peptide Prophet algorithm. FDR, false discovery 
rate. 
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Figure 4.3 Histogram of Scaffold peptide match statistics from resting cells identified by 
QTOF-MS/MS. 
Scaffold used the Peptide Prophet algorithm to translate Mascot scores into peptide probabilities. A 
discriminant score was calculated for each peptide match and separate histograms were plotted for 
doubly (A), triply (B), and quadruply charged peptides (C). The discriminant score is the difference 
between the Mascot ion score (calculated from fragment ion match statistics) and the Mascot 
identity score (calculated from the probability that the precursor mass is a random match; p<0.05). 
The histograms were automatically created by counting the number of spectra at binned values of 
the discriminant score (bin width 2.0 score units). The Peptide Prophet algorithm used Bayesian 
statistics to fit curves to the distribution of incorrect matches (blue) and the distribution of correct 
matches (red).  The peptide probability for a given discriminant score was the ratio of the correct 
distribution divided by the sum of correct and incorrect distributions; the black vertical dashed line 
marks the discriminant score at which the probability of a correct match was 95%. 
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Figure 4.4 Histogram of Scaffold peptide match statistics from LPS-treated cells identified by 
QTOF-MS/MS. 
Scaffold used the Peptide Prophet algorithm to translate Mascot scores into peptide probabilities. A 
discriminant score was calculated for each peptide match and separate histograms were plotted for 
doubly (A), triply (B), and quadruply charged peptides (C). The discriminant score is the difference 
between the Mascot ion score (calculated from fragment ion match statistics) and the Mascot 
identity score (calculated from the probability that the precursor mass is a random match; p<0.05). 
The histograms were automatically created by counting the number of spectra at binned values of 
the discriminant score (bin width 2.0 score units). The Peptide Prophet algorithm used Bayesian 
statistics to fit curves to the distribution of incorrect matches (blue) and the distribution of correct 
matches (red).  The peptide probability for a given discriminant score was the ratio of the correct 
distribution divided by the sum of correct and incorrect distributions; the black vertical dashed line 
marks the discriminant score at which the probability of a correct match was 95%. 
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To assess whether the additional tandem mass spectra validated by Scaffold 
confidently identified phosphopeptide sequences, the Mascot matches with the 
lowest discriminant scores (i.e. ≥ 0.0) were compared against the additional 
Scaffold matches that had the lowest discriminant scores (mostly < 0.0) in each 
dataset. From resting cells, the doubly charged phosphopeptide 
SLYSSsPGGAYVTR with a discriminant score of 0.0 was confidently identified, 
including location of the phosphorylation site (Figure 4.5, A); the triply charged 
phosphopeptide DELHIVEAEAmNYEGSPIKVTLAtLK with a discriminant score of -
2.8 was identified with less confidence and undetermined phosphorylation 
placement, but its ion score of 30.6 was well above the homology score of 18, 
adding confidence to the sequence assignment (Figure 4.5, B). From LPS-treated 
cells, the quadruply charged phosphopeptide 
mLPHAPGVQmQAIPEDAVHEDsGDEDGEDPDKR with a discriminant score of 0.1 
was identified with some confidence, its ion score of 34.2 well above the homology 
score of 19, but no product ions diagnostic of the phosphorylation site were 
detected (Figure 4.6, A); the triply charged phosphopeptide 
GHSDSSASESEVSLLsPVK with a discriminant score of -3.1 was confidently 
identified, including location of the phosphorylation site (Figure 4.6, B). This 
indicated that additional Scaffold matches identified phosphopeptide sequences 
and located phosphorylation sites with similar confidence to the lowest-scoring 
Mascot matches.  
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Figure 4.5 Comparison of least confident Mascot and Scaffold phosphopeptide 
identifications from resting cells analysed by QTOF-MS/MS. 
(A) Tandem mass spectrum for the phosphopeptide SLYSSsPGGAYVTR from vimentin, with a 
discriminant score of 0.0 and Mascot ion score of 31.5. The sequence and phosphorylation site are 
confidently assigned with plausible fragment ion intensities, including abundant y8 resulting from 
breakage N-terminal to proline, abundant immonium ion from non-phosphorylated tyrosines, 
phosphate loss (-98) from b6 and y10-12, and b- and y-ions mapping non-phosphorylated S, T, and 
Y residues. (B) Tandem mass spectrum for the phosphopeptide 
DELHIVEAEAmNYEGSPIKVTLAtLK from nucleophosmin, with a discriminant score of -2.8, and 
Mascot ion score of 30.6 and homology score of 18. The spectrum is dominated by the 
unfragmented parent ion and is shown normalised to the second most intense peak. Only the N-
terminus is mapped by b- and y-ion series. Because of the length of the peptide and presence of an 
internal basic residue it is difficult to predict fragment intensities; preferred breakage C-terminal to 
the first alanine residue and further fragmentation of that sequence would explain the series of low 
mass b-ions and high mass y-ions, and also the dominant y18 with neutral loss of water (from 
several E, S, and T residues) and neutral loss from oxidised methionine (-64). The location of the 
phosphorylation site is not defined.  
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Figure 4.6 Comparison of least confident Mascot and Scaffold phosphopeptide 
identifications from LPS-treated cells analysed by QTOF-MS/MS. 
A) Tandem mass spectrum for mLPHAPGVQmQAIPEDAVHEDsGDEDGEDPDKR from HDAC2, 
with a discriminant score of 0.1, and Mascot ion score of 34.2 and homology score of 19. Part of the 
N-terminus and the middle of the peptide are mapped by b- and y-ions. Because of the length of the 
peptide and presence of an internal basic residue it is difficult to predict fragment ion intensities; 
abundant y20 and y31 from breakage N-terminal to proline are plausible; phosphorylated serine is 
the only phosphorylatable residue. (B) Tandem mass spectrum for GHSDSSASESEVSLLsPVK 
from PP4R2, with a discriminant score of -3.1, and Mascot ion score of 29.6 and homology score of 
22. Most of the sequence is mapped by contiguous b- and y-ion series. Dominant y7 is plausible 
from preferred breakage N-terminal to serine and C-terminal to valine; the phosphorylation site is 
located by phosphate loss (-98) from y4 onward. 
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The total number of non-redundant phosphorylation sites identified by QTOF-
MS/MS with a Scaffold probability of 95% was 356, of which 30% were unique to 
resting cells, 34% unique to LPS-treated cells, and 36% common to both (Figure 
4.7, A). The distribution of phosphorylated serine, threonine, and tyrosine residues 
for the complete dataset was 89%, 6%, and 5%, respectively (Figure 4.7, B). 
Overall, the proportion of tyrosine phosphorylations was threefold greater than 
published figures (Olsen et al., 2006), split approximately 7 : 2 : 1 between resting 
cells, LPS-treated cells, and common to both. 
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Figure 4.7 Distribution of phosphorylation sites identified by QTOF-MS/MS. 
(A) Venn diagram of non-redundant phosphorylation sites. (B) Distribution of phosphorylated 
amino acid residues. 
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4.3 Second Screen – LTQ-Orbitrap Data 
4.3.1 Sample Preparation and Analysis by LTQ-Orbitrap-MS/MS 
RAW cells were grown and treated as described for the first experiment. Following 
lysis with 8 M urea buffer, the protein concentration of cleared lysate was 
determined with the bicinchoninic acid (BCA) protein assay. Equal amounts of 
lysate (100 µg) were digested in-solution with trypsin, desalted on C18 cartridges, 
and enriched for phosphopeptides with TiO2. Enriched samples of 10 µg (500-fold 
less than the first experiment) were analysed by LC-LTQ-Orbitrap-MS/MS, with 
separation over a 120 min acetonitrile/ 0.1% formic acid gradient. 
4.3.2 Data Analysis 
Following optimisation of search parameters as described for the QTOF dataset 
(data not shown), Mascot searches were conducted with precursor and fragment 
ion tolerances of ± 5 ppm and ± 0.6 Da, respectively, with all other parameters set 
as for the QTOF dataset. Mascot FDRs were 1.08% and 0.48% for resting and 
LPS-treated cells, respectively. Mascot output was further validated with Scaffold 
at a peptide identification probability of 95%. A total of 415 peptides were identified 
from LPS-treated cells, which was 12% more than from resting cells (Table 4.3). A 
third of these were phosphopeptides, which was 1.7-fold more than from resting 
cells (all identified phosphopeptides are listed in Appendix C). Doubly 
phosphorylated peptides accounted for 2% of total phosphopeptides and were 
exclusive to LPS-treated cells. On average, 5% of peptides contained oxidised 
methionine residues. Scaffold validated 10% more phosphopeptides than Mascot 
alone, the majority of which were from LPS-treated cells.  
131
Chapter 4                                                                                                   Phosphoproteomics Screen 
Table 4.3 Peptide match statistics for LTQ-Orbitrap dataset. 
 Resting LPS 
Mascot FDR 1.08% 0.48% 
Scaffold a   
Peptide matches 369 415 
Non-phosphopeptides 281 266 
Phosphopeptides 88 149 
Percentage phosphopeptides 24% 36% 
Scaffold gain over Mascot   
Non-phosphopeptides 6 8 
Phosphopeptides 8 13 
   
Doubly phosphorylated peptides 0 5 
Methionine-oxidised peptides 22 17 
aPeptide identifications were at greater than 95% probability as 
specified by the Peptide Prophet algorithm. FDR, false discovery 
rate. 
 
 
 
For peptide matches from resting and LPS-treated cells, Scaffold 95% thresholds 
were lower than Mascot thresholds, especially for triply charged peptides, whereas 
for quadruply charged peptides from resting cells, the Scaffold threshold was 
marginally higher (Figures 4.8 and 4.9). 
  
132
Chapter 4                                                                                                   Phosphoproteomics Screen 
A 
 
Charge +2 
B 
 
Charge +3 
C 
 
 
Charge +4 
Figure 4.8 Histogram of Scaffold peptide match statistics from resting cells identified by 
LTQ-Orbitrap-MS/MS. 
Scaffold used the Peptide Prophet algorithm to translate Mascot scores into peptide probabilities. A 
discriminant score was calculated for each peptide match and separate histograms were plotted for 
doubly (A), triply (B), and quadruply charged peptides (C). The discriminant score is the difference 
between the Mascot ion score (calculated from fragment ion match statistics) and the Mascot 
identity score (calculated from the probability that the precursor mass is a random match; p<0.05). 
The histograms were automatically created by counting the number of spectra at binned values of 
the discriminant score (bin width 2.0 score units). The Peptide Prophet algorithm used Bayesian 
statistics to fit curves to the distribution of incorrect matches (blue) and the distribution of correct 
matches (red).  The peptide probability for a given discriminant score was the ratio of the correct 
distribution divided by the sum of correct and incorrect distributions; the black vertical dashed line 
marks the discriminant score at which the probability of a correct match was 95%. 
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Figure 4.9 Histogram of Scaffold peptide match statistics from LPS-treated cells identified by 
LTQ-Orbitrap-MS/MS. 
Scaffold used the Peptide Prophet algorithm to translate Mascot scores into peptide probabilities. A 
discriminant score was calculated for each peptide match and separate histograms were plotted for 
doubly (A), triply (B), and quadruply charged peptides (C). The discriminant score is the difference 
between the Mascot ion score (calculated from fragment ion match statistics) and the Mascot 
identity score (calculated from the probability that the precursor mass is a random match; p<0.05). 
The histograms were automatically created by counting the number of spectra at binned values of 
the discriminant score (bin width 2.0 score units). The Peptide Prophet algorithm used Bayesian 
statistics to fit curves to the distribution of incorrect matches (blue) and the distribution of correct 
matches (red).  The peptide probability for a given discriminant score was the ratio of the correct 
distribution divided by the sum of correct and incorrect distributions; the black vertical dashed line 
marks the discriminant score at which the probability of a correct match was 95%. 
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As for the QTOF dataset, the Mascot matches with the lowest discriminant scores 
were compared against the additional Scaffold matches that had the lowest 
discriminant score in each dataset. From resting cells, the triply charged 
phosphopeptide KQEFMsDTNLSEHAAIPAR with a discriminant score of 0.0 was 
identified with some confidence, but the location of the phosphorylation site was 
not defined clearly (Figure 4.10, A); the triply charged phosphopeptide 
AAELAEtQSEEEKEEDFREK with a discriminant score of -2.3 was confidently 
identified, including location of the phosphorylation site (Figure 4.10, B); with 
Mascot ion scores of 23.5 and 21.9, respectively, both assignments were well 
above their homology thresholds of 15. From LPS-treated cells, the triply charged 
phosphopeptide SLtMVEDNEDDDEDGEELLHHHR with a discriminant score of 
0.1 was confidently identified with an ion score of 22.5 and no alternative sequence 
assigned by Mascot, but limited confidence in phosphorylation site placement 
(Figure 4.11, A); the triply charged phosphopeptide 
EFITGDVEPTDAESAWHsENEEEDKLAGDMK with a discriminant score of -4.4 
was confidently identified, its Mascot ion score of 20.3 well above the homology 
score of 15, but the location of the phosphorylation site was undetermined (Figure 
4.11, B). This indicated that additional Scaffold matches identified phosphopeptide 
sequences and located phosphorylation sites with similar confidence to the lowest-
scoring Mascot matches.  
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Figure 4.10 Comparison of least confident Mascot and Scaffold phosphopeptide 
identifications from resting cells analysed by LTQ-Orbitrap-MS/MS. 
(A) Tandem mass spectrum for the phosphopeptide KQEFMsDTNLSEHAAIPAR from DOCK2 with 
a discriminant score of 0.0, and Mascot ion score of 23.5 and homology score of 15. No ions are 
present at low or high m/z (inset) and the spectrum is shown for the informative mass range. The 
spectrum is dominated by phosphate loss (-98) from the parent ion. Much of the C-terminal 
sequence is mapped by b- and y-ions. The phosphorylation site is placed on the first serine, but 
phosphate loss from doubly charged b11 onward makes phosphorylation of the second serine more 
plausible, in which case b6/7/10/12 and y9/10 would probably be noise level matches, and doubly 
charged y12/13 would be unassigned. (B) Tandem mass spectrum for the phosphopeptide 
AAELAEtQSEEEKEEDFREK from WDHD1 with a discriminant score of -2.3, and Mascot ion score 
of 21.9 and homology score of 15. No ions are present at low or high m/z (inset) and the spectrum 
is shown for the informative m/z range. Phosphate loss from the parent ion is dominant, with singly 
and doubly charged b-ions and y-ions mapping much of the sequence, including the 
phosphorylation site. 
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Figure 4.11 Comparison of least confident Mascot and Scaffold phosphopeptide 
identifications from LPS-treated cells analysed by LTQ-Orbitrap-MS/MS. 
(A) Tandem mass spectrum for the phosphopeptide SLtMVEDNEDDDEDGEELLHHHR from lamin 
A/C with a discriminant score of 0.1, and Mascot ion score of 22.5. No ions are present at low or 
high m/z (inset) and the spectrum is shown for the informative mass range. The spectrum is 
dominated by phosphate loss (-98) from the parent ion, and by doubly charged y18 from favoured 
breakage C-terminal to valine. Much of the sequence is mapped by b-ions and mainly doubly 
charged y-ions; the phosphorylation site is located by a single ion (doubly charged y21). (B) 
Tandem mass spectrum for the phosphopeptide EFITGDVEPTDAESAWHsENEEEDKLAGDMK 
from NP1L4 with a discriminant score of -4.4, and Mascot ion score of 20.3 and homology score of 
15. No ions are present at low m/z or high (inset) and the spectrum is shown for the informative m/z 
range. The spectrum is dominated by phosphate and ammonia loss from the parent ion. N- and C-
terminal stretches of the sequence are mapped by singly and doubly b- and y-ions; location of the 
phosphorylation site is possible to either of the two serine residue. 
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The total number of non-redundant phosphorylation sites identified by LTQ-
Orbitrap-MS/MS with a 95% Scaffold probability was 152, of which 19% were 
unique to resting cells, 51% unique to LPS-treated cells, and 30% common to both 
(Figure 4.12, A). The distribution of phosphorylated serine, threonine, and tyrosine 
residues for the complete dataset was 84%, 12%, and 4%, respectively (Figure 
4.12, B). Overall tyrosine phosphorylation was about twofold more abundant than 
published figures (Olsen et al., 2006), with about twice as many phosphotyrosine 
identifications from LPS-treated cells than resting cells, and none common to both. 
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Figure 4.12 Distribution of phosphorylation sites identified by LTQ-Orbitrap-MS/MS. 
(A) Venn diagram of non-redundant phosphorylation sites. (B) Distribution of phosphorylated amino 
acid residues. 
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4.4 Assessing the Confidence of Phosphorylation Site Placement Using 
Delta-Ions Scores 
4.4.1 Introduction to Delta-Ions Scores 
While stringent Mascot search criteria and further validation with Scaffold permit a 
certain degree of confidence in the correct assignment of peptide sequences, the 
exact site of phosphorylation is often not distinguishable when peptides contain 
more than one phosphorylatable residue. Mascot calculates ion scores not only for 
the peptide sequence with the highest identification probability, but also for other 
possible sequences of lower probability. The difference in ion score between the 
two highest ranking Mascot assignments divided by the ion score of the top-
ranking assignment can determine the degree of ambiguity between them, defined 
by Gygi and co-workers as the normalised delta-ions score (∆I) (Elias et al., 2004). 
For peptides with several phosphorylatable residues Mascot ranks plausible 
phosphorylation site locations by decreasing ion score and in such cases ∆I is a 
metric of confidence in phosphorylation site placement (Beausoleil et al., 2006). ∆I 
ranges from 1.0 for unambiguous phosphorylation site location, such as peptides 
containing a single phosphorylatable residue or peptides with a different amino 
acid sequence for the second rank, to ∆I of 0.0 when first and second ranking 
assignments have equal ion scores. The Gygi group tested this metric on a large 
dataset of manually validated phosphopeptides analysed on a LTQ-FT instrument, 
and concluded that 99% of sites were assigned correctly at ∆I ≥ 0.4 (Beausoleil et 
al., 2006). LTQ-Orbitrap-MS/MS achieves comparable mass accuracy and 
resolving power to LTQ-FT-MS/MS (Domon and Aebersold, 2006), and others 
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have validated phosphoproteomics datasets acquired by LTQ-Orbitrap-MS/MS 
using the ∆I metric (Endler et al., 2009; Reiland et al., 2009). 
4.4.2 Comparison of Delta-Ions Scores for QTOF and LTQ-Orbitrap 
Phosphopeptide Matches 
Because QTOF and LTQ-Orbitrap employ different methods of peptide 
fragmentation and mass measurement of fragment ions (Elias et al., 2005), and 
Mascot modifies its scoring model dependent on the type of mass spectrometer, it 
was not clear if the ∆I metric would be valid for QTOF data. If Mascot identifications 
of phosphopeptide tandem mass spectra obtained by QTOF-MS/MS differed 
significantly in the confidence of phosphorylation site placement from those 
obtained by LTQ-Orbitrap-MS/MS, it would be expected that the distributions of ∆I 
differ between the two types of mass spectrometer. In order to test this hypothesis, 
∆I were calculated for all phosphopeptides identified by QTOF and LTQ-Orbitrap-
MS/MS, binned at 0.1 ∆I intervals, and their distributions were compared. Despite a 
threefold difference in sample size the distributions were similar, with 16% and 
18% of phosphorylation sites assigned unambiguously with a ∆I of 1.0 for QTOF 
and LTQ-Orbitrap, respectively (Figure 4.13, A and B). For both datasets, lower ∆I 
followed a bimodal distribution with great overlap at 0.4. Median ∆I were 0.34 and 
0.37, with 45% and 49% of peptides identified with ∆I ≥ 0.4 by QTOF and LTQ-
Orbitrap, respectively. The difference in unbinned ∆I distributions was not 
statistically significant as determined by two-tailed Mann-Whitney test (Figure 4.13, 
C). 
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In order to quantify the gain in confidence of phosphorylation site placement for a 
combined non-redundant dataset, 68 phosphorylation sites that were identified by 
both QTOF and LTQ-Orbitrap were merged by retaining the phosphopeptide match 
with higher ∆I for each site (Figure 4.13, D). For those 68 phosphorylation sites, 
median ∆I were 0.41, 0.49, and 0.55 for QTOF, LTQ-Orbitrap, and merged data, 
respectively, and peptides with ∆I ≥ 0.4 comprised 51%, 56%, and 65% of the 
datasets, respectively. Not considering 10 phosphorylation sites from 
phosphopeptides with ∆I of 1.0 in both QTOF and LTQ-Orbitrap datasets, the 
merged data contained a majority (59%) of phosphopeptides identified by LTQ-
Orbitrap. Thus, combining data from QTOF and LTQ-Orbitrap resulted in a 14% 
increase in the number of sites identified with 99% certainty (i.e. ∆I ≥ 0.4) 
compared with QTOF alone, and 9% compared with LTQ-Orbitrap alone.  
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Figure 4.13 Distribution of normalised delta-ions scores for QTOF and LTQ-Orbitrap 
datasets. 
Normalised delta-ions scores (∆I), defined as the difference between Mascot ion scores of the two 
top-ranking matches divided by the ion score of the top-ranking match, were calculated for all 
phosphopeptide matches from (A) QTOF and (B) LTQ-Orbitrap datasets. ∆I were binned at 0.1 
intervals and the number of peptide matches at each bin centre were plotted as histograms. (C) 
Comparison of ∆I distributions for QTOF (left) and LTQ-Orbitrap phosphopeptides (right); the 
difference of the distributions was not statistically significant (two-tailed Mann-Whitney test, 
p=0.3677; medians (red lines) not significantly different). (D) ∆I distributions for 68 phosphopeptides 
that identified the same phosphorylation sites in each dataset; ∆I and medians (red lines) were 
plotted for QTOF (left), LTQ-Orbitrap (middle) and the merged non-redundant data (right). 
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Validity of the ∆I metric was further assessed by comparing Mascot matches for 
the same phosphopeptide sequence, identified twice by the same LC-MS/MS 
platform with ∆I greater and smaller than 0.4. Several spectra were examined and 
identifications with ∆I ≥ 0.4 always showed convincing evidence of correct 
phosphorylation site placement, regardless of the type of mass spectrometer; 
representative examples are described. For QTOF, tandem mass spectra of similar 
quality with high intensity sequence specific ions were obtained for the 
phosphopeptide TDSREDEIsPPPPNPVVK. The ions assigned by Mascot to the 
spectrum with ∆I of 0.40 confidently located the phosphorylation site, whereas for 
the spectrum with ∆I of 0.07 Mascot placed the phosphate moiety at the less likely 
first serine residue (Figure 4.14). For LTQ-Orbitrap, tandem mass spectra for the 
phosphopeptide LKNGLSQPsEEEADIPKPK showed low levels of sequence 
specific ions due to dominant facile loss of phosphate from the precursor ion. The 
fragment ion matches assigned by Mascot to the spectrum with ∆I of 0.55 placed 
the phosphorylation site more confidently at the second serine residue, with the 
less likely first serine assigned to the spectrum with ∆I of 0.08 (Figure 4.15). To 
assess the significance of small differences around ∆I of 0.4, Mascot identifications 
were compared for the phosphopeptide IDIsPSALR, identified by LTQ-Orbitrap-
MS/MS with ∆I of 0.48 and by QTOF-MS/MS with ∆I of 0.33. Spectra were of 
similar high quality, and fragment ions assigned by Mascot confidently located the 
phosphorylation site for either spectrum, except for an additional phosphorylation 
specific ion assigned to the spectrum with greater ∆I (Figure 4.16), indicating that 
the ∆I metric is sensitive to small differences in confidence of phosphorylation site 
placement. 
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Figure 4.14 Comparison of tandem mass spectra identified by QTOF-MS/MS with dissimilar 
normalised delta-ions scores. 
Tandem mass spectra for phosphopeptides from cAMP-dependent protein kinase type I-alpha 
regulatory subunit. (A) TDSREDEIsPPPPNPVVK from LPS-treated cells, with normalised delta-ions 
score of 0.40, Mascot ion score of 38.4, and discriminant score of 5.4. (B) 
TDsREDEISPPPPNPVVK from resting cells, with normalised delta-ions score of 0.07, Mascot ion 
score of 33.8, and discriminant score of 1.1. Both spectra are dominated by phosphate loss (-98) 
from the parent ion and abundant y7-9 from breakage N-terminal to proline residues; abundant b9-
12 probably stem from the same bond breakage, and their high intensity might be due to the 
arginine residue near the N-terminus retaining the charge. The phosphorylation site placement is 
more plausible for the top spectrum, with phosphate loss from b9 onwards and from y14 clearly 
locating the phosphorylated serine. The bottom spectrum also more plausibly places the phosphate 
moiety on the second serine when considering the ions shown in boxes, i.e. presence of b7 and 
phosphate loss from y14, which excludes phosphorylation of the N-terminal serine, and double 
water loss from b4 due to the N-terminal threonine, aspartic acid, and serine residues. 
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Figure 4.15 Comparison of tandem mass spectra identified by LTQ-Orbitrap-MS/MS with 
dissimilar normalised delta-ions scores. 
Tandem mass spectra for the phosphopeptide LKNGLSQPsEEEADIPKPK from DDX21 (A) from 
resting cells, with normalised delta-ions score of 0.55, Mascot ion score of 22.5, and discriminant 
score of -0.4. No ions are present at low m/z or high (inset) and the spectrum is shown for the 
informative m/z range. The spectrum is dominated by phosphate loss (-98) from the parent ion. 
Singly and doubly charged b- and y-ions map most of the sequence, including the phosphorylation 
site. (B) The same peptide identified from LPS-treated cells, with normalised delta-ions score of 
0.08, Mascot ion score of 20.6, and discriminant score of -2.3. The spectrum is dominated by 
phosphate loss from the parent ion. The C-terminus is mapped by singly and doubly charged b- and 
y-ions. Unlike the spectrum at the top, the phosphate group is assigned to the first serine. However, 
the spectrum also more plausibly locates the phosphate group to the second serine when 
considering b7 (boxed); y12 would then probably be a noise level peak. 
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Figure 4.16 Comparison of tandem mass spectra identified by LTQ-Orbitrap-MS/MS and 
QTOF-MS/MS with similar normalised delta-ions scores. 
Tandem mass spectra for the phosphopeptide IDIsPSALR from bcl-2-associated transcription factor 
1 from LPS-treated cells, identified by (A) LTQ-Orbitrap-MS/MS with normalised delta-ions score of 
0.48, Mascot ion score of 37.7, and discriminant score of 17.8; (B) QTOF-MS/MS with normalised 
delta-ions score of 0.33, Mascot ion score of 39.7, and discriminant score of 9.7. Both spectra 
confidently identify the sequence and phosphorylation site with plausible fragment ion intensities, 
including abundant y5 from breakage N-terminal to proline and phosphate loss (-98) from y6 
onward; for the LTQ-Orbitrap spectrum, phosphate loss from b4 adds confidence to the 
phosphorylation site placement. 
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4.5 iTRAQ LTQ-Orbitrap Dataset 
4.5.1 Sample Processing and Analysis by LTQ-Orbitrap-MS/MS 
Aliquots of 100 µg of the digest described in section 4.3.1 were reacted with iTRAQ 
reagents #117 for resting and #114 for LPS-treated cells, and mixed at equal 
amounts. The majority of the labelled digest was enriched for phosphopeptides 
with TiO2. Samples of 5 µg of non-enriched digest, and 1 µg and 5µg of TiO2 
enriched digest were analysed by LTQ-Orbitrap-MS/MS in HCD mode, under the 
same experimental conditions described in section 4.3.1. Mascot searches were 
conducted with precursor ion and fragment ion mass tolerances of ± 5 ppm and ± 
0.05 Da, respectively. iTRAQ labelling of the peptide amino terminus and lysine 
residues was set as fixed modification, and iTRAQ labelling of phosphotyrosine 
was excluded owing to its slow labelling reaction, which would result in inaccurate 
quantitation if included. iTRAQ reporter ion ratios were read off the Mascot file for 
individual peptides. Mascot output was further validated with Scaffold at a 95% 
identification probability. 
4.5.2 Normalisation of iTRAQ Ratios 
To determine accurate phosphorylation fold-changes from phosphopeptide iTRAQ 
ratios, it was necessary to establish precise estimates of the amount of digest 
mixed from resting and LPS-treated cells. For this purpose, iTRAQ ratios of non-
phosphorylated peptides from abundant proteins were averaged and used to 
normalise phosphopeptide ratios. Tandem mass spectra from analysis of non-
enriched digest were validated manually to ensure accurate quantitation, and 
peptides were required to have Mascot ion scores of ≥ 30 and Scaffold 
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discriminant scores of ≥ 10; additionally, only tandem mass spectra with iTRAQ 
reporter ions of at least 20% relative signal intensity were accepted. Only peptides 
from proteins with at least five manually validated peptides were considered, 
resulting in a set of 74 high confidence identifications from nine proteins (Figure 
4.17) (Appendix D). The iTRAQ ratios of the 74 peptides were normally distributed, 
with a mean ratio of 0.7365 (Figure 4.18, A). 
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Figure 4.17 Tandem mass spectra for iTRAQ-labelled non-phosphorylated peptides. 
Digests from resting and LPS-treated cells were labelled with iTRAQ reagents #117 and #114, 
respectively, and analysed by LTQ-Orbitrap-MS/MS in HCD mode. Representative spectra are 
shown for three of the 74 non-phosphorylated peptides used to normalise phosphopeptide iTRAQ 
ratios. The reporter ion region is shown expanded (right panes). The peak at m/z 145.1 is from the 
non-fragmented iTRAQ label. Peptides were (A) VNLAMDVGK from pyruvate kinase, 117/114 ratio 
of 0.642; (B) EITALAPSTMK from actin, 117/114 ratio of 0.720; (C) ILLAELEQLK from vimentin, 
117/114 ratio of 0.865. iTRAQ-labelled residues are indicated by +144 in the sequence. 
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Figure 4.18 Distribution of iTRAQ ratios of non-phosphorylated peptides. 
Digests from resting and LPS-treated cells were labelled with iTRAQ reagents #117 and #114, 
respectively, and analysed by LTQ-Orbitrap-MS/MS in HCD mode. 117/114 ratios for 74 non-
phosphorylated peptides with strong reporter-ion signals were binned at 0.01 intervals and the 
number of peptide matches at each bin centre was plotted as a histogram. The distribution of 
unbinned iTRAQ ratios (mean 0.7365) was normal as assessed by Kolmogorov-Smirnov test 
(alpha=0.05). 
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4.5.3 Phosphopeptide Quantitation 
Phosphopeptide tandem mass spectra from analyses of enriched digest were 
manually inspected, with a requirement for iTRAQ reporter ion signals of at least 
10% relative intensity and identification with positive Scaffold discriminant score. In 
this way, 89 phosphopeptides were identified (Appendix E). iTRAQ ratios from 
peptides identifying the same phosphorylation site were averaged (conflicting 
assignments were resolved by manual validation), resulting in 62 phosphorylation 
sites from 53 proteins. Averaged 117/114 reporter ion ratios were normalised 
against the mean ratio of 0.7365 determined for the 74 non-phosphorylated 
peptides and statistical significance was assessed by Student’s t-test. Almost 90% 
of phosphopeptides with multiple identifications were detected in both MS/MS runs 
and their iTRAQ ratios showed little run-to-run variation (Table 4.4). 
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Table 4.4 Phosphopeptides with at least two iTRAQ identifications. 
Protein ID Peptide sequence 
Phos. 
res. 
Fold 
Mean 
117/114 
SEM p-val. 
# MS 
runs 
Peptide 117/114 
STMN1_MOUSE ASGQAFELILsPR s 25 6.6 0.151 0.002 *** 2 0.153 0.149   
ARHG2_MOUSE LEsFESLRGER s 646 3.0 0.333 0.051 *** 2 0.384 0.282   
PLSL_MOUSE GsVSDEEMMELR s 5 2.1 0.466 0.077 *** 2 0.659 0.356 0.327 0.521 
DOCK2_MOUSE vEEEPIsPGSTLPEVk s 1683 1.6 0.632 0.028 *** 2 0.653 0.653 0.673 0.549 
CDC2_MOUSE iGEGTyGVVYk y 15 1.3 0.761 0.013 *** 1 0.774 0.748   
IF4G1_MOUSE eATLPPVsPPk s 1231 1.2 0.821 0.027 *** 2 0.800 0.789 0.874  
G3BP1_MOUSE STsPAPADVAPAQEDLR s 231 1.1 0.923 0.044 n.s. 2 0.984 0.836 0.948  
ARHG7_MOUSE msGFIYQGK s 497 1.0 0.962 0.036 n.s. 2 0.926 0.998   
GFPT1_MOUSE VDsTTcLFPVEEK s 259 1.0 0.969 0.035 n.s. 2 0.934 1.005   
EIF3C_MOUSE qPLLLsEDEEDTkR s 39 1.0 1.012 0.018 n.s. 2 0.994 1.031   
SRRM_MOUSE VSsPVLETVQQR s 1360 1.0 1.030 0.093 n.s. 1 0.937 1.123   
TR150_MOUSE IDIsPSTFR s 679 1.0 1.045 0.013 n.s. 2 1.058 1.032   
BCLF1_MOUSE iDIsPSALR s 656 1.0 1.050 0.003 n.s. 2 1.047 1.054   
CALX_MOUSE aEEDEILNRsPR s 582 0.9 1.084 0.035 n.s. 2 1.116 1.123 1.014  
VAMP_MOUSE RNLLEDDsDEEEDFFLR s 30 0.9 1.103 0.034 * 2 1.077 1.169 1.062  
NOP5_MOUSE EELAsDLEEmATSSAK s 513 0.9 1.114 0.036 * 2 1.051 1.113 1.177  
ABCF1_MOUSE QLSVPAsDEEDEVPAPIPR s 107 0.8 1.182 0.021 ** 2 1.203 1.161   
PKHO_MOUSE SSsLGDLLR s 395 0.8 1.272 0.002 *** 2 1.270 1.274   
Data are shown by decreasing iTRAQ fold-change. Modified amino acid residues are in lowercase 
in the peptide sequence. Phos. res.; phosphorylated residue, Fold; fold-change with LPS 
stimulation, 117/114; normalised iTRAQ reporter-ion ratio, SEM; standard error of the mean, p-val.; 
p-value (paired Student’s t-test against 74 non-phosphorylated peptides), n.s.; not significant, *; 
p<0.05; **; p<0.01, ***; p<0.001. 
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iTRAQ reporter ion ratios were expressed as fold-changes with LPS stimulation. 
The spread of fold-changes for the 62 non-redundant phosphorylation sites was 
similar to that of the 74 non-phosphorylated peptides, with the exception of four 
phosphorylations increasing and one phosphorylation decreasing at least twofold 
with LPS stimulation (Figure 4.19, A).  
In order to test if the ∆I metric for assessing confidence of phosphorylation site 
placement could be applied to iTRAQ-labelled phosphopeptides, the ∆I distribution 
of the 89 iTRAQ-labelled phosphopeptides was compared with that of the 
qualitative LTQ-Orbitrap phosphopeptide dataset. The distributions did not differ 
significantly, as assessed by two-tailed Mann-Whitney test (Figure 4.19, B). 
Manual validation of the spectra identifying the five phosphorylation sites regulated 
at least twofold confirmed that matches with ∆I ≥ 0.4 confidently located the 
phosphorylated residue (Figures 4.20, 4.21, and 4.22). 
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A B 
 
 
 
Figure 4.19 Comparisons of phosphopeptide fold-changes and normalised delta-ions scores. 
(A) 117/114 reporter ion ratios of 74 non-phosphorylated peptides and averaged iTRAQ ratios of 
phosphopeptides were normalised against the mean ratio of non-phosphorylated peptides (0.7365) 
and expressed as fold-changes; red lines are medians. (B) Comparison of normalised delta-ions 
score distributions for phosphopeptides from qualitative LTQ-Orbitrap data (left) and iTRAQ LTQ-
Orbitrap data (right); the difference of the distributions was not statistically significant (two-tailed 
Mann-Whitney test, p=0.8417; medians (red lines) not significantly different). 
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Figure 4.20 Tandem mass spectra for stathmin and Rho GEF2 from iTRAQ labelling. 
(A) The phosphopeptide ASGQAFELILsPR from stathmin was identified with mean 117/114 ratio of 
0.151, equalling a 6.6-fold change increase with LPS treatment (∆I of 0.96). The spectrum is 
dominated by phosphate loss (-98) from the parent ion, and iTRAQ reporter ions (shown expanded 
on right pane). The complete sequence is mapped and phosphate loss from y3 onward identifies 
the phosphorylation site. (B) The phosphopeptide lEsFESLRGER from Rho GEF2 was identified 
with mean 117/114 ratio of 0.333, equalling a 3.0-fold increase with LPS treatment (∆I of 0.83). The 
spectrum is dominated by phosphate loss from the parent ion, and iTRAQ reporter ions (shown 
expanded on right pane). Most of the sequence is mapped by b- and y-ions, and the 
phosphorylation site is located by phosphate loss from b3 and y6 onward 
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Figure 4.21 Tandem mass spectra for plastin-2 and osteoclast stimulating factor 1 from 
iTRAQ labelling. 
(A) The phosphopeptide GsVSDEEMMELR from plastin-2 was identified with mean 117/114 ratio of 
0.466, equalling a 2.1-fold increase with LPS treatment (∆I of 0.23). The spectrum is dominated by 
phosphate loss (-98) from the parent ion; iTRAQ reporter ions are shown expanded on the right 
pane. The complete sequence is mapped by b- and y-ions, and the phosphorylation site is located 
by phosphate loss from b2 and y11 onward. (B) The phosphopeptide TLSNAEDYLDDEDsD from 
the C-terminus of osteoclast-stimulating factor 1 was identified by a single peptide with 117/114 
ratio of 1.996, equalling a 2.0-fold decrease with LPS treatment (∆I of 0.54). The spectrum is 
dominated by b7, phosphate loss from y3, and iTRAQ reporter ions (shown expanded on right 
pane). The N-terminal sequence is mapped by b-ions. Phosphorylation of tyrosine is excluded by 
the presence of the non-phosphorylated immonium ion. The phosphorylation is located to the C-
terminal serine by phosphate loss from y2 onward. 
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Figure 4.22 Tandem mass spectra for HN1 from iTRAQ labelling and unlabelled. 
(A) The phosphopeptide SNsSEASSGDFLDLK from HN1 was identified by a single peptide with 
117/114 ratio of 0.467, equalling a 2.1-fold increase with LPS treatment (∆I of 0.00). The spectrum 
is dominated by y3 from favoured breakage C-terminal to leucine, and the phenylalanine immonium 
ion. iTRAQ reporter ions are shown expanded on the right pane. Much of the sequence is mapped 
by b- and y-ions. Phosphate loss (-98) from b3 onward indicates phosphorylation of the second 
serine, but the signal intensity is similar to several unassigned peaks. (B) The same peptide was 
identified by QTOF-MS/MS (∆I of 0.18). Most of the sequence is mapped by y- and b-ions, and 
phosphate loss from b3 and y13 onward adds confidence to the location of the phosphorylation site 
to the second serine. 
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4.6 Analysis of the Merged Non-Redundant Dataset 
4.6.1 Dataset Characteristics 
The two qualitative and one quantitative datasets from analyses of two 
independent experiments were merged to create a set of non-redundant 
phosphorylation sites. Phosphopeptides in the final set were those identifying 
phosphorylation sites with highest ∆I; spectra were manually validated when 
alternative sites were assigned to the same sequence with similar ∆I. The final 
dataset contained 445 phosphorylation sites from 338 proteins, which were 
distributed over 16 subsets according to cell treatment and type of mass 
spectrometer (including the set of sites exclusive to iTRAQ labelling) (Figure 4.23, 
A). The largest subsets were sites identified exclusively from LPS-treated cells, 
comprising 35% of total phosphorylations, followed by sites unique to resting cells 
at 27%. Phosphorylation fold-changes from iTRAQ labelling did not follow a 
discernable trend for cell treatment, with the exception that two of the four sites 
upregulated at least twofold were also exclusive to LPS-treated cells (Figure 4.23, 
C). The distribution of phosphorylated serine, threonine, and tyrosine residues for 
the complete dataset was similar to published figures (Olsen et al., 2006), except 
for a 2.5-fold greater incidence of tyrosine phosphorylation (Figure 4.23, B). 
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A B 
 
 
 
C  
 
 
 
Figure 4.23 Distribution of phosphorylation sites for merged QTOF and LTQ-Orbitrap data. 
(A) Venn diagram of 430 non-redundant phosphorylation sites; a further 15 sites were unique to the 
iTRAQ dataset (not shown). (B) Distribution of phosphorylated amino acid residues (including 
iTRAQ data). (C) Phosphorylation fold-change with LPS treatment for sites quantitated with iTRAQ, 
plotted by cell treatment; red lines are medians. Res; resting. 
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The contribution of LTQ-Orbitrap identifications to the total number of 
phosphopeptides was 25%, increasing to 32% of non-redundant phosphorylation 
sites located with ∆I ≥ 0.4. In total, almost half of all non-redundant phosphorylation 
sites were located with ∆I ≥ 0.4 (Table 4.5). 
 
 
Table 4.5 Peptide match statistics for the combined dataset. 
 QTOF Orbitrap Merged 
Percentage of total phosphopeptides a 75% 25% N/A 
Percentage of non-redundant 
phosphorylation sites with ∆I < 0.4 74% 26% 51% 
Percentage of non-redundant 
phosphorylation sites with ∆I ≥ 0.4 68% 32% 49% 
aPeptide identifications were at greater than 95% probability as specified by the 
Peptide Prophet algorithm. 
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4.6.2 Annotation of Phosphoproteins 
Gene identifiers of phosphoproteins detected in resting and LPS-treated cells were 
submitted to the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) (Dennis et al., 2003) to perform enrichment analyses of biological 
annotations (phosphoproteins unique to the iTRAQ dataset were grouped with 
those detected in resting cells if the fold-change in phosphorylation with LPS 
stimulation was < 2; those with fold-changes ≥ 2 were grouped with 
phosphoproteins detected in LPS-treated cells). Up to 10-fold enrichment of 
annotation terms against the mouse genome was observed for phosphoproteins 
detected in resting cells (Table 4.6) and LPS-treated cells (Table 4.7). Considering 
only terms enriched with significant p-values and FDR ≤ 5% (Segal et al., 2004; 
Huang da et al., 2009), the majority of enriched annotation terms (70%) were 
common to both datasets and showed similar enrichment against the genome, with 
the most enriched terms being initiation factor, ribosome biogenesis, 
serine/threonine-specific protein kinase, and translation regulation. Annotation 
terms enriched exclusively in resting cells were isomerase and spliceosome, and 
those enriched exclusively in LPS-treated cells were phosphotransferase, mitosis, 
SH3-domain, cell division, cell cycle, repressor, and cytoskeleton. Of the 
phosphoproteins detected in resting and LPS-treated cells, 98% and 99%, 
respectively, were proteins annotated as phosphorylated.  
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Table 4.6 Enrichment analysis of biological annotations of 
phosphorylated proteins detected in resting cells against 
the mouse genome. 
Annotation term % 
P-
Value 
Fold 
enrich. 
FDR 
(%) 
Initiation factor 3 <0.001 10.8 <0.1 
Translation regulation 3 <0.001 9.4 <0.1 
Serine/threonine-specific protein kinase 2 0.002 9.3 2.5 
Ribosome biogenesis 2 0.003 8.2 3.9 
Protein biosynthesis 4 <0.001 5.3 0.1 
Isomerase 3 0.001 5.0 1.4 
RNA-binding 13 <0.001 4.7 <0.1 
Spliceosome 3 0.004 4.7 4.9 
mRNA splicing 5 <0.001 4.7 0.1 
mRNA processing 6 <0.001 4.6 <0.1 
Acetylation 59 <0.001 4.6 <0.1 
Ribonucleoprotein 6 <0.001 3.9 0.1 
Isopeptide bond 5 0.001 3.2 1.7 
Serine/threonine-protein kinase 7 <0.001 3.1 0.3 
Phosphoprotein 98 <0.001 2.8 <0.1 
Ubiquitin-like conjugation 7 0.001 2.5 1.0 
Cytoplasm 40 <0.001 2.3 <0.1 
Kinase 9 0.001 2.3 0.8 
ATP-binding 16 <0.001 2.2 <0.1 
Nucleus 44 <0.001 2.1 <0.1 
Nucleotide-binding 18 <0.001 2.0 <0.1 
Coiled coil 18 <0.001 1.8 0.2 
Alternative splicing 43 <0.001 1.7 <0.1 
Data are shown by decreasing fold-enrichment. Enrichment 
analysis was performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID), functional 
annotation chart tool, by retrieving terms from the category 
SP_PIR_KEYWORDS (annotations from the SwissProt and 
Protein Information Resource databases). Only results with 
significant p-values and FDR ≤ 5% are shown. Fold enrich.; 
fold-enrichment, %; percentage of total phosphoproteins in the 
dataset, FDR; false discovery rate. 
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Table 4.7 Enrichment analysis of biological annotations of 
phosphorylated proteins detected in LPS-treated cells 
against the mouse genome. 
Annotation term % 
P-
Value 
Fold 
enrich. 
FDR 
(%) 
Ribosome biogenesis 2 <0.001 9.3 0.5 
Serine/threonine-specific protein kinase 2 0.002 8.8 3.1 
Initiation factor 2 0.001 7.6 1.4 
Translation regulation 2 0.002 6.7 2.5 
Phosphotransferase 4 <0.001 5.1 0.5 
RNA-binding 13 <0.001 4.9 <0.1 
Mitosis 5 <0.001 4.7 0.1 
Protein biosynthesis 4 0.001 4.5 1.1 
mRNA splicing 5 <0.001 4.4 0.1 
Acetylation 55 <0.001 4.2 <0.1 
SH3 domain 5 <0.001 4.1 0.2 
mRNA processing 5 <0.001 3.8 0.2 
Ribonucleoprotein 5 <0.001 3.7 0.2 
Cell division 5 <0.001 3.6 0.4 
Cell cycle 9 <0.001 3.4 <0.1 
Isopeptide bond 5 0.001 3.3 0.8 
Repressor 6 0.001 2.9 0.6 
Phosphoprotein 99 <0.001 2.8 <0.1 
Serine/threonine-protein kinase 6 0.001 2.7 1.6 
Ubiquitin-like conjugation 8 <0.001 2.7 0.2 
Cytoplasm 39 <0.001 2.3 <0.1 
Cytoskeleton 7 0.002 2.3 2.2 
Kinase 8 0.003 2.1 3.5 
ATP-binding 15 <0.001 2.0 0.1 
Nucleus 42 <0.001 2.0 <0.1 
Coiled coil 19 <0.001 2.0 <0.1 
Nucleotide-binding 17 <0.001 1.9 0.1 
Alternative splicing 38 <0.001 1.5 <0.1 
Data are shown by decreasing fold-enrichment. Enrichment 
analysis was performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID), functional 
annotation chart tool, by retrieving terms from the category 
SP_PIR_KEYWORDS (annotations from the SwissProt and 
Protein Information Resource databases). Only results with 
significant p-values and FDR ≤ 5% are shown. Fold enrich.; 
fold-enrichment, %; percentage of total phosphoproteins in the 
dataset, FDR; false discovery rate. 
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In order to test if the annotation terms enriched exclusively in either dataset 
represented cellular processes regulated by LPS-induced phosphorylation, the 
DAVID tool was used to search annotations from several databases for positive or 
negative enrichment with LPS treatment, where 1.5-fold enrichment or greater 
indicates significance (Huang da et al., 2009). The terms mRNA processing and 
mRNA metabolic process were enriched in resting cells with significant p-values; 
however, false discovery rates were greater than 30% (Table 4.8). The terms cell 
cycle and intracellular transport were enriched with significant p-values in LPS-
treated cells, but also with very high false discovery rates (> 40%) (Table 4.9). 
(Note: acetylation appeared to be slightly enriched in both resting and LPS-treated 
cells, but at 21% the false discovery rate in LPS-treated was 100-fold greater than 
in resting cells). DAVID searches were repeated against all available annotation 
categories, also using DAVID’s functional annotation clustering option, without 
obtaining significant results (data not shown). Overall, owing to high false discovery 
rates, no significant positive or negative enrichment of cellular processes with LPS 
treatment was detected. 
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Table 4.8 Enrichment analysis of biological annotations of 
phosphorylated proteins detected in resting cells against those 
detected in LPS-treated cells. 
Annotation category Term % 
P-
Value 
Fold 
enrich. 
FDR(%) 
SP_PIR_KEYWORDS Acetylation 40 <0.001 1.2 0.2 
GOTERM_BP_FAT mRNA processing 6 0.02 1.5 30.8 
SP_PIR_KEYWORDS mRNA processing 5 0.04 1.6 39.0 
GOTERM_BP_FAT mRNA metabolic process 6 0.04 1.5 47.5 
SP_PIR_KEYWORDS mRNA splicing 5 n.s. 1.6 53.2 
GOTERM_BP_FAT RNA processing 7 n.s. 1.3 75.1 
SP_PIR_KEYWORDS Nucleotide-binding 13 n.s. 1.2 68.8 
Data are shown by increasing p-value. Enrichment analysis was 
performed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID), functional annotation chart tool, by 
retrieving terms from 13 default categories, including 
SP_PIR_KEYWORDS (annotations from the SwissProt and Protein 
Information Resource databases) and GOTERM_BP_FAT (Gene 
Ontology terms of biological processes). N.s.; not significant, fold enrich.; 
fold-enrichment, %; percentage of total phosphoproteins in the dataset, 
FDR; false discovery rate. 
 
Table 4.9 Enrichment analysis of biological annotations of 
phosphorylated proteins detected in LPS-treated cells against 
those detected in resting cells. 
Annotation category Term % 
P-
Value 
Fold 
enrich. 
FDR(%) 
SP_PIR_KEYWORDS Acetylation 38 0.02 1.1 21.3 
GOTERM_BP_FAT Cell cycle 6 0.04 1.4 43.1 
GOTERM_BP_FAT Intracellular transport 5 0.04 1.5 50.3 
SP_PIR_KEYWORDS Cell cycle 5 n.s. 1.5 56.3 
SP_PIR_KEYWORDS mRNA splicing 4 n.s. 1.5 70.1 
Data are shown by increasing p-value. Enrichment analysis was 
performed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID), functional annotation chart tool, by 
retrieving terms from 13 default categories, including 
SP_PIR_KEYWORDS (annotations from the SwissProt and Protein 
Information Resource databases) and GOTERM_BP_FAT (Gene 
Ontology terms of biological processes). N.s.; not significant, fold enrich.; 
fold-enrichment, %; percentage of total phosphoproteins in the dataset, 
FDR; false discovery rate. 
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Proteins and their phosphorylation sites exclusive to LPS-treated cells are detailed 
in Table 4.10 and those not exclusive to LPS-treated cells in Table 4.11. Proteins 
were grouped by functional category or cellular process based on annotations 
retrieved from the Uniprot database with GORetriever (McCarthy et al., 2006). 
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4.7 Discussion 
4.7.1 First Screen – QTOF Data 
4.7.1.1 LPS Stimulation and Sample preparation 
The selection of ERK as readout of optimal overall phosphorylation levels (Figure 
4.1) was based on the rationale that ERK activation presents a midpoint between 
receptor proximal events and the large number of downstream targets of MAP 
kinase and NF-κB signalling (Guha and Mackman, 2001). The absence in the final 
dataset of any phosphorylations of signalling proteins upstream of ERK (apart from 
possible negative feedback to MKK2) probably indicates that receptor proximal 
phosphorylations were more transient and require earlier timepoints to be detected.  
Having determined an optimal duration of LPS stimulation, the preparation of 
identical preparative gels from resting and LPS-treated RAW cells extracts (Figure 
4.2) was critical to enable cutting of slices of equal width from each gel in order to 
minimise unequal ion suppression effects between pairs of gel strips that would 
prevent like-for-like comparison. 
4.7.1.2  Mascot Search Parameters 
Optimisation of Mascot search parameters was important to enable confident 
identification of the maximum number of candidates for further validation, and 
showed that using sub-optimal parameters results in fewer identifications and 
increased FDR (Table 4.1). The presence of peptides with missed tryptic cleavage 
sites probably explains the low number of matches obtained when requiring 
complete tryptic cleavage. Others have reported that up to 50% of 
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phosphopeptides contain missed tryptic sites (Bodenmiller et al., 2007) and that 
phosphopeptides were four times more likely to contain missed tryptic sites with 
nearby phosphorylated residues (Molina et al., 2007). Permitting two missed tryptic 
sites for database searches is generally considered optimal for phosphoproteomics 
studies, which was confirmed by the highest number of matches obtained under 
that condition. The small decrease in the number of matches at a mass tolerance 
of ± 25 ppm despite a lower identity threshold indicates that fewer peptides were 
measured at such high accuracy. A reduction in the number of matches at a mass 
tolerance of ± 100 ppm is explained by the increased identity threshold, with fewer 
peptides having ion scores exceeding that threshold. This phenomenon was also 
described by Gygi and co-workers, who analysed phosphopeptide-enriched 
samples by LTQ-FT-MS/MS, and reported an almost twofold reduction in the 
number of Mascot phosphopeptide identifications when the precursor mass 
tolerance was increased from ± 10 ppm to 500 ppm (Bakalarski et al., 2007). 
Similarly, searching the large NCBInr database also reduced the number of peptide 
matches because of the increased identity threshold not being met by spectra with 
low ion scores. 
In order to explain the effect of search parameters on FDR it is necessary to 
consider that database search tools such as Mascot are designed to find the best 
possible match within the effective database, i.e. the in silico digested peptides that 
fall within the mass tolerance and tryptic cleavage setting. When the peptide 
sequence that is the correct match is not present in the effective database, either 
because the mass tolerance was too tight or fewer missed tryptic sites were 
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considered than those present in the correct phosphopeptide sequence, Mascot 
will match the spectrum to the next best in silico sequence; if that sequence 
exceeds the identity threshold it is a false positive (Resing et al., 2004). 
Furthermore, phosphopeptide spectra are generally of poorer quality than those of 
non-phosphorylated peptides, because facile loss of the phosphate group results in 
incomplete fragmentation of the precursor, producing fewer sequence specific 
fragment ions that have low signal intensity and also show phosphate losses, 
further reducing spectral quality (Bakalarski et al., 2007). Ion scores for 
phosphopeptide spectra are therefore generally lower than those of non-
phosphorylated peptides (with the exception of tyrosine phosphorylation, which 
normally does not exhibit facile phosphate loss), and may not exceed the identity 
threshold if the effective database is too large. Consequently, any deviation from 
the optimal precursor mass tolerance and tryptic cleavage setting will create an 
effective database that is either too small or too large, resulting in fewer correct 
matches and a concomitant increase in the proportion of false positive matches, 
which explains the higher FDR observed for Swiss-Prot searches with sub-optimal 
settings. The low FDR from searching NCBInr reflects the absence of matches to 
spectra of poorer quality, because their ion scores did not exceed the identity 
threshold; in fact, 23% of the 718 phosphopeptide identifications made by QTOF-
MS/MS would not have met the NCBInr identity threshold. These findings agree 
with published guidelines that recommend searching the smallest possible 
database, with the exception being the identification of sequence variants, which is 
not supported by Swiss-Prot and requires larger databases such as NCBInr 
(Nesvizhskii, 2007). 
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4.7.1.3 Dataset Characteristics 
The similarity between the datasets from resting and LPS-treated cells indicates 
good repeatability of the workflow, and the large number of methionine-oxidised 
peptides is explained by the multiple sample handling steps of the gel-based 
workflow (Table 4.2). The greater yield of singly and doubly phosphorylated 
peptides, and lower FDR from LPS-treated cells might indicate greater 
phosphorylation site occupancy induced by LPS treatment, resulting in better 
spectral quality. 
The observed enrichment efficiency of 40% is lower than that achieved by Gygi 
and co-workers, who detected 65% phosphopeptides with a similar gel-based 
workflow using TiO2 enrichment (Wilson-Grady et al., 2008). However, the group 
analysed phosphopeptide enriched fractions by nanoHPLC on-line to LTQ-
Orbitrap-MS/MS, permitting more efficient separation and detection of 
phosphopeptides than the off-line HPLC workflow employed in this work, which 
might explain the greater selectivity reported in that study. 
In order to attain added confidence in phosphopeptide identifications, Mascot 
output was analysed with Scaffold’s implementation of the Peptide Prophet 
algorithm (Keller et al., 2002; Searle et al., 2008). Whereas Mascot computes the 
probability of a random match for individual peptide ions dependent on the size of 
the database alone, Peptide Prophet uses Bayesian statistics to calculate the 
probability that a match is correct by considering the entire population of correct 
and incorrect matches. Validation of Mascot identifications with Scaffold therefore 
takes advantage of Mascot’s reliable ion scoring model, while at the same time 
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taking into account factors that affect the entire population of spectra, such as 
instrument performance (Nesvizhskii, 2007). 
Scaffold considers spectra separately for each charge state because spectral 
quality and the distribution of correct and incorrect matches is affected by the 
charge state-dependent fragmentation behaviour of peptides (Wysocki et al., 
2000). The better spectral quality of peptides of higher charge state is reflected in 
the lower 95% probability thresholds for those populations (Figures 4.3 and 4.4). 
Manual validation of the lowest-scoring phosphopeptides identified by Mascot and 
Scaffold from both resting and LPS-treated cells indicated that, rather than 
discriminant score, peptide size might be critical for confident matching, as 
sequence and phosphorylation site were assigned with less confidence for longer 
peptides regardless of their discriminant scores (Figures 4.5 and 4.6). Size is a 
well-known obstacle to the detection and fragmentation of peptides by ESI-MS/MS 
because large peptides are more likely to exist in different charge states, splitting 
the total number of protonated molecules over several channels; fragmentation of 
less abundant precursors then results in poorer spectral quality, which is especially 
detrimental to phosphopeptide analysis (Neubauer and Mann, 1999).  
The gain over Mascot in the number of peptides achieved by Scaffold is not 
surprising, because it is has been shown that database search algorithms such as 
that implemented in Mascot invalidate many correct peptide matches through 
conservative cut-off thresholds (Resing et al., 2004), as is revealed when manually 
validating phosphopeptide matches that did not pass the cut-off (Moser and White, 
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2006). Scaffold analysis of Mascot results therefore presents a statistically valid 
approach to identify some of these ‘missed’ correct matches.  
4.7.2 Second Screen – LTQ-Orbitrap Data 
Because the overlap between resting and LPS-treated cells for the dataset of non-
redundant phosphorylation sites identified by QTOF-MS/MS was nearly as great as 
the overlap observed by Gygi and co-workers for triplicate analyses of a single 
phosphopeptide extract using a similar workflow to that described here (Bakalarski 
et al., 2007), a second gel-free experiment was conducted, with in-solution 
digestion of RAW cell extracts, TiO2 enrichment and analysis by nanoLC-LTQ-
Orbitrap-MS/MS. This set-up identified nearly half as many peptides as the first 
experiment (Table 4.3), despite a 500-fold reduction in the amount of sample 
analysed, although the elaborate workflow of the first experiment probably entailed 
considerable losses of material that reduced the actual amount analysed by QTOF-
MS/MS. 
Phosphopeptide enrichment efficiency from LPS-treated cells was 36%, which is 
similar to the first experiment (42%), but was significantly lower from resting cells at 
24% compared with the first experiment (39%). As the total number of peptides 
from LPS-treated and resting cells was comparable, this difference was unlikely to 
be due to variations in the LC-MS/MS runs. It may in fact reflect the 25% lower 
amount of material from resting cells, as determined by iTRAQ labelling of the 
same extract. A lower amount of starting material would be expected to decrease 
the number of phosphopeptides detected because of their already low abundance, 
without having much effect on the more abundant population of non-
193
Chapter 4                                                                                                   Phosphoproteomics Screen 
 
phosphorylated peptides. As for the QTOF data, the lower FDR from LPS-treated 
cells might indicate greater phosphorylation site occupancy induced by LPS 
treatment, and may also be the result of the greater amount of starting material 
from LPS-treated cells. FDRs for the second experiment were twofold greater than 
for the first experiment, which is probably due to the poorer quality of LTQ-Orbitrap 
spectra caused by more abundant neutral loss of phosphate from the precursor ion 
in the linear ion trap. As for the first experiment, doubly phosphorylated peptides 
contributed 2% of the total and were exclusive to LPS-treated cells, indicating that 
these represented inducible phosphorylations. Indeed, three of the five doubly 
phosphorylated peptides identified the doubly phosphorylated ‘T-E-Y’ activation 
loop motif of ERK1/2. 
Scaffold 95% probability thresholds were again lowest for triply charged peptides 
(Figures 4.8 and 4.9) and extended to discriminant scores below -5.0, explaining 
the 10% gain in phosphopeptides over Mascot, which was twofold greater than the 
first experiment. Peptide Prophet’s curve fitting for the distributions of matches was 
less ideal than for the first experiment, especially for quadruply charged 
precursors, suggesting that the dataset was too small for accurate fitting. The 
lowest-scoring Mascot and Scaffold matches from resting and LPS-treated cells 
were all triply charged (Figures 4.10 and 4.11) and of poorer spectral quality than 
the lowest-scoring matches identified by QTOF-MS/MS. This is probably the result 
of the lower identity threshold for LTQ-Orbitrap matches compared with QTOF 
matches, as spectra from QTOF and LTQ-Orbitrap matches with similar scores 
were also of comparable spectral quality (see Figure 4.16). 
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Despite the smaller number of phosphorylation sites identified from resting cells, 
the overlap between resting and LPS-treated cells was almost as great as that 
observed for the first experiment (compare Figures 4.7 and 4.12), suggesting that a 
fairly constant proportion of phosphorylations was identified from both resting and 
LPS-treated cells in each experiment. One might speculate that these are 
constitutive rather than induced phosphorylations (Lienhard, 2008), which would 
support the notion that phosphorylations exclusive to the treated sample are more 
likely to be stimulus-induced. 
4.7.3 Assignment of Phosphorylation Sites for QTOF and LTQ-Orbitrap Data 
Having identified several hundred phosphorylation sites from two independent 
biological experiments with two different LC-MS/MS platform and shown that 
tandem mass spectra from both platforms correctly identified phosphorylated 
peptide sequences, it was also clear that phosphorylation sites were not located 
with the same degree of confidence for each peptide match. The Gygi group 
developed the Ascore algorithm (Beausoleil et al., 2006), which uses a probabilistic 
scoring model to determine how confidently a phosphorylation has been located, 
and the group showed that Ascore assigned 62% of phosphorylation sites with 
99% certainty from a HeLa cell phosphopeptide extract analysed by LTQ-FT-
MS/MS. A similar algorithm was described by Mann and co-workers (Olsen and 
Mann, 2004; Olsen et al., 2006). However, Ascore is tied to the propriety database 
search tool Sequest and does not support Mascot files, and Mann’s algorithm is 
not available as a stand-alone tool, but only through the MSQuant software suite 
(Schulze and Mann, 2004). Furthermore, the suitability of the algorithms for QTOF 
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data is not clear, because both were developed for LTQ-FT/ LTQ-Orbitrap data. In 
contrast, the ∆I metric first described by Gygi (Elias et al., 2004) presents a simple 
way of using the available Mascot output to determine the degree of confidence in 
phosphorylation site placement independent of instrument type or software suites 
used. 
When comparing phosphopeptide data obtained by QTOF and LTQ-Orbitrap, a 
difference in their ∆I distributions would have indicated that the Mascot ion scores 
of the two top-ranking matches for a given phosphorylated sequence were better 
separated for one platform than the other, which would have been reflected in a 
shift toward higher ∆I for that platform. No such difference was observed, either by 
visual inspection of binned ∆I distributions or statistical testing (Figure 4.13), and 
manual validation of tandem mass spectra confirmed that phosphorylation sites 
identified with ∆I ≥ 0.4 were located with high confidence (Figures 4.14, 4.15, and 
4.16). (Experience shows that phosphorylation sites with ∆I ≥ 0.3 are almost 
certain to be located correctly.) Interestingly, binned ∆I distributions were bimodal 
around a ∆I of 0.4, which suggests that the upper and lower modes represent 
unequivocal and ambiguous phosphorylation site placements, respectively, and 
that an algorithm similar to Peptide Prophet might be used to model the two modes 
and calculate probability thresholds. Gygi and co-workers reported a fourfold gain 
over Mascot in the number of phosphorylation sites located with 99% certainty by 
Ascore from a sample consisting mainly of synthetic phosphopeptides (Beausoleil 
et al., 2006). By contrast, phosphopeptides identified in this work with ∆I ≥ 0.4 
comprised 45% and 49% of QTOF and LTQ-Orbitrap matches, respectively, which 
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is not far below the 62% reported by Gygi from analysis of a HeLa cell extract by 
LTQ-FT-MS/MS (Beausoleil et al., 2006), indicating that Ascore provides little gain 
over the ∆I metric when dealing with complex biological samples. 
The slightly higher median ∆I observed for LTQ-Orbitrap matches may not be 
significant, because the LTQ-Orbitrap dataset contained less than half the 
phosphopeptide matches of the QTOF dataset, and may have been biased toward 
inducible phosphorylations due to the lower amount of sample from resting cells, 
which would result in more abundant phosphopeptides identified with higher 
confidence and therefore increased mean ∆I. On the other hand, a similar increase 
in mean ∆I was observed from like-for-like comparison of 68 phosphorylation sites 
identified by each platform, suggesting that phosphopeptide spectra obtained by 
LTQ-Orbitrap indeed permit more confident phosphorylation site allocation. 
4.7.4 iTRAQ LTQ-Orbitrap Dataset 
As part of the second experiment, iTRAQ-labelled samples were prepared from the 
same digests and analysed by LTQ-Orbitrap MS/MS in HCD mode. Unlike labelling 
techniques that impart a mass difference at the peptide level and permit several 
quantitative measurements of precursor ions over their chromatographic elution 
window, iTRAQ quantitation is based on the detection of a single set of isotopic 
peaks per spectrum, resulting in less reliable quantitation (Hackett, 2008). 
Therefore, stringent criteria for identification and normalisation of iTRAQ-labelled 
peptides were imposed to ensure accurate quantitation. Both non-phosphorylated 
and phosphorylated peptides were accepted only when spectra showed strong 
reporter ion signals, because iTRAQ ratios measured by low level reporters have 
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been shown to result in inaccurate quantitation (Trinidad et al., 2008). Variation in 
the amount of starting material is the most obvious source of quantitative error, and 
was corrected for by normalisation against average reporter ion ratios of non-
phosphorylated peptides from abundant proteins identified by several peptides 
(Figure 4.18), as has been described by Zhang and co-workers (Zhang et al., 
2005). It is not clear whether the BCA protein assay underestimated the amount of 
material from LPS-treated cells by 24% or overestimated that from resting cells by 
35%, but when taking into account losses from TiO2 enrichment, it is possible that 
considerably less than 1 µg and 5 µg of enriched extract were used for the two LC-
MS/MS runs. Marto and co-workers analysed pre-fractionated phosphopeptide 
extracts (five fractions) from 100 µg starting material per iTRAQ-labelled condition 
and quantified over 800 phosphopeptide HCD tandem mass spectra obtained from 
five LTQ-Orbitrap-MS/MS runs (Zhang et al., 2009), suggesting that more starting 
material and a more elaborate workflow would have yielded far greater numbers 
than the 62 phosphorylation sites quantitated here. The small amount of sample 
material may also have been the cause for poor reporter ion signals of spectra that 
did not pass the stringent quality criteria (not shown), which would be more 
pronounced for phosphorylations of low abundance. Nonetheless, the excellent 
run-to-run variation achieved for those phosphopeptides quantified multiple times 
(Table 4.4) indicates that small amounts of labelled sample or variation in the 
amount of sample analysed per run do not affect accuracy of quantitation for 
spectra of high quality. 
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Statistical testing and manual inspection of tandem mass spectra suggested that 
the ∆I metric also applied to iTRAQ-labelled HCD-fragmented peptides (Figures 
4.19, 4.20, 4.21, and 4.22), although comparison of ∆I distributions for unlabelled 
peptides fragmented by conventional CID in the linear ion trap with iTRAQ-labelled 
peptides fragmented by HCD may have limited import owing to the small sample 
size. 
About 8% of phosphorylation sites were regulated by LPS treatment when applying 
a conservative threshold of at least twofold change with LPS treatment that was 
deemed necessary because possible sources of error were not assessed in 
advance, even though statistical testing indicated significant difference at 1.2-fold 
change. In comparison, other large-scale quantitative studies of stimulus-induced 
phosphorylation reported at least twofold changes for 15% of sites regulated by 
TNF (Cantin et al., 2006) or EGF stimulation of HeLa cells (Olsen et al., 2006), 
10% of sites regulated by IFN-γ stimulation of J774 murine macrophages 
(Marcantonio et al., 2008), and 6% of sites regulated by T cell receptor activation in 
Jurkat cells (Mayya et al., 2009). This suggests that either the number of quantified 
sites in this study was too small to represent the population of regulated sites, or 
that changes in phosphorylation levels downstream of TLR4 are more akin to those 
induced by T cell receptor and cytokine signalling; alternatively, the differences 
might be cell type-specific. 
Overall, the iTRAQ-labelled dataset had too little overlap with the qualitative data to 
permit any conclusions about the likelihood that phosphorylations identified 
exclusively from treated cells were regulated. Given that two of the four 
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upregulated sites were also detected in resting cells and fold-changes did not 
follow a discernable trend with cell treatment for the 47 phosphorylations shared 
with the qualitative data, it is questionable that such conclusions could be drawn 
even from a larger quantitative dataset. 
4.7.5 Analysis of the Merged Non-Redundant Dataset 
4.7.5.1 Dataset Characteristics 
From two biological experiments, 356 phosphorylation sites were identified by 
QTOF-MS/MS from the first experiment, and 152 non-quantitated and a further 62 
quantitated sites from the second experiment by LTQ-Orbitrap-MS/MS. Not 
surprisingly, the merged dataset of 445 phosphorylation sites contained a majority 
of sites exclusive to LPS stimulation (Figure 4.23), as fewer sites were identified 
from resting cells by LTQ-Orbitrap-MS/MS. The greater than expected incidence of 
tyrosine phosphorylation may not be significant as the dataset was probably too 
small to be representative. Tyrosine phosphorylated sites were overrepresented in 
resting cells from the first experiment, identified mainly from PLCγ2, and 
overrepresented in LPS-treated cells from the second experiment, showing that 
there was no trend with cell treatment. The greater stability of tyrosine-
phosphorylated residues in CID, resulting in better spectral quality and higher 
identification rates, may also explain the overrepresentation of tyrosine sites, which 
might be more pronounced in a small dataset. 
The merits of conducting a repeat experiment using a different LC-MS/MS platform 
are not only evident from the 25% additional phosphorylation sites identified (89 
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sites gained over the first experiment), but also from the gain in confidence of 
phosphorylation site location: QTOF data alone comprised 45% peptides identified 
with ∆I ≥ 0.4, increasing to 49% for the merged dataset, which is attributable 
almost exclusively to LTQ-Orbitrap data. Cutillas and co-workers recently 
compared phosphopeptide identifications made by QTOF- and LTQ-Orbitrap-
MS/MS and reported significant differences between them (Alcolea et al., 2009). In 
their work, despite a similar number of tandem mass spectra acquired by each 
platform, LTQ-Orbitrap spectra were matched to almost three times more 
phosphopeptide sequences than QTOF spectra, with 10% of all LTQ-Orbitrap 
spectra matched at 3% FDR by Mascot. Although the authors did not assess 
confidence of phosphorylation site placement, they speculated that LTQ-Orbitrap 
spectra may be more readily matched to phosphopeptide sequences owing to a 
greater number of b-ions detected by ion trap MS/MS, and the greater mass 
accuracy and sensitivity of the LTQ-Orbitrap compared with QTOF-MS/MS. By 
contrast, close to 20% of spectra from both platforms were matched in this work, 
suggesting that LTQ-Orbitrap-MS/MS does not have a fundamental advantage 
over QTOF-MS/MS in the number of matched spectra. However, it is difficult to 
compare the two studies, as Cutillas and co-workers analysed the same amount of 
phosphopeptide-enriched sample and used a similar chromatographic setup for 
both platforms, whereas sample amounts and workflows differed greatly for the two 
platforms used in this work. Furthermore, Cutillas and co-workers smoothed and 
centroided spectra from both platforms, whereas only QTOF spectra were charge 
state de-encrypted and de-isotoped in this work, possibly influencing Mascot 
identification rates. Interestingly, the difference in size between the datasets 
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acquired on two platforms was similar for Cutillas’ work and this study (Cutillas: 
2.9-fold; LTQ-Orbitrap vs. QTOF, this study: 2.3-fold; QTOF vs. LTQ-Orbitrap), but 
Cutillas reported only a 10% gain over the larger dataset when merging data from 
both platforms, whereas a 25% gain was achieved in the present work. This may 
indicate that complementarity of peptide identifications from different mass 
spectrometers, as reported by Cutillas and others (Elias et al., 2005), is less 
important than variation in experimental workflow when attempting to increase the 
total number of peptide identifications. 
4.7.5.2 Annotation of Phosphoproteins 
In order to try to identify LPS-regulated cellular processes, I performed Gene 
Ontology (GO) analyses of the phosphoproteins identified. Enrichment analysis of 
GO annotation terms using the DAVID tool revealed that the majority of biological 
processes were enriched equally against the whole genome in resting and LPS-
treated cells (Tables 4.6 and 4.7). The most highly enriched terms were common to 
resting and treated cells and can be grouped into the categories translation 
(initiation factor, ribosome biogenesis, translation regulation) and serine/threonine 
phosphorylation (serine/threonine-specific protein kinase), showing that 
phosphoproteins involved in these processes were identified with equivalent 
frequency from resting and LPS-activated cells, which suggests absence of 
regulation with LPS treatment. Exclusive enrichment against the mouse genome of 
annotations associated with transcription in both resting and LPS-treated cells 
(spliceosome and repressor, respectively) indicates that LPS-induced regulation of 
transcription by phosphorylation was also not detected. The high FDRs of 
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transcription-associated annotations that showed modest enrichment in resting 
cells compared with LPS-treated cells (mRNA processing, mRNA metabolic 
process) (Table 4.8) also indicate that this enrichment was not significant. 
Other phosphoproteins that were enriched against the genome exclusively in LPS-
treated cells can be grouped into the categories cell cycle (mitosis, cell division, 
cell cycle), cytoskeleton, and signal transduction (phosphotransferase, SH3-
domain). Of these, only the term cell cycle was modestly enriched with significant 
p-value in LPS-treated cells compared with resting cells, together with the term 
intracellular transport. As both of these terms had FDRs almost ten-fold higher than 
those considered significant for GO annotations (Segal et al., 2004; Huang da et 
al., 2009), overall no significant enrichment indicating regulation of biological 
processes by LPS-induced phoshorylation could be shown. iTRAQ quantitation of 
the conserved activation site of the three cyclin-dependent kinases (CDKs) (Table 
4.4) also suggests that LPS did not regulate cell cycle proteins to a significant 
level: CDKs are important regulators of the cell cycle (Nurse, 2002), but their 
phosphorylation showed only a 1.3-fold increase with LPS, indicating that 30 
minutes of LPS treatment did not activate these kinases to a significant level. 
The failure to detect cellular processes regulated by LPS-induced phosphorylation 
might indicate that major changes in macrophage function are effected 
predominantly by altered gene expression levels (Jenner and Young, 2005), and 
that the main function of reversible phosphorylation is signal transduction to induce 
such changes in gene expression. However, it is likely that the observed results 
are due to limitations of the experimental set-up. Mass spectrometers detect and 
203
Chapter 4                                                                                                   Phosphoproteomics Screen 
 
identify preferentially peptides that ionise with higher efficiency than the bulk of 
proteolytic peptides, so-called proteotypic peptides (Kuster et al., 2005). In a set of 
relatively small LC-MS/MS experiments, such as those conducted in this work, 
where the degree of chromatographic separation of peptides is not sufficient to 
permit detection of phosphopeptides of poorer ionisation efficiency, it might be 
expected that the majority of phosphopeptides detected is common to both resting 
and treated cells. This is reflected in the large overlap between sites detected in 
resting and LPS-treated cells from the two experiments (see Figures 4.7 and 4.12). 
As a consequence, it would not be possible to identify cellular processes that are 
regulated, because insufficient numbers of phosphoproteins associated with 
specific cellular processes would have been detected exclusively in resting or LPS-
treated cells. 
Nonetheless, the detection exclusively in LPS-treated cells of known LPS-activated 
kinases, such as ERK1/2 and protein kinase D (PKD)1/3 (Table 4.10) shows that 
this population does contain LPS-induced phosphorylations, some of which might 
be novel or previously uncharacterised.  
Several phosphorylations exclusive to LPS-treated cells were also identified from 
cytoskeletal remodelling proteins, which regulate cytoskeletal restructuring and 
breakage of focal adhesions to permit macrophage migration and capture and 
phagocytosis of pathogens. These included members of the family of Rho 
GTPases known to regulate cell migration (Jones, 2000), such as Rho guanine 
nucleotide exchange factors (GEFs)2 and 7, Rho GTPase activating protein 
(GAP)1, and other known regulators of cytoskeletal rearrangement such as afadin, 
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Ena/vasodilator-stimulated phosphoprotein (VASP)-like protein, ARF GTPase-
activating protein GIT1, paxillin, plastin-2, and stathmin. Of these, S646 of Rho 
GEF2 was upregulated threefold in LPS-treated cells and was identified exclusively 
in LPS-treated cells in both experiments (see Figure 4.20, B). S25 of stathmin, a 
known target of cell division control protein (CDC)2 (also known as CDK1) (Beretta 
et al., 1993) and MAP kinases (Marklund et al., 1993), was upregulated sixfold 
(see Figure 4.20, A), and S5 of plastin-2 was upregulated 2.1-fold with LPS 
treatment (see Figure 4.21, A). As other phosphorylation sites of Rho GEFs 2 and 
7 were also detected in resting cells (Table 4.11), this indicates regulation of these 
proteins by multisite phosphorylation (Cohen, 2000), as was shown for the 
cytoskeletal remodelling protein catenin (Alema and Salvatore, 2007).  Multisite 
phosphorylation of cytoskeletal proteins may not be surprising when considering 
that cytoskeletal changes are important for numerous cellular processes and thus 
require regulation by multiple inputs. 
Other kinases known to be activated by LPS that were detected exclusively in LPS-
treated cells included MKK2, which activates ERK1/2 to regulate the transcription 
of LPS-induced inflammatory genes, and cAMP-dependent protein kinase (PKA). 
Phosphatases included protein tyrosine phosphatases (PTPs) 6, 7, and 12, and 
serine/ threonine phosphatases 1, 4, and 6, all of which are important in 
terminating signalling through tyrosine and serine/ threonine kinases downstream 
of activated receptors. 
As enrichment analysis of GO terms was unable to identify cellular processes that 
were regulated by LPS, but some known LPS-regulated phosphoproteins were 
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clearly present in the dataset, I conducted literature searches of proteins 
phosphorylated exclusively in LPS-treated cells to identify phosphorylations that 
have so far not been shown to play a role in TLR4 signalling, but may plausibly do 
so. These are discussed in the following section, along with phosphorylations of 
known LPS targets, and some notable phosphorylations exclusive to resting cells. 
Kinase motifs and phosphorylation-dependent protein binding motifs were 
predicted using a Web-based tool, NetPhorest (http://netphorest.info/) (Miller et al., 
2008). NetPhorest probabilities for the highest ranking kinase motifs and binding 
motifs are shown in brackets. 
 
4.7.5.3 Phosphorylations Exclusive to LPS-Treated Cells 
4.7.5.3.1 Known LPS Signalling Proteins 
ERK1/2 and MKK2 
LPS stimulation of macrophages results in phosphorylation of the ‘T-E-Y’ sequence 
within the activation loops of ERK1/2 by MKK1/2, leading to the downstream 
phosphorylation and activation of the transcription factor ELK-1 and other ERK 
targets (Guha and Mackman, 2001). Phosphopeptides identifying T203/ Y205 of 
ERK1 and T183/ Y185 of ERK2 with maximum ∆I of 0.6 and 0.5, respectively, were 
detected in both experiments. Immunoblotting the extract from the second 
experiment with a phospho-specific antibody against these residues confirmed that 
ERK1/2 phosphorylation was exclusive to LPS-treated cells (Figure 4.24). 
206
Chapter 4                                                                                                   Phosphoproteomics Screen 
 
A phosphopeptide from MKK2 was identified from the first experiment with ∆I of 
0.0, the most likely phosphorylated residues being S23 or T25 (Figure 4.25, A). 
Several proteomics studies have reported phosphorylation of residues within the 
identified phosphopeptide sequence, and the majority of studies located the 
phosphorylation to S23 (NetPhorest: p38; 0.32). Mann and co-workers suggested 
negative feedback from ERK to MKK2 as the function of S23 phosphorylation, 
based on kinetic profiling of the site in epidermal growth factor (EGF)-stimulated 
HeLa cells and because the peptide sequence around the site (G-P-S23-P) 
matches the minimal consensus recognition motif (X-X-S-P) for ERK (Olsen et al., 
2006). 
JUN 
In RAW cells and other macrophages JNK phosphorylates the transcription factor 
JUN at S63, which is required for its activation and for transcription of genes 
encoding cytokines and inflammatory mediators (Franklin et al., 1992; Guha and 
Mackman, 2001). Phosphopeptides identifying S63 with a maximum ∆I of 0.2 were 
detected from LPS-treated cells in both experiments and also from resting cells in 
the first experiment, and manual validation confirmed phosphorylation at S63 
(Figure 4.25, B). Detection of phosphorylation of JUN in resting cells from the first 
experiment, but not the second experiment (confirmed by immunoblotting, Figure 
4.24), may be due to basal phosphorylation of JUN in the first batch of cells, as has 
been reported for other immortalised cell lines (Sampath and Plunkett, 2000; Gilad 
et al., 2005), but might equally indicate a proportion of activated cells in the resting 
population. 
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Figure 4.24 Immunoblot of ERK and JUN phosphorylation in LPS-treated RAW cells. 
Cells were treated with 10 ng ml-1 LPS for 30 min and lysed. An aliquot of lysate was 
immunoblotted with a phospho-ERK (P-ERK) antibody. The membrane was stripped and 
reprobed with a phospho-Jun (P-JUN; Ser63) antibody, and a total p38 antibody as loading 
control. 
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A  
 
B  
 
Figure 4.25 Tandem mass spectra for MKK2 and JUN. 
(A) The phosphopeptide RKPVLPALTINPTIAEGPSPtSEGASEANLVDLQK from MKK2 was 
identified by QTOF-MS/MS with ∆I of 0.02 and Mascot ion score of 102.0. The C-terminus is 
mapped by abundant y-ions, including abundant y4 from favoured breakage C-terminal to valine, 
and the middle of the sequence is mapped by b-ions, including dominant b11, probably from 
breakage N-terminal to proline retaining the charge due to N-terminal lysine. Apart from the first 
threonine and last serine residue, all other phosphorylation site locations are possible. (B) The 
phosphopeptide NSDLLTsPDVGLLK from JUN was identified by LTQ-Orbitrap-MS/MS with ∆I of 
0.21 and Mascot ion score of 40.3. Most of the sequence is mapped by abundant b-ions and y-ions, 
including dominant y7 from breakage N-terminal to proline and y9 from breakage C-terminal to 
leucine. Phosphate loss (-98) from b7 adds confidence to the phosphorylation site placement. 
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p105/ NFKB1 
p105 plays a central role in TLR4 signalling: it is constitutively processed to 
generate the NF-κB transcription factor p50, and in its mature cytoplasmic form 
also functions as an inhibitor of NF-κB transcription factors and regulator of MAP 
kinase signalling (Beinke and Ley, 2004). Phosphopeptides identifying S940 of 
p105 were detected from the first experiment (maximum ∆I of 0.2, confirmed by 
manual validation; Figure 4.26, A) (NetPhorest: Ca2+/calmodulin-dependent protein 
kinase (CaMK)II; 0.35, CDC2-like kinase (CLK); 0.32). S940 is just upstream of 
four phosphorylation sites at the C-terminus of p105 known to regulate its LPS- 
and TNF-α-induced proteasomal degradation, resulting in release of NF-κB dimers, 
which activate transcription of inflammatory genes (Beinke and Ley, 2004). 
Degradation of p105 also frees the kinase TPL2/ Cot to phosphorylate MKK1/2, 
which in turn activate ERK1/2. In vitro phosphorylation of a murine splice variant of 
p105 at S940 by PKA has been reported, and the p105 splice variant failed to 
inhibit DNA binding of p50 and c-Rel in the presence of PKA in vitro (Gerondakis et 
al., 1993). A second report has implicated the site in prostaglandin E2 (PGE2)-
mediated suppression of LPS-induced expression of TNF-α, possibly regulated by 
stabilisation of p105 through phosphorylation at S940 (Wall et al., 2009). 
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A  
 
Figure 4.26 Tandem mass spectrum for p105/ NFKB1. 
The phosphopeptide KLsFTESLTGDSPLLSLNK from p105 was identified by QTOF-MS/MS with ∆I 
of 0.17 and Mascot ion score of 112.0. The spectrum is dominated by phosphate loss (-98) from the 
parent ion, with b- and y-ions mapping the whole sequence, and phosphate loss from b3/4 and y17 
locating the phosphorylation site. 
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PKD1/3 
PKD1/ protein kinase C (PKC)µ is a kinase of the PKC family that has been shown 
recently to be essential for MyD88-dependent TLR signalling. PKD1 was required 
for ubiquitination of TRAF6 and downstream activation of pro-inflammatory gene 
expression in RAW macrophages and bone marrow-derived DCs (Park et al., 
2009). The authors also showed that in RAW cells in response to LPS and other 
TLR ligands, PKD1 was phosphorylated at its activation loop at serines 744 and 
748, which is known to be required for PKD1 activation (Waldron and Rozengurt, 
2003). PKD3/ PKCν is closely related to PKD1 and has been shown to be 
abundantly expressed in B cells and to be activated by B cell receptor signalling 
(Matthews et al., 2003). A phosphopeptide identifying S748 (∆I of 0.5) from PKD1 
or the homologous residue S734 from PKD3 was detected in the first experiment. 
4.7.5.3.2 Regulators of Macrophage Biology 
Caspase 8 
Apart from its function in apoptotic signalling, caspase 8 is known to be important 
for monocyte-to-macrophage differentiation, effecting specific cleavage of proteins 
necessary for cytoskeletal rearrangement, and also inhibition of apoptotic 
activation of NF-κB through cleavage of RIP1 (Maelfait and Beyaert, 2008). Serine 
188 (∆I of 1.0), a site just upstream of the second death-effector (DED) domain that 
is required for caspase 8 function, was identified from the first experiment 
(NetPhorest: dystrophia myotonica-protein kinase (DMPK); 0.39).  
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Cytochrome b-245 light chain/ p22phox 
This protein is a crucial part of the NADPH oxidase, generating superoxide that 
permits phagocytic microbial killing (Ueno et al., 2005). A phosphopeptide 
identifying either S168 or T188 (∆I of 0.0; Figure 4.27, A) was detected from the 
second experiment (NetPhorest: S168 - casein kinase (CK)2; 0.59, T188 - 
microtubule affinity-regulating kinase (MARK); 0.16, CK2; 0.13). 
FYB 
FYN binding protein (FYB) is a Src homology (SH)2 and SH3 domain-containing 
adaptor protein (SH2 and SH3 domains enable interaction with proteins containing 
phosphotyrosine and proline-rich sequences, respectively) that is tyrosine 
phosphorylated on multiple residues, and binds the tyrosine kinase FYN 
downstream of T cell receptor signalling to modulate the expression of IL-2 (da 
Silva et al., 1997). In macrophages, FYB is a known target of the tyrosine 
phosphatase YopH from pathogenic Yersinia spp., a bacterium which injects 
macrophages with YopH via its type III secretion mechanism to evade 
phagocytosis, possibly via disruption of adhesion complexes involving FYB (Hamid 
et al., 1999). A phosphopeptide identifying Y559 with ∆I of 0.5 was detected from 
the second experiment (NetPhorest: insulin receptor; 0.22, Src; 0.12). 
Phospholipase A2 
Cytosolic phospholipase A (cPLA)2 is a key effector of the inflammatory response 
and is activated by phosphorylation by MAP kinases at S505 and increased 
intracellular Ca2+. The activated enzyme releases arachidonic acid from membrane 
phospholipids as a precursor for inflammatory lipid mediators such as 
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prostaglandins (Leslie, 1997).  A phosphopeptide identifying either S501 or S505 
(∆I of 0.0) was detected from the first experiment (Figure 4.27, B). 
 
 
A 
 
B 
 
Figure 4.27 Tandem mass spectra for cytochrome b-245 light chain and cytosolic 
phospholipase A2. 
(A) The phosphopeptide KKPsEGEEEAASAGGPQVNPmPVTDEVV from cytochrome b-245 light 
chain was identified by LTQ-Orbitrap-MS/MS with ∆I of 0.03 and Mascot ion score of 26.5. No ions 
are present at low or high m/z (inset) and the spectrum is shown for the informative mass range. 
The spectrum is dominated by phosphate loss (-98) from the parent ion, with y-ions and singly and 
doubly charged b-ions mapping much of the sequence. Presence of y16 and y17 establishes that 
the second serine is not phosphorylated, but phosphorylation is possible for the first serine or 
threonine. (B) The phosphopeptide VHNFmLGLNLNTsYPLSPLR from cytosolic phospholipase A2 
was identified by QTOF-MS/MS with ∆I of 0.04 and Mascot ion score of 50.0. The spectrum is 
dominated by phosphate loss (-98) from the parent ion and most of the sequence is covered by y- 
and b-ions. Threonine and tyrosine (immonium ion at m/z 136.1) are established as non-
phosphorylated, but there are no phosphorylation-specific product ions for either serine. 
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4.7.5.3.3 Potential Regulators of MAP Kinase and NF-κB Signalling 
LYRIC 
TNF-α stimulation of HeLa cells has been shown to result in association of LYRIC 
with the NF-κB transcription factor p65, and overexpression of LYRIC in HeLa cells 
enhanced transcription of NF-κB reporter constructs driven by NF-κB consensus 
sequences and also endogenous NF-κB sensitive genes such as IL-8. (Emdad et 
al., 2006). LYRIC has recently been identified in human monocytes as an LPS-
induced gene, and small interfering RNA (siRNA) knockdown of LYRIC in the 
human promonocytic cell line U937 suppressed LPS-induced expression of TNF-α 
messenger RNA (mRNA) and production of PGE2 (Khuda et al., 2009). 
Phosphorylation of LYRIC at T96 (∆I of 1.0) was detected from the second 
experiment (NetPhorest: CDK2/3; 0.39, p38; 0.34). 
HN1 
The protein product of hematopoietic- and neurologic-expressed sequence 1 (HN1) 
was originally shown to be expressed in murine yolk sack, brain, spleen, and bone 
marrow (Tang et al., 1997), and orthologues have been detected in several species 
(Zhou et al., 2004). Little is known about its function, but a recent report showed 
that in a murine melanoma cell-line depletion of HN1 decreased basal ERK 
phosphorylation and increased basal p38 phosphorylation (Laughlin et al., 2009), 
suggesting a possible role for HN1 in the regulation of MAP kinase signalling. 
Phosphopeptides indentifying S87 were detected from both experiments 
(maximum ∆I of 0.2, confirmed by manual validation; see Figure 4.22), and also 
from iTRAQ labelling by a single peptide, showing a 2.1-fold increase in 
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phosphorylation at S87 with LPS stimulation (NetPhorest: 14-3-3 binding site; 0.31, 
RCK kinase family; 0.26). 
PKA type II-alpha regulatory subunit 
PKA is known to be a downstream effector of LPS signalling, in particular 
regulating the function of NF-κB transcription factors (Perkins, 2006). Regulatory 
PKA subunits are complexed with numerous A-kinase adaptor proteins (AKAPs) 
that localise PKA to specific cellular locations and substrates, and phosphorylation 
of regulatory subunits can regulate interaction with AKAPs (Griffioen and 
Thevelein, 2002). Phosphopeptides identifying S96 (maximum ∆I of 0.5) of the type 
II regulatory subunit of PKA were identified from both experiments. This site has 
been shown to be phosphorylated by the catalytic subunit of PKA, regulating the 
association of the regulatory subunit with AKAP15/ 18 in cardiomyocytes (Manni et 
al., 2008). 
PTPN6/ SHP1 
The protein tyrosine phosphatase PTPN6 has been shown to inhibit activation of 
NF-κB and MAP kinases downstream of TLR4 and other TLRs through binding to 
the kinase domain of IRAK1, preventing the phosphorylation of its downstream 
targets, while at the same time increasing IFN production through an unknown 
mechanism (An et al., 2008). A previously unreported phosphorylation of PTPN6 at 
S10 (∆I of 1.0) was identified from the first experiment, located within the first of 
two SH2 domains of PTPN6 (NetPhorest: CK2 0.41). 
  
216
Chapter 4                                                                                                   Phosphoproteomics Screen 
 
PTPN7 and oxysterol-binding protein 1 
The protein tyrosine phosphatase PTPN7 (HePTP) specifically dephosphorylates 
ERK2 and p38, and is a negative regulator of T cell signalling when not repressed 
through phosphorylation by PKA (Nika et al., 2004). Phosphopeptides identifying 
S143 of PTPN7 with a maximum ∆I of 0.6 were detected from both experiments 
(NetPhorest: ataxia telangiectasia mutated (ATM)/ ataxia telangiectasia and rad-3-
related kinase (ATR) kinase family; 0.39). 
In HeLa cells, oxysterol-binding protein 1 forms an oligomeric phosphatase 
complex comprised of cholesterol, PTPN7, and the serine/ threonine phosphatase 
PP2A, with dual threonine/ tyrosine phosphatase activity toward ERK (Wang et al., 
2005). A phosphopeptide indentifying S184 was identified from the first experiment 
(∆I of 0.2, manually validated; Figure 4.28, A) (NetPhorest: CK2; 0.33, 14-3-3 
binding site; 0.30). 
Serine/threonine-protein phosphatase 6 regulatory subunit 1/ SAPS1 
The regulatory subunit of protein phosphatase 6/ SAPS1 has been shown to 
dephosphorylate IκBε in TNF-α-stimulated HEK 293 cells, and siRNA knockdown 
of SAPS1 resulted in enhanced degradation of IκBε in response to TNF-α 
stimulation; SAPS1 may therefore act as a negative regulator of NF-κB signalling 
by antagonising stimulus-induced degradation of IκBε and release of NF-κB 
transcription factors (Stefansson and Brautigan, 2006). A phosphopeptide 
identifying S738, S739 or S745 (∆I of 0.2; Figure 4.28, B) of SAPS1 was detected 
from the first experiment, of which S739 and S745 were identified by previous 
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phosphoproteomics studies (NetPhorest: S739 and S745 - CDK2/3; 0.39 and 0.36, 
respectively, p38; 0.34).  
 
 
A  
 
B  
 
Figure 4.28 Tandem mass spectra for oxysterol-binding protein 1 and serine/threonine-
protein phosphatase 6 regulatory subunit 1. 
(A) The phosphopeptide SLsELESLKLPAESNEK from oxysterol-binding protein 1 was identified by 
QTOF-MS/MS with ∆I of 0.15 and Mascot ion score of 71.0. The spectrum is dominated by the 
parent ion and also phosphate loss (-98) from the parent, with low level sequence specific ions 
covering most of the sequence, including the phosphorylated residue. (B) The phosphopeptide 
EADmSSIQIPSsPPAHGSPQLR from SAPS1 was identified by QTOF-MS/MS with ∆I of 0.19 and 
Mascot ion score of 30.7. The y13-ion from preferred breakage N-terminal to proline dominates the 
spectrum, with b- and y-ions mapping most of the N-terminal sequence. Placement of the 
phosphorylation is excluded for the two N-terminal serines, but is possible for the remaining three 
serines. 
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4.7.5.4 Phosphorylations Exclusive to Resting Cells 
Osteoclast stimulating factor 1 
Osteoclast stimulating factor (OSTF)1 is a SH3 domain-containing protein 
produced by osteoclasts, which derive from the same monocytic lineage as 
macrophages, and was shown to stimulate osteoclast formation (Reddy et al., 
1998). Serine 214 (∆I of 0.5) was the only phosphorylation site downregulated with 
LPS treatment (NetPhorest: CK2 0.58), identified by a single iTRAQ-labelled 
phosphopeptide (see Figure 4.21, B). 
Phospholipase Cγ2 
Phospholipase C (PLC)γ2 is a phosphoinositide-specific lipase mediating the 
production of the second messengers diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3), which are important for Ca2+ signalling and activation of PKC, 
respectively. Of the two PLCγ isoforms, PLCγ2 is known to be important for mast 
cells, natural killer (NK) cells, B cells, and platelets, but not T cells (Wilde and 
Watson, 2001). The enzyme is activated by phosphorylation on multiple tyrosine 
residues, and contains two SH2 and one SH3 domains. Five phosphotyrosine 
residues from PLCγ2 were identified from the first experiment - Y753, Y759, Y858, 
Y1217, and Y1245 – of which Y858 has not been reported previously (∆I of 0.2, 
manually validated; Figure 4.29, A) (NetPhorest: insulin receptor; 0.19). 
SHIP1 
SH2-containing inositol phosphatase (SHIP)1 is a negative regulator of B cell 
signalling that hydrolyses the membrane phospholipid phosphatidylinositol-3,4,5-
trisphosphate, resulting in negative regulation of the phosphoinositide 3-kinase 
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(PI3K) pathway. SHIP1 activation is known to repress proliferation, survival, and 
activation of hemopoietic cells, and knockout studies have suggested that SHIP is 
required for nitric oxide production in macrophages and may also be involved in the 
regulation of pro- versus anti-inflammatory macrophage subtypes (Sly et al., 2007). 
SHIP1 contains one SH2 domain and three SH3 domains and has several known 
phosphorylated tyrosines. Two phosphorylated serines were identified from the first 
experiment: the previously reported site S972 within the second SH3 domain (∆I of 
0.3, manually validated; Figure 4.29, B) (NetPhorest: DMPK; 0.32), and the novel 
site S297 (∆I of 1.0) (NetPhorest: CDK2/3; 0.39, p38; 0.34). 
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Figure 4.29 Tandem mass spectra for phospholipase Cγ2 and SHIP1. 
(A) The phosphopeptide GILDLNTyNVVK from phospholipase Cγ2 was identified by QTOF-MS/MS 
with ∆I of 0.23 and Mascot ion score of 46.7. The complete sequence is mapped by b- and y-ions, 
with dominant y7 and y9 from favoured breakage C-terminal to leucine. The presence of y5 well 
above noise level and absence of phosphate losses strongly indicates phosphorylation of tyrosine 
and not threonine. (B) The phosphopeptide GEGPPTPPSQPPLsPK from SHIP1 was identified by 
QTOF-MS/MS with ∆I of 0.33 and Mascot ion score of 36.5. Most of the sequence is mapped by b- 
and y-ions, with dominant y-ions from breakage N-terminal to proline. The phosphorylation site 
placement is defined by b- and y-ions mapping the non-phosphorylated threonine, and further 
supported by phosphate loss (-98) from b14 onward. 
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4.7.5.5 Selection of a Phosphorylation Site for Further Characterisation 
A stated aim of this work was the identification by mass spectrometry of a 
previously uncharacterised, LPS-induced phosphorylation that potentially regulates 
macrophage activation, and to validate this phosphorylation by independent 
means. It is difficult, however, to distinguish LPS-inducible sites with a detectable 
level of basal phosphorylation from those that are constitutively phosphorylated or 
non-functional (Lienhard, 2008). This is illustrated by the detection of 
phosphorylation of stathmin at S25, a known regulated site that was detected in 
both experiments in resting and LPS-treated cells, and at the same time showed 
the greatest upregulation with LPS treatment as determined by iTRAQ quantitation. 
Even phosphorylation sites plausibly associated with specific kinases may be 
important only for the particular cell-line studied, as shRNA loss-of-function 
screens have shown that kinase requirements differ considerably between cell 
types (Grueneberg et al., 2008). For example, of 89 kinases required for cell 
proliferation or survival by HeLa or 293T cells, only 20 were required by both cell-
lines. 
Prediction of kinase and phosphorylation-dependent protein binding motifs can 
also be of limited value, as such linear motifs have not yet been described for all 
kinases and binding domains. NetPhorest, the tool used in this work, features the 
most comprehensive atlas of linear motifs (Miller et al., 2008), but covers only 179 
of 518 known kinases in the human genome. As a result, NetPhorest can predict 
other kinases than the kinase shown experimentally to phosphorylate a given site if 
that kinase is not part of the atlas. For example, p105/ NFKB1 has been shown to 
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be phosphorylated by IKK2 at S927 and S932 (Lang et al., 2003), but NetPhorest 
does not contain a recognition motif for IKK2, and predicted kinases for these sites 
are CK2 (probability of 0.41) and PKC (probability of 0.33), respectively, neither of 
which are known to phosphorylate p105/ NFKB1 in vivo. Since most NetPhorest 
predictions for the sites of potential importance for TLR4 signalling were made with 
similar probability to the two IKK2 sites, the kinases predicted may equally not be 
responsible for phosphorylation of these sites in vivo. Furthermore, although 
stimulus-induced phosphorylation is generally considered to be activating and 
dephosphorylation to be deactivating, the opposite can be true, and some of the 
sites exclusive to resting cells may be regulated by stimulus-induced 
dephosphorylation (Hunter, 1995). For instance, S972 within the SH3 domain of 
SHIP1 may regulate its association with other signalling proteins, which might be 
lost upon LPS stimulation, and S214 of OSTF1, which was downregulated twofold 
with LPS treatment (albeit quantitated by a single phosphopeptide), may 
conceivably function in positive regulation of osteoclast differentiation from the 
monocytic lineage, and this phosphorylation might be downregulated by LPS to 
favour the macrophage phenotype.  
When taking into account the cost of reagents required for independent validation 
of a phosphorylation site, such as generation of a phospho-specific antibody, and 
the commitment of time and workforce, a conservative approach is sensible, thus 
limiting potential candidates to those exclusive to LPS-treated cells and with a 
plausible connection to TLR4 signalling. While a number of novel or previously 
uncharacterised sites fulfil these criteria, such as phosphorylations of caspase 8, 
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LYRIC, HN1, or PTPN6, the site that shows the greatest potential importance for 
the regulation of macrophage function by TLR signalling is undoubtedly S940 of 
p105/ NFKB1. Not only does p105/ NFKB1 play a critical role in several 
inflammatory signalling pathways (Beinke and Ley, 2004), but there is evidence 
from two independent studies that phosphorylation at S940 may regulate the 
activity of NF-κB transcription factors. 
4.8 Summary 
I conducted two phosphoproteomics screens of resting and LPS-treated RAW cells 
and identified 445 phosphorylation sites that passed stringent data quality criteria. 
Several of these sites are known to regulate macrophage activation by 
inflammatory stimuli, while others are novel or previously uncharacterised. Serine 
940 of p105/ NFKB1 was identified as a potentially important regulatory site of 
TLR4 signalling. 
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5.1 Review of p105 Signalling 
5.1.1 The Role of p105 in Macrophage Inflammatory Signalling 
Inflammatory stimuli, including microbial products detected by TLRs and other 
PRRs, as well as cytokines such as TNF-α and IL-1, activate the ‘canonical’ NF-κB 
pathway (Vallabhapurapu and Karin, 2009). These signalling pathways converge 
on and activate the IKK complex, leading to the IKK2-mediated phosphorylation of 
NF-κB inhibitory proteins IκBα and p105 at conserved residues.  Phosphorylated 
IκBα and p105 are polyubiquitinated by the SKP1, CDC53/cullin1, and F-box 
protein-β-transducing repeat-containing protein (SCF-βTrCP) (E3) ubiquitin ligase 
complex and degraded by the 26S proteasome. No longer sequestered by IκBs, 
dimeric NF-κB transcription factors translocate to the nucleus to activate 
transcription of inflammatory response genes (Figure 5.1). Unlike IκBα, which 
inhibits NF-κB p50/ p65 (RelA) dimers, p105 is thought to inhibit preferentially p50 
homodimers, although p105-mediated inhibition of heterodimers consisting of p50 
and p65 or c-Rel is possible. Whereas p50/ p65 heterodimers are considered to be 
positive regulators of inflammatory genes, p50 homodimers were thought to 
exclusively repress gene transcription, but have now been shown to activate 
transcription in some circumstances (Vallabhapurapu and Karin, 2009).  
Apart from its IκB function, p105 also regulates activation of ERK1/2 via TPL2 
kinase in macrophages stimulated with LPS (Beinke et al., 2003), other TLR 
ligands (Banerjee et al., 2006), TNF-α (Eliopoulos et al., 2003), and in HeLa and 
HEK cells stimulated with IL-1 (Rodriguez et al., 2006) (Figure 5.1). TPL2 is 
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stabilised through interaction with p105 (Waterfield et al., 2003) and while 
complexed exclusively phosphorylates p105, preventing TPL2 phosphorylation of 
MKK1/2 and thus activation of ERK1/2 (Babu et al., 2006). Regulation of TPL2 by 
p105 in TLR-stimulated macrophages also requires A20-binding inhibitor of NF-κB 
(ABIN)2 to complex with p105 and co-stabilise TPL2 (Lang et al., 2004). 
 
 
 
 
Figure 5.1 The NF-κB p105 pathway in macrophages. 
Inflammatory stimuli, including TNF-α, LPS, and other TLR ligands, activate the IKK kinase 
complex. IKK-2 phosphorylates p105 at S927 and S933, which enables binding of the SCF-βTrCP 
ubiquitin ligase complex. Ubiquitinated p105 is degraded by the 26S proteasome, freeing p50 
dimers to activate transcription of inflammatory genes. Degradation of p105 also releases TPL2 
kinase to activate the ERK MAP kinase pathway. Figure adapted from (Sun and Ley, 2008). 
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5.1.2 Structure of p105 
The nfkb1 gene encodes both full-length p105 and p50, and in murine lymphoid 
tissue also encodes several splice variants of p105 (Inoue et al., 1992; Grumont 
and Gerondakis, 1994). Although constitutive proteasomal processing of p105 to 
p50 was observed in some cell types (Moorthy et al., 2006), p50 generation is 
thought to occur mainly by co-translational processing of the p105 polypeptide, 
resulting in a fixed copy-number of p50 and p105 in each cell (Lin et al., 1998). Co-
translational processing ensures immediate association of p50 with p105 (Lin et al., 
2000) and recent work has shown that dimers of p105/ p105 and p50/ p105 form 
high molecular weight complexes that may serve as signalling platforms (Savinova 
et al., 2009). The domain structure of p105/ p50 reflects its dual role: the N-
terminal half contains the Rel homology domain (RHD) required for p50 
dimerisation, DNA binding, and nuclear localisation, whereas the C-terminal half 
contains ankyrin repeats that are common to all IκBs and enable inhibition of NF-
κB dimers through occlusion of their RHDs (Figure 5.2). The C-terminus of p105 
also contains the death domain (DD) necessary for docking of the SCF-βTrCP (E3) 
ubiquitin ligase complex in response to phosphorylation at S927 and S932 by 
IKK2, resulting in polyubiquitination and degradation of  p105 (Beinke and Ley, 
2004). 
5.1.3 Regulation of p50 and p105 by Phosphorylation 
p50 is phosphorylated by PKA at S337, which enhances DNA binding of the p50 
RHD (Hou et al., 2003) and may enable stable negative regulation of genes by p50 
homodimers (Guan et al., 2005), but this site is not known to regulate full-length 
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p105. Apart from the well-characterised IKK2 phosphorylation sites S927 and 
S932, one report identified two further C-terminal sites at S903 and S907 
phosphorylated by GSK3β (Demarchi et al., 2003). Demarchi and co-workers 
showed that GSK3β and p105 formed a complex in HeLa cells and that GSK3β 
phosphorylated p105 at S903 and S907 in vitro. TNF-α-induced polyubiquitination 
and degradation of p105 was blocked in mouse embryonic fibroblasts (MEFs) from 
gsk3β-/- mice, and TNF-α-induced degradation was blocked in Phoenix cells when 
S903 and S907 were mutated to alanine residues, indicating that phosphorylation 
of these residues by GSK3β was required for TNF-α-induced degradation of p105. 
Treatment of resting gsk3β-/- MEFs with proteasome inhibitors reduced p50 levels 
and increased p105 levels, and exogenous expression of GSK3β also reduced the 
abundance of p50 in these cells, suggesting that GSK3β might be required to 
protect p105 from constitutive processing to p50. Based on these results, 
Demarchi and co-workers proposed a model whereby p105 is stabilised by GSK3β 
phosphorylation at S903 and S907 in resting cells, preventing constitutive 
processing to p50, and that phosphorylation of these sites is a prerequisite for 
IKK2-induced degradation. However, these results have not been replicated by 
others. 
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Figure 5.2 Structure and phosphorylation sites of p105. 
The sequence of human p105 shown. NF-κB p50 spans the N-terminal 433 amino acids and 
includes the Rel homology domain, which enables dimerisation and DNA binding (enhanced by 
phosphorylation at S337 by PKA) and contains the nuclear translocation sequence (NLS). The 
glycine-rich region (GRR) prevents proteasomal degradation of p50 during constitutive processing. 
NF-κB transcription factors are sequestered in the cytoplasm through their interaction with ankyrin 
repeats (ANK) of full-length p105. Stimulus-induced proteasomal degradation of p105 requires 
phosphorylation at S927 and S932 by IKK2 to enable death domain (DD)-dependent recruitment of 
the SCF-βTrCP (E3) ubiquitin ligase complex. Phosphorylation at S903 and S907 by GSK3β might 
be required for TNF-α-induced degradation of p105 in some cell types. The murine homologue of 
the novel phosphorylation at S937 was identified in this work. Figure adapted from (Perkins, 2006). 
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5.1.4 Phosphorylation of p105 at S940 
In the present work, phosphorylation of p105 at S940 was identified by mass 
spectrometry in RAW macrophages stimulated with LPS. The site is close to the 
known IKK2 sites (murine S930 and S935) and the surrounding amino acid 
sequence is conserved between humans, mouse, and rat, and to a lesser degree 
chicken: 
 DSGVETSFRKLS937FTESLTSGA  Human p105 
 DSGVETSFRKLS940FTESLTGDS  Mouse p105 
 DSGVETSFRKLS491FSESLTGDG  Rat p70 
 DSGVETSFRKLS948FTYSDSLNS  Chicken p105 
Figure 5.3 Alignment of C-terminal p105 sequences from human, mouse, rat, and chicken. 
The novel phosphorylation site is identified by amino acid number. Conserved IKK2 sites are 
underlined. 
 
 
Two previous studies have reported phosphorylation of p105 at S940 in vitro. 
Gerondakis and co-workers investigated the function of a murine splice variant that 
comprised the C-terminal 607 amino acids of p105, known as p70 or IκBγ, and 
reported that p70 was widely expressed in murine tissues (Gerondakis et al., 
1993). p70 was phosphorylated by PKA at S576 in vitro (corresponding to p105 
S940), and p70 inhibited DNA binding of p50 or c-Rel homodimers in vitro, which 
was blocked in the presence of PKA. These results indicate that phosphorylation of 
p105 at S940 by PKA might regulate inhibition of p50 homodimers by p105 
independent of degradation. 
231
Chapter 5                                                                                           Phosphorylation of p105 at S940 
 
A recent report by Wall and co-workers implicated phosphorylation of p105 at S940 
in negative regulation of TLR4 signalling through PGE2-induced PKA activity in 
macrophages (Wall et al., 2009). In macrophages activated by inflammatory 
stimuli, PGE2 downregulates expression of pro-inflammatory cytokines, including 
TNF-α, IL-1, and IL-12, and enhances expression of anti-inflammatory cytokines 
such as IL-10 (Harris et al., 2002). PGE2 is produced from arachidonic acid, which 
is liberated from membrane phospholipids by PLA2. Arachidonic acid is converted 
into prostaglandin H2 (PGH2) by cyclooxygenase (COX)2, which is expressed in 
response to inflammatory stimuli. PGH2 is further converted into PGE2 by 
prostaglandin synthase and secreted. PGE2 activates four G-protein-coupled 
receptors (GPCRs) of the EP family, of which EP2 and EP4 are expressed by 
macrophages (Sugimoto and Narumiya, 2007). GPCR signalling activates adenylyl 
cyclase to produce cyclic adenosine monophosphate (cAMP), and binding of cAMP 
to the two regulatory (R) subunits of PKA frees and activates the two catalytic 
subunits. The two types of PKA are distinguished by their RI and RII subunits, 
which also regulate the subcellular localisation of PKA through binding to AKAPs 
(Wong and Scott, 2004). Wall and co-workers showed that PGE2 attenuated early 
LPS-induced expression of TNF-α in RAW cells, and that this effect was 
specifically regulated by type II PKA in association with AKAP95, which formed a 
cytosolic complex with PKA and p105 in unstimulated RAW cells and bone 
marrow-derived macrophages (BMDMs). PGE2 treatment attenuated early LPS-
induced TNF-α expression in wild-type BMDMs, but not in BMDMs from AKAP95GT 
mice, which express non-functional AKAP95. In wild-type BMDMs, but not 
AKAP95GT BMDMs, PGE2 treatment also attenuated LPS-induced phosphorylation 
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of p105 at the IKK2 site S935, which is required for proteasomal degradation of 
p105. The authors showed that PKA phosphorylated p105 at S940 in vitro. In 
stably transfected RAW cells, a cell-permeable cAMP analogue attenuated LPS-
induced degradation of wild-type p105, but not of S940A mutant p105, and a 
S940D phosphomimetic mutant of p105 was resistant to LPS-induced degradation. 
PGE2 treatment had no effect on LPS-induced phosphorylation of ERK.  
5.1.5 Implications of Previous Studies for the Present Work 
These results suggest that phosphorylation at S940 protects p105 from LPS-
induced degradation, and that PGE2-induced PKA might target this mechanism, 
possibly through inhibiting phosphorylation of the nearby IKK2 sites. However, 
PGE2-mediated protection of p105 from LPS-induced degradation would be 
expected to prevent activation of ERK by TPL2, which was not observed. Taken 
together, both reports showed that PKA can phosphorylate p105 at S940 in vitro, 
and suggested that this phosphorylation might regulate p105-dependent NF-κB 
activity. Gerondakis’ work indicates that phosphorylation of p105 at S940 positively 
regulates NF-κB activity by releasing NF-κB dimers, whereas Wall’s data suggest 
negative regulation of NF-κB activity through stabilisation of p105. However, 
Gerondakis studied a truncated form of p105 in an artificial system, and the 
observed mechanism may not operate in vivo. Furthermore, both p50 and c-Rel 
are now known to be phosphorylated by PKA to enhance their transcriptional 
activity (Perkins, 2006), which might explain Gerondakis’ data showing that p50 
and c-Rel transcriptional activity was increased in the presence of PKA. 
Phosphorylation of NF-κB dimers is not known to prevent their inhibition by IκBs, 
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though, which might still indicate that phosphorylation of p70 at S576 (or an 
alternative residue) blocked the IκB activity of p70. Wall’s work is supported by a 
previous report from Minami and co-workers showing that pre-treatment of murine 
BMDMs with PGE2 attenuated LPS-induced degradation of p105 (Minami et al., 
2008). Minami and co-workers reported that PGE2-mediated attenuation of p105 
degradation was lost in BMDMs from mice lacking the PGE2 receptor EP4, and 
showed that p105 is recruited to EP4 by EP4 receptor-associated protein (EPRAP). 
Using overexpression and siRNA knockdown of EPRAP, Minami demonstrated 
that EPRAP is required to protect p105 from LPS-induced phosphorylation by IKK2 
and subsequent degradation. Taking into account Minami’s data as well as their 
own findings, Wall and co-workers have suggested that p105 forms a constitutive 
complex with PKA and AKAP95, and that stimulation with PGE2 activates EPRAP 
to recruit this complex to EP4. This brings PKA to the site of EP4-induced cAMP 
production, which activates PKA to phosphorylate p105 at S940 (Wall et al., 2009). 
It is thus possible that p105 is phosphorylated by PKA in response to PGE2 
stimulation, but it is not clear if the same mechanism would be activated by LPS. 
However, no evidence exists so far for in vivo phosphorylation of p105 at S940, or 
which stimuli might induce this phosphorylation. It also remains to be demonstrated 
that PKA is responsible for this phosphorylation in vivo. 
  
234
Chapter 5                                                                                           Phosphorylation of p105 at S940 
 
5.1.6 Aims 
In this work, phosphorylation of p105 at S940 was identified by mass spectrometry 
in RAW macrophages stimulated with LPS, and a PKA-mediated regulatory 
function of this site has been implicated by two studies. My aims were: 
1. To validate a specific antibody against p105 phosphorylated at S940 
2. To investigate if LPS and other inflammatory stimuli induce phosphorylation 
at this site in RAW cells and primary human cells 
3. To investigate the role of PKA in this phosphorylation 
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5.2 Validation of an Antibody against p105 Phosphorylated at S940 
A polyclonal antibody against p105 phosphorylated at S940 was obtained from a 
custom service (Eurogentec). The phosphorylated peptide antigen was comprised 
of the sequence RKLsFTESLT (conserved between human, mouse, and rat) 
conjugated with keyhole limpet haemocyanin (KLH). Antisera were raised in rabbit 
and were affinity purified by positive and negative selection. In the following, the 
antibody is referred to as P-S940 p105 when used against endogenous murine 
p105, and as P-S937 p105 when used against the human p105 sequence. 
5.2.1 Immunoblotting 
In initial experiments I employed conditions designed to optimise the chance of 
inducing phosphorylation at S940 as well as examine its possible connection to 
LPS signalling.  RAW cells were left unstimulated or treated with LPS for 30 
minutes, or with phosphatase inhibitors as a positive control. Lysates were 
immunoblotted with the anti-P-S940 p105 antibody (Figure 5.4). An inducible 
doublet of bands was detected at the expected molecular weight of p105 from 
LPS-treated and phosphatase inhibitor-treated cells. The existence of a doublet of 
phosphorylated p105 species was reported by the Ley group using an antibody 
against human p105 phosphorylated at S927 (Salmeron et al., 2001), indicating 
that the P-S940 antibody immunoreacted with phosphorylated p105. Additional 
bands were detected at higher and lower molecular weights, though, suggesting 
that the antibody immunoreacted with other proteins or modified and truncated 
p105. The membrane was reprobed with an antibody against total p38 to 
demonstrate equal protein loading in each lane.  
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Figure 5.4 Immunoblot of RAW cell lysate with an antibody against p105 phosphorylated at 
S940. 
RAW cells were serum serum-starved and unstimulated (US), treated with 100 ng ml-1 LPS for 30 
minutes, or treated with phosphatase inhibitors (0.1 mM calyculin A; CLA, 1 mM pervanadate; PV). 
Lysates were prepared and immunoblotted with an antibody against p105 phosphorylated at S940 
(P-S940 p105). The membrane was stripped and reprobed with an anti-p38 antibody as a loading 
control. The arrow marks the proposed p105 species (doublet). 
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5.2.2 Peptide Competition 
Given the detection of multiple bands in the previous experiment, I attempted to 
distinguish between specific and non-specific targets of the antibody on the basis 
of affinity using a peptide competition assay (Figure 5.5). The antibody was mock-
treated or pre-incubated with 50, 100, 150, or 200-fold molar excess of the peptide 
immunogen, its non-phosphorylated counterpart, or both. Lysates from RAW cells 
that were unstimulated or treated with LPS or phosphatase inhibitors were 
immunoblotted with the P-S940 antibody. Detection of bands was unaffected at 50 
or 100-fold molar excess of peptides (top panes). At 150-fold molar excess, band 
intensities were uniformly diminished in the presence of the peptide immunogen 
but not its non-phosphorylated counterpart (bottom left). Pre-incubation with 200-
fold molar excess of the peptide immunogen almost completely blocked detection 
of all bands, whereas the non-phosphorylated peptide had no effect (bottom right), 
indicating that the antibody was specific to the phosphorylated peptide immunogen. 
A phospho-specific ERK antibody was used to demonstrate LPS-induced signalling 
activity, and a total p38 antibody was used to demonstrate equal protein loading in 
each lane (bottom left panes). These results established that the antibody had 
similar affinity for all the species detected. 
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Figure 5.5 Peptide competition assay. 
RAW cells were serum serum-starved and unstimulated, treated with 100 ng ml-1 LPS for 30 
minutes, or treated with phosphatase inhibitors (0.1 mM calyculin A and 1 mM pervanadate). Prior 
to immunoblotting of lysates, P-S940 p105 antibody was incubated for 1 h without peptide, or with 
50, 100, 150, or 200-fold molar excess of the phosphorylated peptide immunogen (P-S940), its non-
phosphorylated counterpart (S940), or both in a peptide competition assay (PCA). The membrane 
was stripped and reprobed with p38 and phospho-ERK (P-ERK) antibodies as loading and 
activation controls, respectively. Blots shown are representative of two experiments. Arrows mark 
the proposed p105 species. 
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5.2.3 Immunoprecipitation of p105 from RAW Cells. 
Because peptide competition could not establish the specificity of the antibody, I 
attempted to demonstrate specificity of the antibody in immunoprecipitation (IP) 
experiments. Lysates from LPS-treated RAW cells were subjected to IP with either 
a total p105 antibody (raised against a sequence within the terminal 50 amino 
acids of human p105), or with the P-S940 p105 antibody. Immunoblotting of total 
p105-depleted lysates and IP products with the P-S940 p105 antibody  resulted in 
detection of a species at the expected molecular weight of p105 from whole and 
depleted lysates and IP products (Figure 5.6, A). Higher and lower molecular 
weight bands that were observed in the previous experiments (compare Figure 5.4) 
were detected from whole and depleted lysates but not from IP products. No bands 
were detected from control IP with rabbit serum. These results established that the 
P-S940-p105 antibody specifically detected p105 and that smaller species 
detected by the antibody did not correspond to p105 that retained an intact C-
terminus but was cleaved or degraded, as these would have been 
immunoprecipitated by the total p105 antibody. 
Immunoblotting of P-S940 p105-depleted lysates and IP products with total p105 
antibody detected a dose-dependent depletion of a single species at the expected 
molecular weight of p105 (Figure 5.6, B). Abundance of the corresponding IP 
products increased in a parallel dose-dependent manner and consisted of a faint 
band at the same molecular weight as the depleted species and a more slowly 
migrating species detected at strong intensity. No bands were detected from 
control IP with rabbit serum. A total p38 antibody was used to immunoblot a 
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fraction of depleted lysates to demonstrate equal amounts of starting material. 
These results established that the P-S940 p105 antibody immunoprecipitated 
p105. The mobility shift of the IP products toward higher molecular weight 
suggested that the P-S940 p105 antibody specifically immunoprecipitated p105 
species of higher phosphorylation state. 
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Figure 5.6 Immunoprecipitation of p105 from RAW cells. 
RAW cells were treated with 100 ng ml-1 LPS for 30 minutes. Lysates were subjected to 
immunoprecipitation (IP) with rabbit serum, followed by (A) IP with total p105 antibody and 
immunoblotting of whole and depleted lysates and IP products with P-S940 p105 antibody, or (B) IP 
with P-S940 p105 antibody and immunoblotting of whole and depleted lysates and IP products with 
total p105 antibody. Starting material was 1 mg per IP, and 1/50 of depleted lysates and total IP 
products were loaded onto the gels. Part of the second membrane was stripped and reprobed with 
p38 antibody as a loading control. Arrows mark the p105 species. Bands around 50 kDa probably 
correspond to IgG heavy chain.  
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5.2.4 Transient Overexpression of S937A Mutant p105 in HEK-293–TLR4-
CD14/MD2 cells 
Having established cross-reactivity of the antibody with p105, I tested specificity 
toward the phosphorylatable epitope. HEK-293–TLR4-CD14/MD2 cells were 
transiently transfected to overexpress human wild-type p105 or a S937A mutated 
p105 sequence. Immunoblotting with the total p105 antibody demonstrated that 
both wild-type and S937A mutant p105 were equally overexpressed (Figure 5.7, 
A). By contrast, only wild-type p105 was detectable above background in the same 
lysates immunoblotted with the P-S937 p105 antibody (Figure 5.7, B). Unlike the 
previous experiments using RAW cells (compare Figure 5.4), a single species of 
overexpressed human p105 was detected by the P-S937 antibody instead of a 
doublet. There was also no LPS-inducible change in the intensity of the p105 
species detected by the P-S937 antibody, suggesting that exogenously expressed 
p105 in HEK cells was not regulated in the same way as endogenous p105 in 
RAW cells. The lack of LPS-induced regulation of exogenous p105 was not 
attributable to faulty LPS stimulation, as LPS-induced phosphorylation of ERK was 
equally represented in each set of transfectants (Figure 5.6, A, middle pane). 
Detection of LPS-induced expression of endogenous p105 by the total p105 
antibody  also indicated different regulation of p105 in HEK cells, as p105 is 
normally degraded in response to LPS stimulation (Figure 5.7, A, empty vector). A 
total p38 antibody was used to demonstrate equal loading in each lane (Figure 5.6, 
A, bottom pane). These results established that the P-S937/940-p105 antibody 
was specific for the phosphorylatable epitope of p105.  
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Figure 5.7 Transient overexpression of S937A mutant p105 in HEK-293–TLR4-CD14/MD2 
cells. 
Cells were transiently transfected using Lipofectamine with empty vector (pcDNA3FLAG), or human 
wild-type (S937) or mutant (A937) p105. Transfected cells were unstimulated or treated with 1 µg 
ml-1 LPS for 45 minutes. Lysates were prepared and split equally, and immunoblotted with (A) total 
p105 antibody or (B) P-S937 p105 antibody. The first membrane was stripped and reprobed with 
p38 and P-ERK antibodies as loading and activation controls, respectively. 
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5.2.5 Immunoprecipitation of S937A Mutant p105 from Stable Expression in 
RAW Cells 
To gain further confirmation of the antibody’s specificity, I generated RAW cell lines 
stably expressing FLAG-tagged human wild-type or S937A mutant p105, together 
with controls expressing empty vector or bovine alkaline phosphatase (BAP). Cells 
were unstimulated or treated with LPS for 2 hours. Anti-FLAG IP followed by 
immunoblotting with anti-FLAG antibody detected inducible expression of a single 
species corresponding to the molecular weight of p105 from both wild-type and 
S937A mutant expressing cells (Figure 5.8, A). Unlike transient overexpression in 
HEK cells, where expression levels were equal for wild-type and mutant p105 and 
not inducible (compare Figure 5.7), in RAW cells basal and LPS-induced 
expression of the mutant sequence was lower than in wild-type p105 expressing 
cells. This was not attributable to faulty LPS stimulation, because LPS-induced 
phosphorylation of ERK, a p105-regulated signalling event, was comparable 
between the transfectants (Figure 5.8, A, middle pane). Other species of lower and 
higher molecular weight were detected in all transfectants. A total p38 antibody 
was used to immunoblot a fraction of depleted lysates to demonstrate equal 
amounts of starting material (Figure 5.8, A, bottom pane). Reblotting with the total 
p105 antibody confirmed that the bands detected by the anti-FLAG antibody were 
p105, and also detected lower expression levels of the mutant sequence (Figure 
5.8, B). Reblotting with the P-S937 p105 antibody detected LPS-induced levels of 
wild-type but not S937A mutant p105 (Figure 5.8, C). These results gave further 
confirmation that the antibody was specific for the phosphorylatable epitope of 
p105 in RAW macrophages.  
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Figure 5.8 Immunoprecipitation of S937A mutant p105 from stable expression in RAW cells. 
RAW cells were nucleofected with FLAG-tagged expression vectors of pcDNA3 (empty vector), 
bovine alkaline phosphatase (BAP), or human wild-type (S937) or mutant (A937) p105pcDNA3. 
Cells were unstimulated or treated with 100 ng ml-1 LPS for 2 hours. Lysates were prepared, 
followed by immunoprecipitation (IP) with anti-FLAG antibody. IP products were immunoblotted with 
(A) anti-FLAG antibody, and the membrane was stripped and reprobed with (B) total p105 and (C) 
P-S937 p105 antibodies. Depleted lysate was immunoblotted with p38 and P-ERK antibodies as 
loading and activation controls, respectively. Starting material was 2.5 mg per IP, and 1/100 of 
depleted lysates and total IP products were loaded onto the gels. Arrows mark the p105 species. 
  
245
Chapter 5                                                                                           Phosphorylation of p105 at S940 
 
5.2.6 Phosphatase Treatment of Immunoprecipitated p105 
A final experiment was conducted to establish that the antibody specifically 
detected p105 phosphorylated at S937 and not the non-phosphorylated sequence. 
RAW cell lines stably expressing FLAG-tagged human wild-type p105 were treated 
with LPS for 30 minutes. Lysates were subjected to anti-FLAG IP and the IP 
product was split and mock-treated (incubated in phosphatase buffer in the 
absence of phosphatase enzyme) or dephosphorylated with shrimp alkaline 
phosphatase (SAP) or protein phosphatase 2A (PP2A) (Figure 5.9). Compared 
with mock-treatment, immunoblotting with the P-S937 p105 antibody detected 
partial loss of immunoreactivity caused by SAP treatment and complete loss of 
immunoreactivity caused by PP2A treatment. As the antibody detected a faint 
doublet corresponding to endogenous p105 in depleted lysates, it was unlikely that 
lack of detection of PP2A-treated IP products was an artefact of insufficient 
exposure of the X-ray film. Reblotting with anti-FLAG antibody demonstrated 
comparable amounts of IP product from each treatment. However, reblotting with 
the total p105 antibody detected less p105 from mock-treatment than from SAP 
treatment, and even less from PP2A treatment. This was possibly caused by 
incomplete removal of the P-S937 p105 antibody from the membrane prior to 
reblotting, resulting in steric occlusion of binding sites for the total p105 antibody. It 
is also possible, though, that the total p105 antibody immunoreacted preferentially 
with the non-phosphorylated form of p105. These results established that the P-
S937/940 p105 antibody was specific to the phosphorylated epitope and thus able 
to detect basal and induced levels of p105 phosphorylation.  
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Figure 5.9 Phosphatase treatment of immunoprecipitated p105. 
RAW cells were nucleofected with FLAG-tagged human p105pcDNA3. Cells were stimulated with 
100 ng ml-1 LPS for 30 minutes and lysates were subjected to immunoprecipitation (IP) with anti-
FLAG antibody. IP product was split equally and mock-treated or incubated with shrimp alkaline 
phosphatase (SAP) or protein phosphatase 2A (PP2A) for 2 hours at 37 C, followed by 
immunoblotting with P-S937 p105 antibody. The membrane was stripped and reprobed with anti-
FLAG and total p105 antibodies. IP input corresponded to 7.5 mg of protein per condition; 1/400 of 
depleted input and total IP outputs were used for immunoblotting.   
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5.3 Characterisation of Pathways Inducing Phosphorylation of p105 at 
S937/940 
The previous experiments demonstrated the specificity of the P-S937/940 p105 
antibody. The first experiment also showed that phosphorylation of p105 at S940 
was indeed induced by LPS (Figure 5.4). In the following experiments, the reagent 
was used to characterise the kinetics of LPS-induced phosphorylation of p105 at 
S940 and investigate if this phosphorylation was induced by other inflammatory 
stimuli. 
5.3.1 LPS Treatment Induces Sustained Phosphorylation of p105 at S940 in 
RAW Cells 
To determine the kinetics of LPS-induced phosphorylation at S940, serum-starved 
RAW cells were treated with LPS over an eight hour timecourse (Figure 5.10, A) 
and immunoblots from replicate experiments were analysed by densitometry. 
Phosphorylation of p105 at S940 increased gradually up to 45 minutes of LPS 
treatment (3-fold over unstimulated control), declined by the 2 hour timepoint (2-
fold over unstimulated control), and increased again up to 8 hours (3.5-fold over 
unstimulated control) (Figure 5.10, B). Over the same period the abundance of 
total p105 decreased by half within 45 minutes of LPS treatment and gradually 
increased to twice the starting amount by 8 hours (Figure 5.10, B). In order to 
express the relative abundance of phospho-S940 and total p105, the phospho-
S940 signal was normalised against that of total p105 (Figure 5.10, C). Normalised 
phosphorylation of S940 peaked at 45 minutes of LPS treatment (6-fold over 
unstimulated control) and gradually declined by 8 hours (2-fold over unstimulated 
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control). Phosphorylation of p105 at S940 was therefore inversely related to the 
abundance of p105. LPS-induced phosphorylation of ERK peaked by 30 minutes of 
LPS treatment (20-fold over unstimulated control) and rapidly declined to basal 
level by 90 minutes (Figure 5.10, C). As expected, phosphorylation of ERK thus 
coincided with the degradation of p105, which is required for activation of ERK by 
TPL2 via MKK1/2. The level of total p38 was unchanged over the same period and 
was used to demonstrate equal loading in each lane (Figure 5.10, A, bottom pane). 
These results demonstrated that LPS induced sustained phosphorylation of p105 
at S940 in RAW cells, and that this phosphorylation was inversely related to the 
abundance of p105.  
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Figure 5.10 LPS treatment induces sustained phosphorylation of p105 at S940 in RAW cells. 
(A) RAW cells were serum-starved and treated for the indicated times with 100 ng ml-1 LPS. 
Lysates were prepared and immunoblotted for phospho-S940 p105 (P-S940 p105) or total p105. 
Membranes were stripped and reprobed with p38 and phospho-ERK (P-ERK) antibodies as loading 
and activation controls, respectively. Blots shown are representative of four experiments. Protein 
levels were quantified by densitometry and normalised against the loading control. Abundance 
changes with LPS stimulation are shown for (B) P-S940 p105 and total p105, (C) P-S940 
normalised against total p105, and (D) P-ERK. Data are means ± SEM.  
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5.3.2 TLR2 and TLR3 Ligands and TNF-α Induce Phosphorylation of p105 at 
S940 in RAW Cells 
In order to test if inflammatory pathways other than TLR4 induced phosphorylation 
of p105 at S940, RAW cells were treated with Pam3CSK4 (Pam3) for TLR2, 
poly(inosine:cytosine) (pIC) for TLR3, and TNF-α. In this way, the MyD88-
dependent and MyD88-independent TLR pathways were compared against the 
TNF pathway, which also activates IKK2, resulting in the degradation of p105 and 
TPL2-mediated activation of ERK (Eliopoulos et al., 2003). Serum-starved RAW 
cells were treated with Pam3, pIC, or TNF-α for 30, 60, and 90 minutes, and 
compared against 30 minutes of LPS treatment (Figure 5.11, A). Immunoblots from 
replicate experiments were analysed by densitometry. Treatment with Pam3 
resulted in a 3-fold increase in phosphorylation of p105 by 60 minutes that started 
to decline by 90 minutes, which was similar to the kinetics of LPS-induced 
phosphorylation of p105 in the previous experiment. Treatment with pIC led to a 
gradual increase up to 2.5-fold by 90 minutes. TNF-α treatment increased p105 
phosphorylation 3.5-fold within 30 minutes, returning to near basal level by 60 
minutes. In comparison, 30 minutes of LPS treatment increased p105 
phosphorylation 4.5-fold over basal level (Figure 5.11., B). Activation of ERK was 
again monitored. Pam3- and TNF-α-induced phosphorylation of ERK peaked within 
30 minutes of treatment, indicating rapid degradation of p105. By contrast, 
treatment with pIC led to a gradual increase in ERK phosphorylation over 90 
minutes, indicating a gradual increase in p105 degradation (Figure 5.11, C). A total 
p38 antibody was used to demonstrate equal loading in each lane (Figure 5.11, A, 
bottom pane). These data demonstrated that phosphorylation of p105 at S940 was 
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induced by the TLR2 and TLR3 pathways and TNF-α in RAW cells. The data also 
showed that phosphorylation of p105 coincided with activation of ERK, indicating 
that phosphorylation of p105 also coincided with the degradation of p105, as was 
observed for LPS in the previous experiment.  
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Figure 5.11 TLR2 and TLR3 ligands and TNF-α induce phosphorylation of p105 at S940 in 
RAW cells. 
(A) RAW cells were serum-starved and treated for the indicated times with 100 ng ml-1 Pam3CSK4 
(Pam3; TLR2 ligand), 40 µg ml-1 poly(inosine:cytosine) (pIC; TLR3 ligand), 100 ng ml-1 TNF-α, or 
100 ng ml-1 LPS. Lysates were prepared and immunoblotted for phospho-S940 p105 (P-S940 
p105). Membranes were stripped and reprobed with p38 and phospho-ERK (P-ERK) antibodies as 
loading and activation controls, respectively. Blots shown are representative of four experiments. 
Abundance changes of (B) P-S940 p105 and (C) P-ERK were quantified by densitometry and 
normalised against the loading control. Data are means ± SEM.  
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5.3.3 IL-1β Induces Phosphorylation of p105 at S937 in Primary Human Skin 
Fibroblasts 
To establish if the induction of p105 phosphorylation by inflammatory stimuli was 
restricted to hemopoietic cells or also occurred in non-hemopoietic cells, I tested 
primary human skin fibroblasts (HSFs), which are less responsive to TLR ligands 
but highly responsive to IL-1. The IL-1 receptor belongs to the TLR/ IL-1 receptor 
(TIR) family and is thus structurally related to TLRs, and also utilises MyD88 to 
activate NF-κB and MAP kinase signalling via IKK2 (Akira et al., 2001), resulting in 
degradation of p105 and activation of ERK (Rodriguez et al., 2006). HSFs were 
treated with IL-1β for 30, 60, and 90 minutes (Figure 5.12, A). Immunoblots from 
replicate experiments were analysed by densitometry. Compared to unstimulated 
cells, IL1-β-induced phosphorylation of p105 at S937 increased 4-fold within 30 
minutes, declining to near basal level by 60 minutes (Figure 5.12, B). 
Phosphorylation of ERK increased 7-fold within 30 minutes of treatment and also 
declined to near basal level by 60 minutes (Figure 5.12, C). The kinetics of IL-1β-
induced phosphorylation of p105 and ERK were thus similar to those observed 
from TNF-α treatment of RAW cells. A total p38 antibody was used to demonstrate 
equal loading in each lane (Figure 5.12, A, bottom pane). These data 
demonstrated that phosphorylation of p105 was induced in non-hemopoietic cells 
by the TLR-related IL-1 pathway.  
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Figure 5.12 IL-1β induces phosphorylation of p105 at S937 in primary human skin 
fibroblasts. 
(A) Cells were serum-starved and treated for the indicated times with 100 ng ml-1 IL-1β. Lysates 
were prepared and immunoblotted for phospho-S937 p105 (P-S937 p105). Membranes were 
stripped and reprobed with p38 and phospho-ERK (P-ERK) antibodies as loading and activation 
controls, respectively. Blots shown are representative of four experiments. Abundance changes of 
(B) P-S937 p105 and (C) P-ERK were quantified by densitometry and normalised against the 
loading control. Data are means ± SEM.  
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5.3.4 The PKA inhibitor H89 Modulates LPS-Induced Phosphorylation of p105 
at S940 in RAW cells 
Because of two reports showing phosphorylation of p105 at S940 by PKA in vitro 
(Gerondakis et al., 1993; Wall et al., 2009), the effect of PKA inhibition on LPS-
induced phosphorylation of p105 was investigated and compared against treatment 
with the cAMP/PKA agonist PGE2. In order to examine the possibility that LPS-
induced phosphorylation of p105 at S940 was caused by auto/paracrine TNF-α 
signalling, the effect of TNF-α neutralisation was also tested. Apart from the two 
TNF-α neutralisation experiments, statistical significance was assessed by paired 
Student’s t-test. A total p38 antibody was used to demonstrate equal loading in 
each lane (Figure 5.13, A and B, bottom panes). 
The kinase inhibitor H89 inhibits PKA at micromolar concentrations (Chijiwa et al., 
1990). In order to test if H89 inhibited the LPS-induced phosphorylation of p105, 
RAW cells were treated simultaneously with LPS and 3, 6, 12.5, or 25 µM H89 for 
30 min. LPS-induced phosphorylation of p105 was inhibited only partially by H89, 
but inhibition increased in a dose-dependent manner at concentrations of 3 µM to 
12.5 µM, and was comparable at 12.5 µM and 25 µM (Figure 5.13, A). 
Phosphorylation of ERK was not affected by H89 treatment at all concentrations 
tested, which indicated that H89 did not inhibit the LPS-induced degradation of 
p105 or signalling upstream of p105. Because the specificity of H89 decreases at 
higher concentrations (Davies et al., 2000), a concentration of 12.5 µM was used in 
further experiments. 
256
Chapter 5                                                                                           Phosphorylation of p105 at S940 
 
Whereas treatment with LPS for 30 minutes induced equal phosphorylation of both 
p105 bands detected by immunoblotting with the P-S940 antibody, treatment with 
PGE2 resulted almost exclusively in phosphorylation of the lower band (Figure 
5.13, B). Densitometry was therefore performed separately for the upper and lower 
bands (Figure 5.13, C). Compared with unstimulated cells, LPS treatment induced 
a 3-fold increase in phosphorylation of both bands. By contrast, simultaneous 
treatment with H89 blocked LPS-induced phosphorylation of the upper band (p = 
0.0068). H89 treatment did not affect LPS-induced phosphorylation of ERK (Figure 
5.13, D), again indicating that H89 did not inhibit signalling to p105. These results 
demonstrated that phosphorylation of p105 at S940 was mediated by a kinase that 
was sensitive to inhibition by H89, possibly PKA. 
LPS-induced phosphorylation of p105 was not affected by 10 minute pre-treatment 
with the TNF-α-neutralising antibody TN3-19.12, although a slight reduction in ERK 
phosphorylation was observed. By contrast, pre-treatment with TN3-19.12 
decreased TNF-α-induced phosphorylation of p105 and ERK more than 2-fold, 
showing that the antibody was effective at neutralising exogenous TNF-α (Figure 
5.13, C). These data demonstrated that LPS-induced phosphorylation of p105 was 
not solely the result of early auto/paracrine signalling by TNF-α. 
Compared with unstimulated cells, PGE2 induced a 4.5-fold increase in 
phosphorylation of the lower band only (Figure 5.13, C). As PGE2 is a strong 
agonist of cAMP/PKA signalling, these data suggested PKA-mediated 
phosphorylation of p105. However, H89 did not inhibit PGE2-induced 
phosphorylation of p105 and minimally increased phosphorylation of the upper 
257
Chapter 5                                                                                           Phosphorylation of p105 at S940 
 
band (p = 0.0156). These data indicated that PGE2-induced p105 phosphorylation 
was mediated by a different kinase than that responsible for LPS-induced p105 
phosphorylation. However, phosphorylation of p105 induced by simultaneous 
treatment with LPS and PGE2 was indistinguishable from LPS treatment alone, 
which, in contrast, indicated that the same kinase was responsible for this 
phosphorylation, unless phosphorylation of p105 was already saturated by a single 
stimulus. I will address this matter in the discussion section. 
PGE2 treatment did not induce phosphorylation of ERK, which is in agreement with 
reported inhibition of ERK by PGE2 via the EP2 receptor (Bos et al., 2004). Low 
levels of ERK phosphorylation were induced, however, by treatment with H89 (p = 
0.0358), 2% dimethyl sulfoxide (DMSO; H89 vehicle), or simultaneous treatment 
with PGE2 and H89 or DMSO (the latter were not statistically significant). H89 
treatment also induced low levels of p105 phosphorylation, and 2% DMSO 
appeared to shift the LPS-induced phosphorylation of p105 to the upper band and 
increased PGE2-induced phosphorylation of p105 (though not to a statistically 
significant level). Therefore, these data suggested that DMSO activated and 
modulated signalling pathways in RAW cells. This matter will also be addressed in 
the discussion section. 
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Figure 5.13 The PKA inhibitor H89 modulates LPS-induced phosphorylation of p105 at S940 
in RAW cells. 
RAW cells were serum-starved and left unstimulated (US) or treated for 30 minutes with (A) 100 ng 
ml-1 LPS alone or together with 3, 6, 12.5, or 25 µM H89, or (B) 100 ng ml-1 LPS, 12.5 µM H89; 
vehicle control 2% DMSO, 10 µM prostaglandin E2 (PGE2); vehicle control 10% ethanol (EtOH), 
100 ng ml-1 TNF-α, or  100 µg ml-1 TNF-α-neutralising antibody TN3-19.12 (10 minute pre-
incubation). Lysates were prepared and immunoblotted for phospho-S940 p105 (P-S940 p105). 
Membranes were stripped and reprobed with p38 and phospho-ERK (P-ERK) antibodies as loading 
and activation controls, respectively. Blots shown are (A) a single experiment and (B) representative 
of at least three experiments for stimulation with LPS, H89, PGE2, and solvent controls, and two 
experiments for LPS/ TNF-α ± TN3. Abundance changes of (C) P-S940 p105 and (D) P-ERK were 
quantified by densitometry and normalised against the loading control. Data are means ± SEM. 
Statistical significance was assessed by paired Student’s t-test. Only significant differences are 
marked by asterisks (*; p < 0.05, **; p < 0.01).  
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5.3.5 TLR Ligands, TNF-α, and PGE2 Induce Phosphorylation of p105 at S937 
in Primary Human Macrophages 
The previous experiments established that phosphorylation of p105 at S940 was 
induced by TLRs, TNF-α, and PGE2 in a murine macrophage cell-line. In the 
following experiments, I attempted to determine to what extent these observations 
might relate to primary human macrophages, since these cells model more 
accurately physiological processes relevant to human immunology and disease. 
Monocyte-derived macrophages (MDMs) were obtained from culture of 
mononuclear blood cells with macrophage colony-stimulating factor (M-CSF) for 
five days. MDMs were treated with LPS, Pam3, TNF-α, or PGE2 for 30 and 60 
minutes, and immunoblots from replicate experiments were analysed by 
densitometry. Averaged abundance changes were generally lower than visual 
inspection suggested (Figure 5.14, A), probably caused by low signal-to-noise ratio 
interfering with densitometric analyses (common for blots from primary cell lysate).  
The kinetics of stimulus-induced phosphorylation of p105 and ERK in MDMs were 
similar to RAW cells, with the exception that TNF-α-induced phosphorylation of 
p105 and ERK increased gradually up to 60 minutes of treatment (Figure 5.14, B 
and C). While in RAW cells LPS was the most potent inducer of p105 and ERK 
phosphorylation, in MDMs LPS induced the lowest levels of p105 phosphorylation, 
but was still the most potent activator of ERK. As in RAW cells, PGE2 induced 
phosphorylation of the lower band within 30 minutes, which had started to decline 
by 60 minutes. Also as in RAW cells, PGE2 did not activate ERK. A total p38 
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antibody was used to demonstrate equal loading in each lane Figure 5.14, A, 
bottom pane). 
These results demonstrated that phosphorylation of p105 at S937 was induced in 
primary human macrophages by TLR2, TLR4, TNF-α, and PGE2 signalling, which 
extended the observations from RAW cells to a physiologically more relevant cell 
system. 
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Figure 5.14 TLR ligands, TNF-α, and PGE2 induce phosphorylation of p105 at S937 in primary 
human macrophages. 
(A) Monocyte-derived macrophages were treated for the indicated times with 10 ng ml-1 LPS, 100 
ng ml-1 Pam3CSK4 (Pam3; TLR2 ligand), 20 ng ml
-1 TNF-α, or 10 µM prostaglandin E2 (PGE2). 
Lysates were prepared and immunoblotted for phospho-S937 p105 (P-S937 p105). Membranes 
were stripped and reprobed with p38 and phospho-ERK (P-ERK) antibodies as loading and 
activation controls, respectively. Blots shown are representative of three experiments. Abundance 
changes of (B) P-S937 p105 and (C) P-ERK were quantified by densitometry and normalised 
against the loading control. Data are means ± SEM. 
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5.3.6 The PKA inhibitor H89 Blocks LPS-Induced Phosphorylation of p105 at 
S937 in Primary Human Macrophages 
To determine whether the LPS-induced phosphorylation of p105 at S937 was 
inhibited by H89 in MDMs, cells were treated for 30 minutes with LPS, 12.5 µM 
H89, or both. Immunoblots from two experiments were analysed by densitometry 
(Figure 5.15, A). Treatment with H89 alone did not induce phosphorylation of p105 
(Figure 5.15, B), and in contrast to RAW cells also did not induce activation of ERK 
(Figure 5.15, C). Importantly, simultaneous treatment with LPS and H89 led to an 
almost complete blockade of LPS-induced phosphorylation of p105 (Figure 5.15, 
B), while having little effect on LPS-induced phosphorylation of ERK (Figure 5.15, 
C). These data provided conclusive evidence that LPS-induced phosphorylation of 
p105 was mediated by a kinase sensitive to inhibition by H89, possibly PKA.  
Taken together, the results in this section showed that phosphorylation of p105 at 
S937/940 was induced not only by LPS, but by several other inflammatory stimuli 
in RAW macrophages, primary human macrophages, and primary human 
fibroblasts. Furthermore, the LPS-induced phosphorylation at S937/940 was 
blocked by the kinase inhibitor H89, indicating that this phosphorylation might be 
mediated by PKA. 
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Figure 5.15 The PKA inhibitor H89 blocks LPS-induced phosphorylation of p105 at S937 in 
primary human macrophages. 
(A) Monocyte-derived macrophages were left unstimulated (US) or treated for 30 minutes with 10 
ng ml-1 LPS, 12.5 µM H89 (PKA inhibitor), or both. Lysates were prepared and immunoblotted for 
phospho-S937 p105 (P-S937 p105). Membranes were stripped and reprobed with p38 and 
phospho-ERK (P-ERK) antibodies as loading and activation controls, respectively. Blots shown are 
representative of two experiments. Abundance changes of (B) P-S937 p105 and (C) P-ERK were 
quantified by densitometry and normalised against the loading control. Data are means ± SEM.  
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5.4 Discussion 
5.4.1 Validation of an Antibody against p105 Phosphorylated at S940 
The first aim of the work presented in this chapter was the validation of a novel 
antibody against p105 phosphorylated at S937/940. While the antibody 
immunoreacted with a number of species with apparently equal affinity, specificity 
could still be established for a doublet of phosphorylated p105 species (Figure 5.4). 
As p105 is phosphorylated at several residues and polyubiquitinated in response to 
LPS stimulation (Beinke and Ley, 2004), it is plausible that the upper band 
corresponds to p105 species that are modified post-translationally to a greater 
degree. The detection of a single species of endogenous and overexpressed 
FLAG-tagged p105 in HEK cells (Figure 5.7) might be due to deficiency of p105-
interacting signalling components in these cells (e.g. kinases, ubiquitin ligases), or 
due to signalling activity from the stress of transfection, as the latter might also 
explain the lack of LPS-induced upregulation of S940 phosphorylation (Figure 5.7, 
B). Immunoprecipitated FLAG-tagged human p105 expressed in RAW cells was 
also detected as a single band by the P-S937 antibody, which might indicate that 
the human sequence cannot be modified post-translationally to the same extent in 
murine cells (Figure 5.9). The observation that the P-S940 antibody 
immunoprecipitated preferentially the p105 species of higher molecular weight 
(Figure 5.6, B), but detected both species by immunoblotting might suggest that 
the phosphorylated epitope was more exposed in post-translationally modified 
p105 under the non-denaturing conditions employed during immunoprecipitation. 
By contrast, the total p105 antibody consistently detected a single band. While this 
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may have been caused by far greater abundance of the p105 species of lower 
molecular weight, resulting in lack of detection of the upper band due to limited 
dynamic range of the ECL detection system, it is also possible that the total p105 
antibody did not recognise the post-translationally modified form of p105 because 
of steric occlusion of the epitope recognised by the antibody. The latter possibility 
was supported by the correlation between greater immunoreactivity of the P-S937 
antibody and reduced immunoreactivity of the total p105 antibody (Figure 5.9). 
Therefore, the total p105 antibody was not used for reblotting in further 
experiments. 
Because most of the bands detected by the P-S940 antibody were not detected by 
the total p105 antibody from P-S940 IP products (Figure 5.6, B), this suggested 
that the P-S940 antibody recognised proteins other than p105. As the peptide 
immunogen was relatively small, the antibody’s promiscuity may not be surprising. 
It is not uncommon for a phospho-specific antibody to recognise other species, 
which can lead to the discovery of other proteins that are phosphorylated in 
response to stimulation, as was demonstrated by two studies that characterised 
phosphoproteins detected by an antibody against phosphorylated JUN (Morton et 
al., 2006; Klevernic et al., 2009). In particular, the LPS-induced species detected at 
a molecular weight of approximately 40 kDa might be a target of future research 
(Figure 5.4), as it was induced by all ligands tested (data not shown). 
Unfortunately, no protein of similar molecular weight that contains the 
phosphorylated sequence or a close homologue could be indentified using the 
basic local alignment search tool (BLAST). 
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In summary, the specificity of the P-S937/940 antibody for phosphorylated p105 
was demonstrated by 1) its detection of a doublet of inducible bands at the 
molecular weight of p105, 2) its ability to immunodeplete the species recognised by 
a total p105 antibody, 3) its failure to immunoreact with S937A mutant p105, and 4) 
the loss of immunoreactivity following phosphatase treatment of 
immunoprecipitated p105. 
5.4.2 Characterisation of Pathways Inducing Phosphorylation of p105 at 
S937/940 
Immunoblotting with the P-S937/940 antibody confirmed that phosphorylation of 
p105 at S937/940 was inducible by LPS stimulation, and further experiments 
showed that this phosphorylation was induced by a number of inflammatory stimuli 
in hemopoietic and non-hemopoietic cells. In murine RAW macrophages, 
phosphorylation of p105 was induced by the TLR ligands LPS, Pam3, and pIC, and 
also by TNF-α. This demonstrated that MyD88-dependent and MyD88-independent 
TLR pathways, as well as the unrelated TNF-α pathway induce phosphorylation of 
p105 at S940. The same stimuli also induced phosphorylation of p105 in primary 
human macrophages, with the exception of pIC, to which these cells are not 
responsive. This demonstrated that p105 phosphorylation is induced by 
inflammatory stimuli in cells that are more relevant than RAW cells to human innate 
immune functions. Phosphorylation of p105 was also induced by IL-1β in primary 
human fibroblasts, which demonstrated that a TLR-related stimulus, which shares 
with TLRs a dependence on the adaptor MyD88, induces phosphorylation of p105 
in non-hemopoietic human cells that have an important function in the  
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inflammatory response through their IL-1-induced amplification of chemokine 
production (Smith et al., 1997). 
There were marked differences in the kinetics of phosphorylation induced by 
different stimuli, however. LPS-induced phosphorylation of p105 in RAW cells was 
sustained and had not returned to basal level by 8 hours of treatment (Figure 5.10). 
Although stimulation with other ligands was not assayed for longer than 90 
minutes, the kinetics of LPS- and Pam3-induced p105 phosphorylation were 
similar, suggesting that phosphorylation may also be sustained in response to 
stimulation of TLR2 (Figure 5.11). Activation of the TLR3 pathway by pIC resulted 
in delayed phosphorylation of p105 and ERK (Figure 5.11), which is in agreement 
with reports of delayed activation of NF-κB (Alexopoulou et al., 2001) and ERK 
(Banerjee et al., 2006) in murine BMDMs in response to TLR3 stimulation 
compared with TLR4. It remains to be investigated whether sustained 
phosphorylation is induced by pIC. In human MDMs, only the 30 minute and 60 
minute timepoints were tested. Phosphorylation of p105 in response to LPS, Pam3, 
and TNF-α was sustained over this period, but phosphorylation of ERK was 
transient in response to LPS and in some experiments also transient in response to 
Pam3 (Figure 5.13), which may suggest that phosphorylation of p105 was also 
sustained in MDMs in response to LPS and Pam3, but this remains to be 
demonstrated. By contrast, TNF-α treatment induced transient phosphorylation of 
p105 in RAW cells (Figure 5.11), as did IL-1β treatment of HSFs (Figure 5.12). 
It is plausible that sustained phosphorylation of p105 in response to LPS and Pam3 
is the result of an auto/paracrine feedback loop. TNF-α is a possible candidate for 
268
Chapter 5                                                                                           Phosphorylation of p105 at S940 
 
this function, because it induced phosphorylation of p105, and is rapidly secreted 
by RAW cells stimulated with LPS or Pam3 (Natarajan et al., 2006). Because 
neutralisation of TNF-α did not affect phosphorylation of p105 induced by 30 
minutes of LPS stimulation (Figure 5.13), early phosphorylation of p105 caused by 
auto/paracrine TNF-α is unlikely, but is possible at later timepoints. Sustained 
phosphorylation of p105 by TLR3-induced TNF-α is also a possibility, as it has 
been shown that RAW cells treated for 6 hours with LPS, Pam3, or pIC produce 
comparable amounts of TNF-α (Naiki et al., 2005). Because HSFs do not produce 
TNF-α in response to IL-1β stimulation (J.L. Dean, Kennedy Institute, personal 
communication), transient phosphorylation of p105 in response to IL-1β is also 
consistent with the hypothesis that sustained phosphorylation of p105 is the result 
of auto/paracrine TNF-α. This hypothesis is testable by TNF-α neutralisation or 
siRNA knockdown of TNF-α expression in LPS stimulated cells, although siRNA 
knockdown might prove to be challenging technically. 
The transient phosphorylation of p105 in response to TNF-α in RAW cells is not 
consistent with the hypothesis of TNF-α auto/paracrine feedback, however, as 
auto-induction of TNF-α production has been demonstrated in these cells 
(Srivastava et al., 1999). By contrast, TNF-α-induced phosphorylation of p105 in 
primary human MDMs was sustained compared with RAW cells, which may have 
been caused by auto/paracrine TNF-α, as auto-induction of TNF-α production has 
been shown in human monocytes (Geng et al., 1993). It is possible that the 
different response of RAW cells and primary human MDMs to TNF-α is the result of 
different expression levels of TNF receptors or differences in stimulus-induced 
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shedding of TNF receptors, but no data are available to confirm this. An alternative 
explanation is that there are differences in TNF signalling mechanisms between 
RAW cells and MDMs, such as kinetics of kinase activity, induction of 
phosphatases, DNA and chromatin methylation dynamics, or signalling 
components utilised. In fact, a recent study has demonstrated that TNF-α-induced 
NF-κB activation in RAW cells is independent of IKK2 and instead mediated by 
GPCR kinases (GRKs) 2 and 5 (Patial et al., 2010). Although it is not known 
whether this pathway activates different signalling pathways than the IKK2 
pathway, one might speculate that in RAW cells TNF-α signalling through GRK2/5 
is subject to auto-regulation by negative feedback, unlike the IKK2-dependent 
pathway in other macrophages, but this remains to be demonstrated.  
An alternative mechanism of sustained p105 phosphorylation might be through 
auto/paracrine PGE2, as PGE2 induced phosphorylation of p105 in RAW cells and 
human MDMs (Figures 5.13 and 5.14), and is produced by most cells in response 
to inflammatory stimuli, including LPS, IL-1β, and TNF-α (Phipps et al., 1991). 
However, since PGE2 has been shown to activate cAMP production in RAW cells 
(Natarajan et al., 2006), similar kinetics of auto/paracrine PGE2-induced 
phosphorylation of p105 would be expected from LPS and TNF-α stimulation, if 
PGE2 signalling was not modulated by the primary stimulus. The different pattern 
of PGE2-induced p105 phosphorylation, which unlike the other stimuli tested did 
not result in phosphorylation of the upper band (Figure 5.14), also suggests that 
auto/paracrine PGE2 is less likely to be the cause of sustained p105 
phosphorylation than TNF-α. In order to test the effect of auto/paracrine PGE2 
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signalling, non-selective COX inhibitors could be used, such as aspirin or 
indometacin, which block the production of prostaglandins. However, mechanisms 
other than auto/paracrine signalling might be responsible for the sustained 
phosphorylation of p105. 
Having shown that phosphorylation of p105 at S937/940 is induced by LPS and 
several other inflammatory stimuli, a possible link to the cAMP/ PKA pathway was 
investigated. PKA regulates the activity of NF-κB transcription factors (Perkins, 
2006), and two previous reports have shown that PKA phosphorylates p105 at 
S940 in vitro (Gerondakis et al., 1993; Wall et al., 2009). The effect of the kinase 
inhibitor H89 was tested, which inhibits PKA at micromolar concentrations (Chijiwa 
et al., 1990). The complete blockade of LPS-induced phosphorylation by H89 in 
human MDMs (Figure 5.15) and partial inhibition in RAW cells (Figure 5.13) 
suggests that PKA may be responsible for this phosphorylation. Other kinases 
cannot be excluded, however, as H89 has been shown to inhibit mitogen- and 
stress-activated protein kinase (MSK)1, ribosomal protein S6 kinase beta-1 
(S6K1), and Rho-associated protein kinase (ROCK)2 with similar potency to PKA 
in in vitro kinase assays (Davies et al., 2000). Of these, MSK1 is of particular 
interest, as MSK1 and MSK2 have been shown to be activated by ERK and p38 in 
TLR-stimulated BMDMs, resulting in suppression of pro-inflammatory cytokine 
production (TNF-α, IL-6, and IL-12) and activation of anti-inflammatory pathways, 
including induction of dual specificity protein phosphatase (DUSP)1, which 
deactivates p38, and expression of IL-10 (Ananieva et al., 2008). Further 
experiments with more specific inhibitors are thus required to confirm that PKA 
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phosphorylates p105 at S937/940 in vivo, such as PKI14-22 amide, which is an 
inhibitory pseudosubstrate of PKA (Dalton and Dewey, 2006). The possibility of 
MSK phosphorylation of p105 could be tested in MSK1/2-deficient macrophages 
(Ananieva et al., 2008). 
PGE2 stimulates cAMP-dependent PKA activity through EP2 and EP4 GPCRs 
expressed by macrophages (Harris et al., 2002), and Wall and co-workers have 
suggested that PGE2 stimulation activates PKA to phosphorylate p105 at S940 
(Wall et al., 2009). To investigate this possibility, the effect of PGE2 stimulation on 
p105 phosphorylation was tested. PGE2 treatment induced phosphorylation of 
p105 in RAW cells and MDMs, but in RAW cells this phosphorylation was not 
inhibited by simultaneous treatment withH89 (not tested in MDMs) (Figure 5.13). 
One might speculate that different kinases are responsible for LPS- and PGE2-
induced phosphorylation of p105, but if that were the case, an additive response 
with simultaneous LPS and PGE2 treatment would be expected, which was not 
observed (Figure 5.13). Saturation of p105 phosphorylation by LPS treatment 
alone is possible, but not likely, as phosphatase inhibitor treatment induced higher 
levels of p105 phosphorylation than 30 minutes of LPS treatment (Figure 5.4). If 
different kinases were responsible, the fraction of p105 that was not 
phosphorylated in response to LPS would be expected to be phosphorylated in 
response to simultaneous treatment with PGE2. A possible explanation is that a 
period of pre-incubation with H89 prior to PGE2 stimulation would have been 
required to inhibit the rapid activation of PKA by cAMP, as PGE2 has been shown 
to induce maximum production of cAMP in RAW cells within 30 seconds (Natarajan 
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et al., 2006). By contrast, LPS-induced activation of PKA is thought to be 
independent of cAMP, and LPS and other TLR ligands do not induce cAMP in 
RAW cells (Natarajan et al., 2006). It has been shown that the catalytic subunit of 
PKA is inhibited by IκBα and IκBβ in unstimulated 70Z/3 B cells, and that 
catalytically active PKA is released in response to LPS-induced degradation of 
IκBα and IκBβ (Zhong et al., 1997). If this pathway of PKA activation was 
responsible for p105 phosphorylation, it would probably be delayed in comparison 
with cAMP-mediated activation of PKA, and may therefore have allowed sufficient 
time for H89 to inhibit PKA in LPS treated macrophages, but this remains to be 
demonstrated. However, ineffective inhibition of cAMP-induced PKA activity in 
RAW cells has been reported even with 10 minutes pre-incubation with H89 
(Natarajan et al., 2006), whereas H89 without pre-incubation has been shown to 
inhibit cAMP-dependent PKA activity induced by forskolin (adenylyl cyclase 
activator) in 293 cells (Filippa et al., 1999), which might indicate that H89 is not 
effective at inhibiting cAMP-dependent PKA activity in RAW cells. In order to 
investigate further the possibility of cAMP-independent PKA signalling, siRNA 
knockdown of catalytic PKA subunits in RAW cells (Zhu et al., 2007), PKA-deficient 
cell lines, or mice deficient for one of the two catalytic subunit isoforms (Qi et al., 
1996; Skalhegg et al., 2002) could be used. 
Unexpected effects on phosphorylation of ERK and p105 were observed when 
treating RAW cells with H89 or 2% DMSO (vehicle control) (Figure 5.13), which 
suggested that 2% DMSO modulated signalling pathways in RAW cells. DMSO 
has anti-inflammatory properties and acts as a scavenger of reactive oxygen 
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species, and owing to these properties is used in the treatment of a variety of 
diseases, including dermatologic and rheumatologic disorders (Santos et al., 
2003). DMSO has been shown to activate ERK in rat RBL-2H3 mast cells (0.5% 
DMSO) (Koo and Kim, 2009), inhibit LPS-induced expression of TNF-α in murine 
J774 macrophages (2% DMSO) (Kelly et al., 1994), and enhance LPS-induced 
expression of IL-1 in human peripheral blood mononuclear cells (1% DMSO) (Xing 
and Remick, 2005). Furthermore, 2% DMSO has been shown to inhibit TNF-α-
induced phosphorylation of NF-κB p65/ RelA at S276 by PKA in the human 
promonocytic cell-line U937 (Jamaluddin et al., 2007). This suggests that DMSO at 
concentrations of 0.5% or more modulates signalling pathways in myeloid cells and 
it may therefore not be surprising that phosphorylation of p105 and ERK was 
modulated by DMSO in RAW cells. It is difficult to explain, however, why 
phosphorylation of p105 was enhanced in the presence of H89 in unstimulated and 
PGE2-treated cells, when H89 clearly inhibited LPS-induced phosphorylation of 
p105 in RAW cells and MDMs. Again, one might speculate that different kinases 
are responsible for PGE2- and LPS-induced phosphorylation of p105, which clearly 
needs to be addressed in future work. 
With regards to the function of phosphorylation of p105 at S937/940, data from 
Wall and co-workers suggested that this phosphorylation protects p105 from LPS-
induced degradation (Wall et al., 2009). Indeed, several observations indicate an 
association between phosphorylation at S937/940 and the degradation of p105. 
First, LPS-induced phosphorylation of p105 at S940 was inversely related to the 
abundance of p105. This relationship extended over an 8 hour timecourse at 
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increasing and decreasing abundance of p105. Second, TLR2-, TLR3-, TNF-, and 
IL-1-induced phosphorylation at S937/940 coincided with activation of ERK, which 
is regulated by stimulus-induced degradation of p105. Interestingly, prolonged LPS 
stimulation did not induce the complete degradation of p105, but of only half the 
cellular pool of p105. This is in contrast to numerous publications stating that p105 
is completely degraded in response to inflammatory stimuli (e.g. (Beinke and Ley, 
2004; Perkins, 2006)). In fact, examination of some of the published data cited in 
support of this statement reveals that p105 is not completely degraded in response 
to inflammatory stimuli, but that some intact p105 remains (e.g. (Belich et al., 1999; 
Heissmeyer et al., 1999; Heissmeyer et al., 2001; Salmeron et al., 2001; Lang et 
al., 2003)). It has been shown that LPS-induced degradation of p105 is required to 
release TPL2, which activates ERK via MKK1/2 (Beinke et al., 2004). Although 
TPL2 is stoichiometrically associated with p105 (Belich et al., 1999; Beinke et al., 
2003), only a fraction of the cellular pool of p105 is required to inhibit TPL2 (Belich 
et al., 1999; Lang et al., 2004). As p105 also regulates the activity of NF-κB dimers, 
especially of p50 homodimers (Liou et al., 1992), and forms high molecular weight 
complexes that may serve as signalling platforms (Savinova et al., 2009), it is 
plausible that sub-populations of p105 exist that participate in different cellular 
processes. Differential regulation of these sub-populations would therefore require 
inducible mechanisms to protect them from unwanted degradation in response to 
inflammatory stimuli. It is possible that phosphorylation of p105 at S937/940 serves 
this purpose, as phosphorylation at this residue coincided with p105 degradation, 
but was sustained long after the activation of ERK, indicating that this 
phosphorylation has a function other than activating ERK. The slight delay 
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observed between phosphorylation of ERK and phosphorylation of p105 might 
indicate that phosphorylation at S940 is triggered by IKK2-induced degradation of 
p105 in order to protect the remaining population of p105 from degradation while 
IKK2 is active and until p105 levels are replenished by de novo synthesis, but this 
remains to be demonstrated.  
If phosphorylation of p105 at S937/940 was regulated by p105 degradation, 
inhibition of the proteasome might modulate this phosphorylation, which is testable. 
However, phosphorylation at S937/S940 and degradation of p105 might be 
coincidental. An intriguing possibility is that the IKK2-induced degradation of 
IκBα/β, which coincides with IKK2-induced p105 degradation, is responsible for 
phosphorylation of p105 by PKA, as PKA is released and activated upon LPS-
induced IκBα/β degradation in 70Z/3 B cells (Zhong et al., 1997). This hypothesis 
might be testable, because TNF-α-induced degradation of IκBα is mediated not by 
IKK2 but by GRK2/5 in RAW cells (Patial et al., 2010). Therefore, if 
phosphorylation of p105 at S940 was blocked by siRNA knockdown of GRK2/5 in 
TNF-α-treated RAW cells and degradation of p105 was unaffected, this might 
indicate that phosphorylation at S940 was dependent on degradation of IκBα but 
not on degradation of p105, which in turn might indicate that IκBα degradation 
resulted in release and activation of PKA. There is one caveat to this experiment, 
though. Wall and co-workers have shown that PKA associates with p105 and 
AKAP95 in RAW cells (Wall et al., 2009), which might indicate that IKK2-induced 
degradation of p105 as well as GRK2/5-induced degradation of IκBα/β would result 
in release and activation PKA. However, Zhong and co-workers have 
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demonstrated that the association of the catalytic subunit of PKA with IκBα/β is 
independent of regulatory PKA subunits and thus cAMP-independent (Zhong et al., 
1997), whereas the association of the PKA holoenzyme with AKAPs is mediated by 
the regulatory subunits and activation of PKA requires the dissociation of the 
catalytic and regulatory subunits, which is dependent on cAMP (Wong and Scott, 
2004). Therefore, degradation of p105 might not activate PKA, as PKA would still 
be complexed with AKAP95 and would not be activated in the absence of cAMP, 
because TLR stimulation does not induce cAMP in RAW cells (Natarajan et al., 
2006),  
These considerations also suggest the possibility that LPS- and PGE2-induced 
phosphorylation of p105 at S940 are both mediated by PKA, but by different 
mechanisms. The PGE2-induced mechanism might function as suggested by Wall, 
taking into account earlier work by Minami and co-workers: in response to PGE2 
stimulation, the p105/AKAP95/PKA complex might be recruited to the PGE2 
receptor EP4 by EPRAP, where EP4-induced cAMP activates PKA to 
phosphorylate p105 at S940, which blocks the IKK2-induced degradation of p105 
in macrophages activated by inflammatory stimuli (Minami et al., 2008; Wall et al., 
2009). The LPS-induced mechanism, on the other hand, might function through 
IKK2-mediated degradation of IκBα/β, which releases and activates PKA to 
phosphorylate p105 at S940 in order to protect the population of p105 that has not 
yet been degraded in response to IKK2 phosphorylation. 
277
Chapter 5                                                                                           Phosphorylation of p105 at S940 
 
5.5 Summary 
I showed that a novel antibody specifically recognises p105 phosphorylated at 
S937/S940. Using this reagent, I demonstrated that phosphorylation of p105 at 
S937/S940 was induced by LPS, other TLR ligands, TNF-α, and PGE2 in RAW 
cells and primary human macrophages, and by IL-1β in primary human fibroblasts. 
Furthermore, LPS-induced phosphorylation at S937/940 was blocked by the PKA 
inhibitor H89. 
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6.1 Summary of Work Achieved 
The primary aims of this work were the identification of novel or previously 
uncharacterised LPS-induced phosphorylation sites in RAW macrophages and the 
subsequent validation and characterisation of one of these proposed regulatory 
sites. The project thus proceeded in two distinct stages: 1) the development and 
application of a methodology for the large-scale identification of phosphorylation 
sites from LPS-activated RAW cells, and 2) the characterisation of p105 
phosphorylation at S940. To briefly summarise the results obtained at each stage: 
1) Methods development and phosphoproteomics screen 
 TiO2 chromatography was shown to be superior to IMAC for the enrichment 
of phosphopeptides from semi-complex mixtures. 
 Optimisation of a gel-based LC-MS/MS workflow incorporating TiO2 
chromatography enabled the identification of more than 200 phosphorylation 
sites from phosphatase inhibitor-treated cells. 
 The delta-ions score metric for phosphorylation site localisation was shown, 
for the first time, to apply to QTOF-MS/MS spectra. 
 In two separate experiments, 445 phosphorylation sites were identified from 
resting and LPS-treated cells. 
 Among the 445 sites were several potential and previously uncharacterised 
LPS-induced phosphorylations, including S940 of the NF-κB protein p105. 
2) Characterisation of p105 phosphorylation at S940: 
 A novel antibody was shown to detect phosphorylation of p105 at S940. 
 Phosphorylation of p105 at S940 was induced by several inflammatory 
stimuli in RAW cells and primary human cells, and LPS-induced 
phosphorylation of p105 at S940 was blocked by the kinase inhibitor H89. 
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The aims of this work were thus achieved, resulting in the identification of a 
previously uncharacterised inflammatory signalling mechanism. The results 
obtained have implications for future studies in the fields of phosphoproteomics 
and immunology. 
6.2 Implications for Phosphoproteomics Research 
Although not a realistic aim of this work, comprehensive coverage of the 
phosphoproteome is now within reach for state-of-the-art laboratories (Olsen et al., 
2010). The following limitations of the present study might be addressed by more 
comprehensive approaches.  
First, the use of a cell-line, rather than primary cells, was required to provide 
enough starting material for the gel-based workflow used in the first experiment. To 
generate data more relevant to human immune function, the analysis of primary 
human macrophage extracts might be possible using the gel-free approach 
described in this study, although sensitivity might still be limited when 
phosphopeptide enrichment is performed off-line. An alternative approach is TiO2 
enrichment on-line to LC-MS/MS, which was developed by Heck’s group (Pinkse et 
al., 2004), and enabled the identification of more than 2000 phosphorylation sites 
from 250 µg of starting material (Pinkse et al., 2007).  
Second, using a lysis buffer free of SDS may have led to incomplete extraction and 
solubilisation of certain classes of proteins (Ngoka, 2008). However, SDS is not 
compatible with in-solution digestion and MS analysis, owing to its ready 
ionisability. Filter-aided sample preparation (FASP), developed by the Mann lab 
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(Wisniewski et al., 2009), which features extraction at high concentrations of SDS, 
followed by removal of SDS by buffer exchange against 8 M urea in spin filters, 
might result in more comprehensive coverage of the phosphoproteome, although 
overall sensitivity might be compromised.  
Third, arguably the greatest limitation of the present work was its reliance 
predominantly on qualitative proteomics. In order to distinguish between basal and 
induced phosphorylations, quantitative MS/MS approaches, including label-free, 
SILAC, iTRAQ, and related methods, should be used in future studies. 
Fourth, this study was limited to one phosphopeptide enrichment method. The 
parallel use of different phosphopeptide enrichment methods, including TiO2 and 
IMAC, or SIMAC to enrich for multiply phosphorylated peptides, and antibody-
based enrichment of tyrosine phosphorylated proteins or peptides is probably 
required to achieve comprehensive coverage of phosphorylated epitopes.  
Fifth, less than 50% of phosphorylation sites identified in this work were localised 
with certainty, highlighting the need for both improved phosphopeptide 
fragmentation methods and algorithms for the interpretation of phosphopeptide 
tandem mass spectra. Data-dependent use of CID and ETD (Swaney et al., 2008) 
might enable the efficient fragmentation of phosphopeptides across the full range 
of charge states and peptide sizes, although at present it is not clear if improved 
algorithms for spectral matching of phosphorylated sequences would enable the 
identification of the exact site of phosphorylation for the majority of 
phosphopeptides even from more information-rich tandem mass spectra.  
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Sixth, the throughput of validation and characterisation of novel phosphorylation 
sites is severely limited when relying on phospho-specific antibodies, which are 
costly in terms of time of production, financial resources, time spent on testing and 
validating them, and, last but not least, the lives of laboratory animals. The use of 
mass spectrometry not only for the discovery but also for the validation and 
characterisation of phosphorylation sites is possible when operating MS/MS 
instruments in multiple reaction monitoring (MRM) mode, such as triple 
quadrupoles. When combined with iTRAQ labelling, MRM can be used to monitor 
the phosphorylation state of hundreds of preselected sites over time, as 
demonstrated by the White lab (Wolf-Yadlin et al., 2007). As the use of MRM in 
biomedical applications becomes more common and accepted, the generation of 
phospho-specific antibodies to validate sites discovered by tandem mass 
spectrometry may be necessary only for high sensitivity applications currently not 
possible using MRM (Fu et al., 2010). 
6.3 Implications for Immunological Research 
The discovery that p105 is inducibly phosphorylated at S940 in response to a 
number of inflammatory stimuli suggests that this phosphorylation regulates the 
function of p105. Since the function of p105 as a scaffold protein that binds and 
inhibits NF-κB transcription factors and the ERK activating-kinase TPL2 is 
regulated by its phosphorylation-induced degradation (Beinke and Ley, 2004), it is 
possible that phosphorylation at S940 also regulates p105 stability. Based on data 
by Wall and co-workers (Wall et al., 2009), phosphorylation at S940 probably 
blocks or limits the IKK-induced degradation of p105, which is testable by 
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reconstitution of p105-/- cells with wild-type or S940A p105 (such experiments are 
planned as follow-up to this work, along with experiments discussed in chapter 5).  
As a consequence of phosphorylation at S940 induced by inflammatory stimuli, 
increased p105 stability might block the activity of p50 homodimers and ERK, and 
also block partially the activity of p50/p65 heterodimers, although the main 
regulator of these dimers is IκBα. Since p50 homodimers have been shown to 
activate transcription of the anti-inflammatory cytokine IL-10 and inhibit 
transcription of TNF-α in LPS-activated macrophages (Wessells et al., 2004), it is 
possible that stabilisation of p105 through phosphorylation at S940 blocks the anti-
inflammatory functions of p50 homodimers. At the same time, however, stabilised 
p105 would also inhibit TPL2/ERK-regulated secretion of TNF-α (Rousseau et al., 
2008), thereby blocking a key pro-inflammatory mediator. Therefore, the effects of 
p105 stabilisation via phosphorylation at S940 are difficult to predict, and might 
depend on factors including crosstalk between different TLRs and/or other 
signalling pathways, phosphorylation kinetics, and the dynamics of histone and 
DNA methylation (Saccani and Natoli, 2002; Cheng and Blumenthal, 2010). 
Furthermore, p105-dependent inflammatory signalling is cell-type dependent, as 
macrophages from nfkb1-/- mice show normal secretion of TNF-α in response to 
LPS, whereas TNF-α secretion is reduced in DCs from the same mice 
(Lamhamedi-Cherradi et al., 2003). The interpretation of such data is complicated 
by the fact that nfkb1-/- cells display a compound phenotype, because nfkb1-/- cells 
are deficient in p50 as well as p105, and also have severely reduced levels of 
TPL2 and consequently impaired ERK activation via TLR, IL-1, and TNF pathways 
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(Beinke et al., 2003). Nonetheless, studies of nfkb1-/- mice have demonstrated that 
p105/p50 are required for the onset of inflammatory diseases, such as collagen- 
and methylated BSA/IL-1-induced arthritis (Campbell et al., 2000), allergic airway 
inflammation (Yang et al., 1998), and pro-inflammatory gene expression and 
enhanced neointimal formation in a mouse model of vascular disease (Ruusalepp 
et al., 2006). It is thus possible that p105 phosphorylation at S940 plays a 
protective role in these processes and other inflammatory diseases. 
An anti-inflammatory function of p105 is also suggested by studies of tpl2-/- mice, 
as loss of TPL2 protects from endotoxin-induced septic shock (Dumitru et al., 
2000) and TNF-mediated inflammatory bowel disease (Kontoyiannis et al., 2002). 
Since p105 inhibits TPL2, increased p105 stability might mimic these phenotypes. 
By contrast, stabilisation of p105 might interfere with the negative regulation of  
NF-κB signalling by A20, which is essential to limit LPS- and TNF-induced 
inflammation (Lee et al., 2000), because p105 associates with and possibly inhibits 
the A20-interacting protein ABIN2 (Van Huffel et al., 2001). However, such 
apparently opposing effects of p105 stabilisation might be regulated by other 
mechanisms and occur in sequence, providing the potential for a negative 
feedback loop following the initial pro-inflammatory response. 
Beyond TIR domain and TNF-α signalling in innate immune cells, phosphorylation 
of p105 at S940 might also be induced by TLR signals in B-cells (Iwasaki and 
Medzhitov, 2004) and thus play a role in the regulation of B-cell-mediated 
autoimmune responses. Increasing evidence suggests that auto-reactive B-cells 
can be activated through TLR signals, in particular through recognition of 
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endogenous unmethylated CpG DNA by TLR9 and ssRNA by TLRs 3, 7, and 8, 
resulting in auto-antibody production, and possibly also increasing their potential to 
present antigens to auto-reactive T-cells (Meyer-Bahlburg and Rawlings, 2008). 
Moreover, S940 phosphorylation of p105 might be induced by T-cell receptor 
ligation through activation of the canonical NF-κB pathway, although the function of 
p105 phosphorylation might differ from inflammatory pathways because different 
signalling components are utilised by T-cell receptors (Vallabhapurapu and Karin, 
2009).  
Finally, tumorigenesis and chemoresistance can be promoted by inflammatory TLR 
signalling (Chen et al., 2008). For example, IL-6, which is induced by TLRs through 
canonical NF-κB  activation, has been shown to regulate methyltransferase activity 
(Hodge et al., 2001), leading to epigenetic changes that maintain the transformed 
state of cancer cells (Iliopoulos et al., 2009). Thus, phosphorylation of p105 at 
S940, especially if it is part of an anti-inflammatory mechanism, might be a 
potential target for cancer therapy.  
In summary, the function of phosphorylation of p105 at S940 in the regulation of 
inflammation and auto-immunity remains to be investigated. Nonetheless, there are 
a number of intriguing hypotheses worthy of exploration that have been generated 
as a result of this work, which may ultimately further our understanding of 
inflammation and related diseases and lead to the development of novel therapies. 
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